DMU-16/55/RC/Testing of Drugs/2016/CS ESIC Re E-Tender

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

ESIC Re e-Tender enquiry form for Rate Contract for Testing Of Drugs e-Tender enquiry form (Free of cost) CENTRAL STORES, DIRECTORATE (MEDICAL) DELHI ESI DISPENSARY COMPLEX, TILAK VIHAR, NEW DELHI-110018 Phone No.28335358 & 28335360, Fax 28335357

LAST DATE OF SUBMISSION OF ONLINE e-TENDER 16/08/2018.

Page 1 of 112

Name of the Re-e-Tender : DMU-16/55/ RC/ Testing of Drugs /2016/CS

IMPORTANT INSTRUCTIONS FOR BIDDERS REGARDING ONLINE PAYMENT

All bidders/contractors are required to procure class IIIB digital Signature Certificate (DSC) with both DSC components i.e. signing and encryption to participate in the E-tenders.

Bidders should get registered at https://esictenders.eproc.in.

Bidders should add the below mentioned sites under Internet Explorer → Tools → Internet Options → Security → Trusted Sites → Sites of Internet Explorer : https://esictenders.eproc.in https://www.tpsl-india.in https://www4.jpg-online.com

Also , Bidders need to select “Use TLS 1.1 and Use TLS 1.2” under Internet Explorer → Tools → Internet Options → Advanced Tab → Security.

Bidder needs to submit Bid processing Fee charges of Rs.2495/-(Non Refundable) in favour of M/S C1 India Pvt. Ltd. Payable at New Delhi via Online Payment Modes such as Debit Card, Credit Card or NetBanking for participating in the tender.

Bidders can contact our Helpdesk at https://esictenders.eproc.in/html/Support.asp

Page 2 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

CONTENTS

Sr. Headings Page No. No. 1 Date Sheet 4 2 e-Tender enquiry 1-112 3 Instructions to Bidders 6-8 4 Conditions of Contract 9-17 5 Schedule of Requirement 18 6 Technical Bid (Annexure-T) 19 7 Price Bid (Annexure-P) 20 8 Contract Form 21 9 Affidavit of the Laboratory (Annexure-A) 22-24 10 Undertaking (Annexure-B) 25 11 Mandate Form (Annexure-C) 26 12 Bank Guarantee Form For Performance Security(Annexure-D) 27 13 Lowest Rate Certificate (Annexure-E) 28 14 Checklist of the Documents (Annexure-F) 29 15 LIST OF ITEMS (Annexure-S) 30-112

Helpdesk contact No. 28335358 & 28335360, Fax 28335357

Page 3 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

e-TENDER Date Sheet

Name of the e-Tender : DMU-16/55/RC/Testing of Drugs/2016/CS Dated: 17/07/2018

For Testing of Drugs

Sr. Details Dates & time No.

1. Period of availability of e-Tender Enquiry document on ESIC website- www.esic.nic.in 17.07.2018 to 16.08.2018 up to 11.00AM and www.dmdesic.nic.in CPP Portal- www.eprocure.gov.in and ESIC e-Procurement portal- https://esictenders.eproc.in 2. Pre-bid meeting 24.07.2018 at 11.00AM at Conference hall, Directorate (Medical) Delhi, Tilak Vihar, New Delhi – 110018. 3. Last date of Manual and Online Technical Bid 16.08.2018 up to 11.00AM submission 4(i). Opening of Manual Bid and Online Technical 16.08.2018 at 11.30AM at Conference hall, Bid Directorate (Medical) Delhi, Tilak Vihar, New Delhi – 110018.

4(ii) Result of Technical Bid Will be Communicated over Phone/Email/SMS to the Bidders. 4(iii) Representation w.r.t. Technical Bid Will be accepted only within 3 working days of the declaration of result. 5. Opening of Online Price Bid At 11:00A.M. at Conference hall, Directorate (Medical) Delhi, Tilak Vihar, New Delhi – 110018 and information will be communicated to Technically eligible Bidders over Phone/Email/SMS.

6. Validity of offer 365 days from the last date of submission of e-Tender

If the date of opening of tenders is declared a public holiday, the tenders shall be opened on the next working day at the same venue and time. However, the bid shall be accepted at the site of ESIC e-Procurement portal- https://esictenders.eproc.in as per the original schedule, without extension. All tenderers are requested to check further notifications / updates if any on ESIC website- www.esic.nic.in, www.dmdesic.nic.in & ESIC e-Procurement portal - https://esictenders.eproc.in .

Page 4 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

Re-e-Tender Enquiry

EMPLOYEE STATE INSURANCE CORPORATION Room No.5,8,Central Stores, Directorate(Medical)Delhi, Tilak Vihar, New Delhi-110018.

Subject: Formation of ESIC RATE CONTRACT for “Testing of Drugs” for use in ESI Institutions in Delhi/New Delhi/Noida region valid for two years from the date of finalization.

1. E- Tender is hereby invited by Manager Stores Central Stores on behalf of Director(Medical)Delhi under two bid system, only from NABL accredited Laboratories located in the National Capital Territory of Delhi and adjoining cities of Noida, Gurugram, Faridabad and Ghaziabad, for formation of ESIC Rate Contract for Testing of Drugs through e-procurement portal of ESIC-https://esictenders.eproc.in for the purpose of providing safe & potent drugs & dressings to the beneficiaries, for a period of Two years. The Hard copy of following documents in a sealed envelope super scribed as e-Tender No.DMU-16/55/RC/Testing of Drugs/2016/CS are to be submitted:- 1.1 EMD as Specified in the Instructions to Bidders. 1.2 Affidavits/ Authorization letter as per clause 5 of Tender document.

2. E-Tender Enquiry Form may be viewed online or downloaded by the bidders from the website – www.esic.nic.in & www.dmdesic.nic.in, www.eprocure.gov.in and https://esictenders.eproc.in. 2.1 It is mandatory for all bidders to have valid Class III B Digital Signature Certificate (both with signing and encryption component) from any certifying agency as per Information Technology (IT) Act, 2000 for submitting e-bid at the ESIC e-procurement Portal https://esictenders.eproc.in. Bidders can contact helpdesk at https://esictenders.eproc.in/html/support.asp. 2.2 Bidders should get registered at https://esictenders.eproc.in. 2.3 Notwithstanding this, evaluation & finalization of Rate Contract will be based on e- bid submitted by the tenderer. It will be the sole responsibility of the tenderer to scan and upload clear and legible documents for assessment, failing which the tender will be liable for rejection.

3. It is proposed to enter into a Running Rate Contract with Laboratories which fulfill the eligibility criteria approved by ESI Corporation for Testing of Drugs enumerated in the schedule annexed. The eligibility criteria have been given in the terms and conditions. Laboratories intending to participate in the Rate Contract should first ensure that they fulfill all the eligibility criteria as prescribed under the terms and conditions, otherwise the tenders will be summarily rejected. Tenderer should quote only for the items for which they fulfill all the eligibility criteria.

4. The Rate Contract will be governed by the Terms and Conditions enclosed with this Tender Enquiry and no modifications/alterations etc. are allowed in any case. If any modification/alteration is proposed or any other condition advanced by the tenderer is subject to acceptance by the Tender Inviting Authority, Director(Medical) Delhi.

Page 5 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

I. Instruction to Bidders 5. Signing of the tender The tender is liable to be rejected if complete information is not given therein or if the particulars and date (if any) asked for in the schedule to the tender are not filled in. Individual signing the tenders or other documents connected with the bidding process must specify whether he signs as:-

i) A sole proprietor of the Laboratory or constituted Attorney of such sole proprietor. ii) A partner of the Laboratory, if it be in partnership, in which case he must have authority to refer to arbitration disputes concerning the business of the partnership/agreement or a power of attorney. iii) Constituted Attorney of the Laboratory if it is a company. N.B. 5.1 In case of Authorized representative, authorization letter on the letter head of the laboratory duly signed and stamped by proprietor needs to be submitted. 5.2 In case of (ii) a copy of partnership agreement attested by a Notary Public should be furnished unless the same has been previously furnished to the Corporation, or affidavit on stamped paper of all the partners admitting execution of the partnership of the general power of attorney should be furnished. 5.3 In the case of Laboratory run in partnership, where no authority to refer disputes concerning the business of the partnership has been conferred on any partner, the documents must be signed by every partner of the Laboratory. 5.4 A person signing the documents in the Bidding process forming part of the contract on behalf of another shall be deemed to warrant that he has authority to sign the same and, if on enquiry it appears that the person so signing had no authority to do so, the purchaser may without prejudice to other civil and criminal remedy cancel the contract and hold the signatory liable for all costs and damages. 5.5 Each and every page of the document uploaded/submitted in the bidding process should be signed and stamped by the authorized signatory of the Laboratory. The specimen signature of the Authorized Signatory should be submitted to the corporation along with the tender. 6. The tender will be rejected if:- (a) A Laboratory submits conditional tender. (b) All the papers are not complete. (c) Providing incorrect/false information 7. The Item quoted will be rejected if: 7.1 More than one type of rates is quoted for one Item. 7.2 The Rates quoted are not found both in figures and words and if there is any Discrepancy in Rate in words and Rate in figures. 8. Tender will be in two Bid system as follows : 8.1 Technical bid (Hard Copy) 8.1.1 Technical Bid (Hard Copy) should be submitted as : A single sealed envelope super scribed with the e- Tender : DMU-16/55/RC/Testing of Drugs/2016/CS for Testing of Drugs, duly completed and Addressed to Director (Medical) Delhi should be dropped in the tender box kept in office of Manager Stores, Central stores, Tilak Vihar, New Delhi-110018 on or before 11:00 A.M. on 16.08.2018 Containing:- (i) Original Demand Draft/ Banker’s Cheque of Rs. 25,000/- (Rupees Twenty Five Thousand only) as EMD in Favour of ESIC Fund Account No.1 payable at New Delhi (EMD Cover). (ii) Affidavit/Authorization as per clause 5 of Tender Document. • Please note that the sealed envelope (as per para 8.1.1) should contains EMD and Affidavit/Authorization letter only. Any additional documents shall be summarily rejected. Page 6 of 112

• Bidders registered with NSIC (National Small Industries Corporation) shall be exempted from payment of Earnest Money Deposit (EMD). To claim exemption from EMD, the bidder needs to submit a Hard Copy and also to upload the scanned copy of valid NSIC(National Small Industries Corporation) registration certificate, in place of EMD deposit as detailed in clause 8.8.1(i) and clause 8.2.1.

8.2 Technical Bid (Online) should contain SCANNED (signed & Stamped) copies of following Documents:- 8.2.1 Original Demand Draft/ Banker’s Cheque of Rs.25,000/- (Rupees Twenty Five Thousand only) as EMD in Favour of ESIC Fund Account No.1 payable at New Delhi from any commercial Bank of India. 8.2.2 Affidavit/ Authorization as per clause 5 of Tender Document. 8.2.3 Scanned Copies of Tender Document, duly signed & Stamped by Authorized Signatory. 8.2.4 Valid Documents in support of Registration of GST/GST registration certificate. 8.2.5 Valid License for carrying out “Testing Of Drugs & Dressings” issued from Statutory Body, Authorized by Government of India with Approval under Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with schedule annexed therein. 8.2.6 Copy of Form 71and Form 72 of NABL Latest Assessment having relevant SCOPE of Accreditation for at least 30% of the drugs/dressings/vaccines quoted for testing. 8.2.7.1 List of Government Institutions duly signed & stamped, to which Testing of Drugs & Dressing Services are provided by the Testing Laboratories on their letter head. 8.2.7.2 Satisfactory performance certificate from at least Two (02) Government/Autonomous Institutions, duly signed & stamped by such institutes , of last two consecutive years on their letter heads, to whom such services were provided. 8.2.8 Affidavit of the Laboratory{On Non-Judicial stamp paper of Rs.100/-(As per Annexure A)} 8.2.9 Undertaking by the laboratory that the Laboratory is not Blacklisted from any Government Organization/Institution and is in this business in continuation from Year 2014 (As per Annexure B). 8.2.10 Mandate Form as per Annexure-C. 8.2.11 Copy of undertaking (signed and stamped by tender signing authority) that the quoted items have not been / are not being tested for any other organization at the rates lower than being quoted here (As per Annexure E). 8.2.12 Financial report (Balance Sheet, Profit & Loss account Clearly indicating the turnover in Testing of Drugs/dressings/vaccines etc. of Rupees One Crore or above) of last three Financial years (i.e. 2014-15, 2015-16, 2016-17) duly audited by Chartered Accountant. 8.2.13 Covering letter clearly indicating the list of enclosures(As per Annexure F). 8.2.14 Any Other Supportive Documents. * Technical Bids without acceptable authority letter(s) and valid License for Testing of Drugs , shall not be considered. * The Testing Facilities at Laboratory will mandatorily be visited and inspected by Officers/committee appointed by Director(Medical)Delhi. The visit will constitute an essential part of the Technical evaluation. The Inspection of premises will be carried out as per clause 35 of “Conditions of contract” and those failed to comply with standards, will be disqualified from tender processing at Technical Stage. The decision of D(M)D in that reference shall be final and will be binding on all Laboratories and they will submit an undertaking that they will not represent against the decision of D(M)D in any forum. 8.3 Price Bid- Online 8.3.1 Price Bid for quoted Rates of Items as per Table-I of Annexure-P. 8.3.1.1 Price should be filled online. 8.3.2 The Bidder should upload the Price Bid by giving the Rate of Testing Charges for the complete analysis of “single sample” of an Item and not for individual test performed on the sample. * Online Price Bid of only those bidders who are found technically eligible will be opened.

Page 7 of 112

* In case any discrepancy in Rate per unit in figures or Rate per unit in words (Column No. 6 & 7) are found, the Item will not be considered. 9. Pre-bid meeting 9.1 In order to clarify doubts of the prospective Bidders, if any, a Pre-bid meeting will be held at Conference hall, Directorate (Medical) Delhi, Tilak Vihar, New Delhi – 110018 at 11.00 AM on Dated: 24.07.2018. 9.2 The objectives of this Pre-bid meeting inter alia are, to answer the clarifications/questions/queries. 10. Online Technical Bid and Hard copy of bid will be opened as per schedule on given Venue in the presence of representative(s) of the Laboratories, having an authority letter for representation from the Laboratories. If the date of opening of tender is declared a public holiday, the tenders shall be opened on the next working day at the same venue and time. No bid shall be accepted after the prescribed date and time of bid submission. 11. Director(Medical)Delhi reserves the right to accept or reject any or all the tenders at any stage without assigning any reason thereof. 12. Acceptance of tender by competent authority will be communicated by a letter of acceptance after completion of formalities required for the formal acceptance of the tender & will be forwarded to the tenderer as soon as possible and the instructions contained in the communication should be acted upon immediately. 13.1 Withdrawal of tenders along with the earnest money will be allowed before the date of opening of tenders. 13.2 After opening of Tenders:- 10.2.1 Withdrawal of the complete tender can be allowed, but in such cases the earnest money shall be forfeited in full; 10.2.2 No change/alteration in rate or other terms in the tender will be permitted under any circumstances; 10.2.3 Partial withdrawal (In respect of one or more items quoted) will not be allowed under any Circumstances. 13.3 There will be no correspondence between the tenderer and the DIRECTOR (MEDICAL) DELHI till the tender is finalized.

Director(Medical)Delhi

Page 8 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

II. Condition of Contract

1. DEFINITIONS: In the interpretation of the contract and the general and /or special condition governing it, unless the context otherwise requires:- (a) The term 'Contract shall mean the invitation to tender, the instructions to tenderer acceptance of the tender schedule, particulars" hereinafter defined and those general and special conditions that may be added. (b) The term "Contractor" shall mean the person, firm or Company with whom the order for drug testing is placed and shall deem to include the contractor's successor (approved by the purchaser) representatives, heirs, executors and administrators unless excluded by the contract. (c) Contract price’ shall mean the price of tests accepted or the prices calculated in accordance with the prices accepted by or on behalf or of the purchaser. (d) The term “delivery" shall mean delivery of reports by the dates specified in the acceptance of tender of drug testing. (e) The term "Corporation" shall means the “Employees State Insurance Corporation”. (f) The term Director (Medical)Delhi/Medical Superintendent, ESI Hospital also means any other officer authorized for the time being in the administration of ESI Corporation and any other officer authorized for the time being to execute contract relating to the drug testing on behalf of the purchaser. (g) The term “Purchaser” shall mean purchaser or purchasers named in the schedule to tender, his or their successors or assignees. (h) The term "test" shall mean such test or tests as are prescribed by the specification or considered necessary by the purchaser. 2. This rate enquiry is for the purpose of executing Rate Contract for Testing of Drugs in ESI Central Medical Stores Delhi/Hospitals in Delhi/New Delhi/NOIDA region. 2.1 The rates quoted and accepted by the Director (Medical) Delhi, ESI Corporation shall be valid for the quantities of drugs that may be tested from time to time during the course of the contract. 2.2 The tenderer should read carefully the terms and conditions and tenderer should quote only for those items, for which they qualify as per terms & conditions of the Rate Contract and for which they have valid authorization on the date of the tender, supported by documentary evidence. 2.3 The tenderer should quote only one rate for each item Sr.No. without any variation for Testing Charges at different areas of ESIC units in Delhi/New Delhi/Noida or with any escalation clause. Rates quoted should be inclusive of Transportation Charges/ Freight charges etc., given both in words and in figures but should be exclusive of GST. GST should be as per prevailing rate that shall be paid to the laboratory upon submission of claim and proof of GST. 2.4 If the bidder quotes NIL/ZERO Charges in the Price Bid for the quoted item(s), the bid of the Laboratory for that particular item shall be treated as unresponsive and shall not be considered. 3. Validity of Bids The quotations shall remain open for acceptance for 365 days (Three Hundred sixty five days) from the date of opening of tenders. If required this office may ask for extension of validity of bid for a reasonable period. 4. Eligibility Criteria for Bidders Laboratories to be eligible should fulfill the following conditions:- 4.1 The Bidder/Laboratory should be continuously in this business since 01/04/2014. Page 9 of 112

4.2 Bidder(s) participating in Tender must have annual turnover of Rs.10000000/- (Rupees One crore only) or above during last three consecutive Financial years (i.e.2014-2015,2015-2016,2016-17). 4.3 Bidder(s) participating in Tender should not be blacklisted/deregistered and should not have been blacklisted/Deregistered by any other Govt. Institution/Organization during the last five years for Testing of Drugs/Dressings/Vaccines/ Other Items or on any other Grounds. 4.4 Bidder(s) participating in Tender should not be convicted by any court of law in any matter related to Testing of Drugs/Dressings/Vaccines/ Other Items or on any other grounds. 4.5 Bidder(s) participating in Tender must have Valid License for Testing of Drugs/Dressings/Vaccines etc., for Items quoted in the Tender, issued from Statutory body with Approval under Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with schedule annexed therein. 4.6 Family members of officers/officials working in ESIC cannot take part in this tender enquiry. This will also apply to officers/officials who leave/retire from the services of ESI Corporation within 01(one) year of date of opening of tender. 4.7 Bidder(s) participating in Tender should not be convicted in an offence under the prevention of corruption Act, 1988. 4.8 Bidder(s) participating in Tender should not be convicted in an offence under the Indian Penal Code or any other Law for the time being in force, for any cause of life or property or causing a threat to public health as part of execution of a public procurement contract. * Bidders are advised to quote strictly as per eligibility mentioned above. Failure to adhere to the same shall make the tender liable for rejection. 5. Bid Security (Earnest Money Deposit) 5.1 The tenderer shall have to deposit Bid Security/Earnest Money of Rs.25,000/-(Rupees Twenty Five Thousand only) either through Banker’s cheque or Demand Draft only in favour of "ESIC fund Account No.1" Payable at New Delhi failing which the tender is liable to be rejected out rightly. Scanned copy of the same to be uploaded in Technical bid . 5.2 In the event of withdrawal/revocation or submission of false information/document of tender before the date specified for acceptance, the Earnest Money shall stand forfeited. 5.3 The EMD deposited with earlier tenders will not be adjusted against this tender. Tenders without EMD will not be entertained. 5.4 E.S.I. Corporation will not pay any interest on Earnest Money Deposit , which would stand credited to the E.S.I. Corporation Account. 5.5 EMD of unsuccessful tenderer(s) will be returned without any interest after the finalization of contract. 5.6 EMD of successful tenderer will be returned without any interest after deposition of requisite Security Deposit/Performance Guarantee after finalization of tender. 6. Performance Security 6.1 Director (Medical)Delhi, ESI Corporation may at his discretion call upon the successful bidders to deposit a sum as a security for the due performance of the agreement in all respects. 6.2 In case selected, Security of Rs.50,000/-(Rupees Fifty Thousand only) in the form of Bank Guarantee issued by any Nationalized Bank will have to be deposited in the prescribed format in favour of Director (Medical) Delhi, ESI Corporation within the stipulated period as and when informed. 6.3 Performance security of the contractor will be forfeited, if the contractor withdraws or amends without prior consent or impairs or derogates from the tender in any respect within the period of validity of rate contract including extension period or if it comes to notice that information/ documents furnished are incorrect, false, misleading or forged without prejudice to other right of the purchaser. 6.4 The EMD (earnest Money deposit) will also be forfeited without prejudice to other rights of purchaser if it fails to furnish the required performance with in the specified period (validity period).

Page 10 of 112

6.5 Performance Security deposit of successful tenderer will be returned without any interest on receipt of satisfactory performance report from user departments after the expiry of the contract. 7. Bids shall be strictly according to the required Technical Documents. 8. Acceptance of the Tender 8.1 Director (Medical) Delhi does not pledge himself to accept the lowest of any tender and reserves the right of accepting/rejecting the whole or any part of the tender without assigning any reason. 8.2 The purchaser shall communicate acceptance of the quotation if it is acceptable to him, by a letter. The formal acceptance of the tender will be forwarded to the successful tenderer as soon as possible. The instructions contained in the letter should be acted upon immediately by the tenderer. 8.3 The bidder, whose tender is accepted will then send Contract Form in the prescribed format (as per Performa communicated by Director (Medical) Delhi, ESI Corporation on a notarized stamp paper of Rs.100/- to Director (Medical) Delhi, ESI Corporation conveying his agreement and acceptance of the terms and conditions as part of Memorandum of understanding (MOU). The acceptance of this letter by Director (Medical) Delhi , ESI Corporation will conclude the contract and will be enforceable in law. 9. The Director (Medial) Delhi, Employees' State Insurance Corporation, New Delhi reserves the right to reject any or all offers including the lowest quotation at any stage without assigning any reasons whatsoever. The Director (Medial) Delhi, ESI Corporation, New Delhi will also have the authority to accept tenderer's offer in respect of any one or more of the items for which bidders may have quoted and his decision in this respect shall be final. 10. Laboratories debarred by ESI Corporation for participation in ESI Rate Contract will not be considered for award of Rate Contract till the period of debarring and therefore need not apply. 11. Non submission of any desired information in e-Tender will make the bidder Non-Qualified for the said e-Tender. 12. Not following all the Terms & Conditions of e-Tender Enquiry, furnishing wrong information and false documents will make the tenderer ineligible and liable to be debarred/blacklisted from participation in future ESI Rate Contracts for two years along with forfeiting the Earnest Money/Performance Security. 13. Tenderer will have to furnish documents in support of the information given in the tender. Original documents shall be submitted for verification as and when required. 14. In case of any attempt for cartelization by bidder(s) with a view to hike up the prices and/ or influence, pressurize the buyer in any manner with regard to preparation of Rate Contract or any other procedure related to Testing thereafter, Bid(s) of said bidder(s) may be rejected and the bidder(s) may be blacklisted for a minimum period of Two Years/any other action deemed fit by competent authority may be taken. 15. The tenderer, if selected, will have to provide Testing facility directly to the ESIC Delhi/New Delhi/Noida region. 16. After the finalization of Rate contract by the Director (Medical) Delhi, ESI Corporation, Orders for Testing will be placed by the Medical Superintendents/Heads of ESI Corporation run hospitals/Heads of ESI Scheme/Manager Stores as per Schedule attached, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director (Medical) Delhi, ESI Corporation in all matters connected with the execution of Orders and/or wherever specifically provided in the terms and conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate any of his subordinate Officer as Direct Demanding Officer (DDO) to operate this contract. 17. Orders for Testing will be placed from time to time during the currency of the contract in which the exact quantities to be tested on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers. 18. Orders for Testing against the contract will be accepted as long as these reach the contractor on or before last date of the currency of the contract. Orders received during the closing days should be complied within due course, in accordance with the contract, even though in some cases owing to contract having

Page 11 of 112

expired, orders are to be executed after the expiry of the last date of contract. 19. No guarantee can be given as to the maximum number of Orders for testing that may be placed against this Contract, but the contractor will have to provide Testing Facility as may be ordered by the Direct Demanding Officers during the currency of the contract. 20. The rate quoted by tenderer for Testing of Drugs/Dressings/Vaccines to the Corporation, whichever is lower, shall in no event exceed the lowest price at which the contractor provides the testing facility of identical description to any other person(s)/ institutions during the said period of agreement. If at any time during the said period, the contractor reduces the price of such Items to any other person(s)/ institutions at a price lower than the price chargeable under the agreement, he shall forthwith notify such reduction in Testing price to the Director (Medical) Delhi ,E.S.I. Corporation and Chief Direct Demanding Officers and the price payable under the agreement for such Items after the date of its coming into force will be the reduced price. The approved price in Rate Contract shall stand correspondingly reduced. 21. The price must be quoted F.O.R Destination per unit as shown in the schedule annexed and should be inclusive of Freight Charges/Transportation Charges etc. but exclusive of GST. GST should be as per prevailing rate that shall be paid to the laboratory upon submission of claim and proof of GST. 22. Samples of Drug Testing shall be given to the selected tenderers on rotation and if samples are not collected by the assigned tenderer on the day allotted, sample will be given to next tenderer on rotation. 23. Samples must be collected from various ESIC units in Delhi/New Delhi/Noida Region, as and when called for or as desired by competent authority of ESIC at cost and risk of the Laboratory. 23a.Samples will be given to tenderer/authorized representatives and reports will be accepted accordingly. 23b. “COMPLIES” or “PASS” or “WITHIN LIMIT” in the result column of the report is treated as incomplete report, if the result has some value, the actual value on analysis is to be reported. Every report must have specific remarks (i.e.) Standard Quality or Not of Standard Quality. Any ambiguity/cutting will not be accepted. 23.c Every Test Report should have Sr. No., Description of Tests, Specifications and Results obtained including protocol of Test applied. In case of non-pharmacopoeial products, the method of analysis should be mentioned in the report AND PROTOCOL OF TEST APPLIED TO BE MENTIONED ON EACH REPORT. 23.d In case of failure of a sample, the result should be communicated immediately to the undersigned or his representative though phone/E-mail and the report should be sent with protocols. 23.e The test analysis will be carried out as per the pharmacopoeial monographs with the use of Pharmacopoeial Reference Standards. In case of non pharmacopoeial methods, the laboratory can use methods that are validated as per ICH guidelines. 24. All the disputes relating to this tender inquiry and Rate Contract shall be subject to the territorial jurisdiction of courts at Delhi/New Delhi only. 25. Testing reports are to be submitted within 3 days of the stipulated time as specified against each item enlisted below respectively.

S. NO. Name of the dosage form Number of days required for submission of testing report

01 Capsule/Granules/PowderSachet 15 days

02 Inhaler 15 days

03 Lotion/Syrup/Oral Drops/ 15 days Solution 04 Ointment 15 days

Page 12 of 112

05 Dressings 15 days

06 Rotacap 15 days

07 Respules/Resp. Sol./Spray 15 days

08 Tablet/Lozenges 15 days

09 Suppository 15 days

10 Injection/Dye/Sealant/Implant 25 days

11 Eye/Ear/Nasal Drop 25 days

12 CAPD Fluid 25 days

If laboratory fails to provide the testing report within 3 days from the stipulated period specified against each item, penalty of 5 % of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10 % of the total value of the test/tests. 26. List of govt. institutes to be provided for which such services are provided by testing laboratory. 27. An undertaking that the testing charges are not more than the rates charged from other institutions, under Lowest Rate Cetificate (As per Annexure E). 28. Copy of valid license for carrying out testing of drugs from appropriate authority need be provided with Approval under Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with schedule annexed therein. 29. The rates should be applicable for ESI Scheme Delhi/New Delhi & Noida. 30. Tenderer must quote the rates strictly as per the given Format (Table-I) and as per the list of Items attached with the tender form, mentioning the Serial No. and Item Code of Items. Table-I

1 2 3 4 5 6 7 Group No. Sr. No. Item No. Dosage Item name Rate per Test in Figures Rate per Test in words Form (in Rs.){inclusive of (in Rs.) {inclusive of Transportation Transportation charges/freight charges etc. charges/freight charges etc. & exclusive of GST} & exclusive of GST}

31. The tenderer should also submit an undertaking that all the Terms & Conditions of the Tender are acceptable In complete. 32. Tenderer must be in this business w.e.f 1st April 2014 which should be supported by Undertaking on the Laboratory’s Letter Head as per enclosed format i.e. Annexure-B. 33. The tenderer should submit an Undertaking that the firm is not blacklisted in any Govt. Organization/Institution as per enclosed format i.e. Annexure-B. 34. Price Offer:- (i) The lowest rates(L1 Rates) of all the Drugs/Dressings quoted against individual Drug/Dressing etc. in the price bid by the eligible Bidder(s) will be intimated to all “Technically Approved Bidder(s)” by a “Letter Of Offer(Counter Offer)” for acceptance of lowest rates(L1 Rates) within stipulated time period. Page 13 of 112

(ii) Those Bidder(s) who accept the “Counter Offer” will have to mandatorily accept Lowest Rates (L1 Rates) for all Drugs, for which they have quoted in their price Bid. (iii) Those Bidder(s) who do not accept the “Counter Offer” will however continue to be eligible for Testing of Drugs for those Items in which they individually qualify at “Lowest Rates(L1 Rates)” and it is mandatory for such Bidder(s) to give acceptance letter for Testing of Drugs in which they individually qualified at “Lowest Rates(L1 Rates)”. (iv) EMD of those Bidder(s), who do not give acceptance for Testing of Drugs for those Items in which they individually qualify at “Lowest Rates(L1 Rates), will be forfeited. (v) D(M)D reserves the right to accept any Rate other than the lowest Rate, in case the Competent Authority Identifies an attempt of Cartelization or Monopolization by one or more tenderers. The same will apply in case the lowest rate quoting laboratory and counter-offer accepting laboratories is/are found to be incapable of carrying out Tests and to provide satisfactory Tests Reports. 35. Inspection : The Director (Medical)Delhi, ESI Corporation, reserve the right for Inspection of the premises of the bidder participating in the tenders, by officers appointed by the Director(Medical) Delhi. They can also carry out inspection for assessing the capacity/capability/eligibility of the Laboratory(s) and their staff employed, their attendance records, functional status of equipments along with their calibration status and SOP’s for various testing services on the basis of ESI Rate Contract and to ensure that Good Laboratory practices are being followed by Laboratory. The Laboratory shall extend all facilities to the team to enable them to inspect the premises, testing facilities, technical personals, reference standards/working standards/ documentation as mandatory under D & C Act 1940 and Rules 1945, in the Laboratory. The decision of the Director(Medical) Delhi shall be final in this regard. 35.1 Inspection authority The Director (Medical)Delhi/Medical Superintendent or any other officer nominated by him. 36. Payment Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the Testing Report) directly by the chief Direct Demanding Officers or through nominees to whom bills are submitted. Bills should be submitted within period specified in the Tender document, to enable timely payment. 37. Any dues or payments that have arisen to the Corporation from the contractor for which no specific time limit has been laid down in the terms and conditions shall be payable by the contractor within such time limit as may be prescribed in the letters/orders addressed to the contractors. 38. Any payments that have been demanded as per the provisions of clause 37 or under any other clause shall be payable within the time laid down. On failure to do so: - 38.1 The contractor shall be liable to be debarred for bidding to the ESI Corporation for a period not Less than three years. 38.2 The contractor is liable to be prosecuted in court of law. 39. Subletting of contract: The Contractor shall not sublet, transfer or assign the contract or any part thereof. In the event of the contractor contravening this condition the Director(Medical) Delhi, will be entitled to place the contract elsewhere on the contractors account at his risk and the contractor shall be liable for any loss or damage to the Director(Medical)Delhi, may sustain in consequence of arising out of such replacing of the contract. 40. Rate Revision : Successful tenderers shall not be entitled to any rate revision of price for any reason except that allowed by Government of India, except downward revision as mentioned in clause 26. 41. Recovery of sums due: 41.1 Whenever any claim for the payment of a sum of money arises out of or under this contract against the contractor the purchaser shall be entitled to recover such sum by appropriating, in part or whole from the security deposited by the contractor, if a security money is taken against the

Page 14 of 112

contract. 41.2 In the event of the security money being insufficient, then the balance or the total sum to be recoverable, as the case may be, shall be deducted from any sum then due or which at any time thereafter may become due to contractor under this or any other contract with the purchaser. 41.3 Should this sum not be sufficient to cover the full amount recoverable, the contractor shall pay to the purchaser on demand the remaining balance due. 41.4 Any dues or payments that have arisen to the corporation from the contractor for which no specific time limit has been laid down in the terms and conditions shall be payable by the contractor within such time limit as may be prescribed in the letter/order addressed to the contractors. 42. Fraud & Corruption 42.1 The bidder, supplier and the contractor observe the highest standard of ethics during the procurement & execution of such contracts in pursuit of this: 42.1.1 Defines, for the purposes of this provision, the terms set forth below as follow:- 42.1.1.1 “Corrupt Practice” means the offering, giving, receiving or soliciting directly or indirectly of anything of value to influence the action of public official in the procurement process or in contract execution. 42.1.1.2 “Fraudulent Practice” means a misrepresentation or omission of facts in order to influence a procurement process or the execution of a contract. 42.1.1.3 “Collusive Practice” means a scheme or arrangement between two or more bidders, with or without the knowledge of the purchaser, designed to establish bid prices at artificial, non -competitive levels; 42.1.1.4 “Coercive Practices” means harming or threatening to harm, directly or indirectly, person or their property to influence their participation in the procurement process or affix to execution of a contract. 42.1.1.5 Will reject a proposal for award, if it determines that the bidder recommended for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive practices in competing for the contract in question. 43. Insolvency and Breach of Contract: 43.1 The Director (Medical) Delhi/Medical Superintendent may at any time by notice in writing summarily terminate the contract without Compensation to the contractor in any of the following contingencies, that is to say:- 43.1.1 If the contractor being an individual or if Laboratory, any partner in the Laboratory, shall at any time be adjudged insolvent or shall have a receiving order or orders for administration of his estate made against him or shall take any proceedings for liquidation or composition under any insolvency Act for the time being in force or shall make any conveyance or assignment of this effects or enter into any arrangements or composition with his creditors or suspend payment or if the Laboratory be dissolved under Partnership Act, or 43.1.2 If the contractor being a company shall pass a resolution or the courts shall make an order for the liquidation of the affairs or a receiver or Manager on behalf of the debenture holder shall be appointed or circumstances shall have arisen which entitled the court or debenture holders/share holders to appoint a receiver or Manager, or 43.1.3 If the contractor commits any breach of this contract not herein specifically provided for in the tender document. Provided always that such determination shall not prejudice any right of action or remedy which shall have accrued or shall accrue thereafter to the purchaser and provided also that the contractor shall be liable to pay the purchaser for any extra expenditure incurred thereby put to but shall not be entitled to any gain on repurchased.

Page 15 of 112

44. Arbitration In the event of any dispute or difference arising under these conditions or any special conditions or contract or in connection with this contract, except as to any matters the decision on which is specially provided for by these or special conditions the same shall be referred to the sole arbitration of the Director (Medical) Delhi ,Employees' State Insurance Corporation or some other person appointed by him. There shall be no objection that the arbitrator is a Government/Corporation servant and that he had to deal with matters to which contract relates or that in the course of his duties as Govt./ Corporation servant he had expressed views on all or any of the arbitration dispute or differences. The award of the arbitrator shall be final and binding on both the parties to this contract. It is term of this contract: 44.1 If the arbitrator be the Director (Medical) Delhi, Employees' State Insurance Corporation: 44.1.1 In the event of his being transferred or vacating his office by resignation or otherwise, it shall be lawful for his successor-in-office either to proceed with the reference himself, or to appoint another person as arbitrator; or 44.1.2 In the event of his becoming unable to act, for any reason, it shall be lawful for the Director (Medical)Delhi, Employees ‘ State Insurance Corporation to appoint another person as arbitrator. 44.2. If the arbitrator be a person, appointed by the Director (Medical)Delhi, Employees' State Insurance Corporation: 44.2.1 In the event of his delaying neglecting or refusing to act, being unable to act, for any reason, it shall be lawful for the Director (Medical) Delhi, E.S.I.C. either to proceed with the reference himself or to appoint another person as arbitrator in place of the outgoing arbitrator. 44.3 It is further a terms of this contract that no person, other than the Director(Medical)Delhi, E.S.I.C. or the person appointed by him should act as arbitrator and that, if for any reason that is not possible, the matter is not to be referred to arbitrator at all. 44.4. Upon every such reference, the assessment of the cost incidental to the reference and award respectively shall be at the discretion of the arbitrator. 44.5. Subject as aforesaid, the Arbitration Act, 1940 and the rules there under and any statutory Modifications thereof for the time being in force shall be deemed to apply to the arbitration proceedings under this clause. 44.6. Work under the contract shall, if reasonably possible, continue during the arbitration proceedings and no payment due to or payable by the purchaser shall be with-held, on account of such proceedings. 44.7. The venue of the arbitration shall be Delhi/New Delhi. 44.8. In this clause the expression the Director (Medical) Delhi , E.S.I.C. means the Director (Medical) Delhi ESIC for the time being and includes, if there be no Director (Medical)Delhi of ESIC, the officer who is for the time being the Administrative head of the Directorate(Medical)Delhi, Employees' State Insurance Corporation whether in addition or otherwise. 44.9. For the purpose of the contract including proceedings there under, the Director (Medical)Delhi, ESIC shall be entitled to exercise all the rights and powers of the purchaser. 45. All the disputes relating to this tender enquiry and Rate Contract shall be subject to the territorial Jurisdiction of Courts at Delhi/New Delhi only. 46. Tenderer will be liable for cancellation of the contract for any misleading information found at any time during the currency of the contract. 47. Validity of the Rate Contract is two years from the date of finalization of the contract, but in case of exigencies, period can be extended further for a period of one year as desired by Director(Medical)Delhi. In case of extreme exigencies the rate contract may further be extended for a period of one year more by mutual consent of both the parties.

Page 16 of 112

48. It may be noted that If the above instructions are not adhered to by the tenderer, the quotation may summarily be rejected. 49. Force Majeure: If at any time during the applicability of Rate Contract the bidder fails to discharge its obligation due to force majeure(natural disaster or act of God etc.) he will promptly notify the Director(Medical)Delhi or its representative about the happening of such an event. The Director(Medical)Delhi or its Representative is solely entitled to terminate the order/contract in respect of such performance of the bidders obligations if he so desires. The obligations under the contract on behalf of bidder for the contract shall be resumed as soon as practicable after the event has come to an end or ceased to exist. 50. It may be noted that, no correspondence shall be entertained between bidder and Director(Medical)Delhi till the tender is finalized. However the bidder has to provide necessary information if called upon by Director(Medical)Delhi to do so , at any stage. 51. It may also be noted that the unsuccessful tenderer will not be informed of the result of his tender. 52. It is the sole responsibility of the tenderer to submit the tender both Online and Manually ( As Specified). All documents as listed above should be clear and legible, duly attested/ notarized, properly indexed and serially page numbered. All documents should be duly signed digitally for online submission and manually for hard Copy by the Authorized Signatory. Copies to be uploaded and submitted online should be in proper resolution. 53. The above said instructions should be followed strictly, failing which the tender will be summarily rejected. 54. The tenderer who submits false, forged or fabricated documents or conceals facts with intent to win over the tender, EMD/ Performance Security of such tenderers will be forfeited and Laboratory will be liable for blacklisting in addition to legal action as deemed fit.

Director(Medical)Delhi

Page 17 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

III. Schedule of Requirement

Central Store on behalf of Director(Medical)Delhi intends to provide Testing Services by framing ESIC Rate Contract for Testing of Drugs through e-procurement portal of ESIC - https://esictenders.eproc.in for a period of Two years from the date of finalization of the contract for the quantities of Drugs/dressings/Vaccines that may be Tested from time to time during the course of the contract as per the requirement raised by the user units.

Page 18 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS Annexure ”T”

IV. Technical Bid

• Documents required to be submitted by the Bidder Manually/Online, as detailed in Clause 8 and Sub- clauses 8, under “Conditions of Contract” on page no.-6 and 7 of the tender document.

• The Testing Facilities at Laboratory will mandatorily be visited and inspected by Officers/committee appointed by Director(Medical)Delhi. The visit will constitute an essential part of the Technical evaluation. The Inspection of premises will be carried out as per clause 35 of “Conditions of contract” and those failed to comply with standards, will be disqualified from tender processing at Technical Stage. The decision of D(M)D in that reference shall be final and will be binding on all Laboratories.

Page 19 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS Annexure ”P”

V. PRICE BID

Table-I

** Comparative Price evaluation of the above said item(s) will be done on the basis of Rate per Test in words(in Rs.)(as in Column 7).

** Rates quoted should be inclusive of Transportation Charges/ Freight charges etc., given both in words(in Rs.) and in figures(in Rs.) but should be exclusive of GST. GST should be as per prevailing rate that shall be paid to the laboratory upon submission of claim and proof of GST.

Page 20 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

(ONLY TO BE FILLED BY THE SUCCESSFUL BIDDER AT THE TIME OF AWARD OF CONTRACT) VI.CONTRACT FORM AGREEMENT (on stamp paper of Rs.100/- BETWEEN DIRECTOR (MEDICAL) DELHI, ESIC AND M/S______This agreement is made on the th day of between the Director (Medical) Delhi, ESI Corporation, New Delhi having its office at ESI Dispensary Complex, Tilak Vihar, Near works department Opp. Police Chowki, New Delhi 110018.(herein after called ESIC, which expression shall, unless repugnant to the context or meaning thereof, be deemed to mean and include its successors and assigns) of the First party. AND

M/S______

Address______

______

(herein after called the RC Holder for Testing of Drugs as the second party to facilitate Testing services at the approved rates for a period of two years(GST should be as per prevailing rate that shall be paid to the laboratory upon submission of claim and proof of GST) (______– ______) ,unless short closed before that, by Director (Medical) Delhi at his discretion on the following terms & conditions.

1. Second party will maintain uninterrupted Facility for Testing services to user unit(s) in Delhi/New Delhi/Noida Region. 2. The second party shall ensure that Testing of Drugs/Dressings/Vaccines should be done well within the days specified in the “Terms & Conditions” of Tender document. 3. The second party shall know that, in case of failure or refusal by second party for Testing of Drugs/Dressings to the unit(s) during the contract period, the contract is liable to be cancelled at his risk and cost, and any extra cost involved in arranging Testing Service from alternative source will be recovered from his subsequent/pending bills/security deposit. Failure to fulfill the terms of contract may entail for closure of contract and for forfeit of Security Deposit. 4. The second party shall abide by all the terms & conditions mentioned in Tender documents of the Tender No.:- DMU-16/55/RC/Testing of Drugs/2016/CS opened on ______.

Signature of the 1st party Signature of second party / his representative

In the presence of In the presence of Signature of the witness Signature of the witness

Page 21 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS Annexure- “ A” Affidavit of the Laboratory (On Non-Judicial Stamp Paper of Rs.100/-)

From:- Name of the Laboratory/Company: Address for correspondence: Telephone No.: Working Fax No. E-mail address Details of Person responsible for conduct of business (Name, Mobile No. & e-mail address) To Director (Medical) Delhi, Directorate (Medical) Delhi, ESI Dispensary Complex, Tilak Vihar, New Delhi-110018

Sub: Testing of Drugs at the quoted rates to Director (Medical) Delhi, ESI Corporation for a period of Two years w. e. f. date of finalization of Tender.

Sir, I/We/am/are authorized signatories of M/s.______I/ we hereby undertake as follows:- 1. I/we hereby undertake to do Testing of Drugs in areas specified by the Director (Medical) Delhi, ESI Dispensary Complex, Tilak Vihar for a period of two years from the date of signing of agreement at the rates quoted by me/us and offered to me/us by D(M)D and in the quantities specified in the prescribed tender form, which is submitted herewith according to the instructions and the terms and conditions. The duration of the said contract may be extended on the same terms and conditions & rates if the Director(Medical)Delhi so desires. 2. I/we hereby undertake that the rates quoted against each item by me/us in the tender are FOR destination and inclusive of all freight charges, transportation charges and duties payable during the contract period but exclusive of GST.GST should be as per prevailing rate that shall be paid to the laboratory upon submission of claim and proof of GST. 3. I/we hereby undertake that I/we have submitted the necessary documents as required are enclosed herewith in the order in which they are mentioned. 4. I/we understand that security deposit submitted on entering into contract, is likely to be forfeited In the event of lapse on my/our part to comply with the terms and conditions of the tender and/or if proven to have followed unscrupulous practices apart from the liability of penal action for violating the law of the land. 5. I/we have carefully read and understood the terms and conditions to avoid any error, omission. I/we shall abide by these conditions. I/we will follow them very scrupulously. Any conditional acceptance shall make my tender liable for rejection. 6. I/We hereby undertake that My/our Laboratory is not blacklisted/deregistered currently and has not been Blacklisted/deregistered by any other Govt. institution/ Organization during the last five Years for Testing of Drugs/Dressings/Vaccines/Other items or on any other grounds and is in this business in continuation from year 2014. I/We further stated and undertake that I/We have not been convicted by

Page 22 of 112

any court of law in any matter related to Testing of Drugs/Dressings/Vaccines /Other items or on any other grounds. 7. I/We hereby undertake that My/our Laboratory is not convicted in an offence under the prevention of Corruption Act,1988. 8. I/We hereby undertake that My/our Laboratory is not convicted in an offence under the Indian Penal Code or any other law for the time being in force, for any cause of life or property or causing a threat to public health as part of execution of a public procurement/service contract. 9. I/we also undertake cognizance of the fact that failure to furnish the information called for by the Director (Medical) Delhi or to comply with any requirements laid down under the conditions will be considered as disqualification and the tender by rejection on that account. 10. I/we hereby undertake to abide by the instructions issued by the Director (Medical) Delhi from time to time. 11. In case of my/our Laboratory’s Report declared wrong by any Government/ Government Approved Agency I/We am/are liable for Appropriate Action. 12. I/we hereby undertake , that the rate quoted by me/us are not higher than the rate quoted by me/us to any Govt. Institution/agency within Delhi, New Delhi and Noida during the contract period and the quoted Items have not been & are not being tested for any other organization at rates lower than being quoted here. 13. I/we hereby undertake that, if at any time during the currency of the contract, I/we reduce the price for Testing of Drugs/ Dressings/Vaccines, as are covered under the contract, to any govt. organization in Delhi/New Delhi/ Noida, at a price lower than the price chargeable under the contract, I/we shall forthwith notify such reduction to Director(Medical) Delhi/Director(Medical) NOIDA / Medical Superintendent and the price payable under the contract for the Testing of Drugs, after the date of coming into force of such deduction, shall stand correspondingly reduced. I/We further undertake that in case of any down-ward revision same will be passed on to the ESI Corporation from the effective date during the currency of the contract and in case of failure to do so we are liable to be debarred from future ESIC Tender Enquiry for a further period of two years along with forfeiting the Performance security. 14. I/We hereby undertake that our Laboratory has experience for Testing of Drugs/Dressings/Vaccines of last three financial years for the item(s) quoted in e-Tender. 15. I/We hereby undertake that I/We have Valid License for the Testing of Drugs/Dressings/Vaccines etc. quoted in e-tender issued from Statutory Body, Authorized by Government of India with Approval under Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with schedule annexed therein. 16. I/we hereby undertake to abide by the terms and conditions of the contract modified from time to time and I/we have signed all the papers of terms and conditions. 17. I/We hereby undertake that I/We have carefully perused the Terms and Conditions of the Rate Contract and accept the same. 18. I/We hereby undertake that our Laboratory has successfully executed all the Rate Contract/ Tender(s) awarded to my/our Laboratory by Govt. organization(s)/institution(s) during last three years i.e. w.e.f. April 2014 to March 2015,April 2015 to March 2016& April 2016 to March 2017 and till date. 19. I/We hereby undertake and declare that none of my/our family members is/are working in ESI Corporation, Nor I/our family members superannuated/left/retired from the services of ESI Corporation in the last 01(one) year from the date of opening of the tender. 20. I/we hereby undertake that if at any time, any information is found to be false, my/our tender/ Contract is liable to be rejected at any stage by Director(Medical)Delhi, without assigning any reason. 21. I/we hereby undertake that the test analysis will be carried out as per the pharmacopoeial monographs

Page 23 of 112

with the use of Pharmacopoeial Reference Standards and in case of non use of pharmacopoeial methods, I/We shall use methods that are validated as per ICH guidelines. 22. I/We shall undertake that I/We have valid Form 71and Form 72 of NABL Latest Assessment having relevant SCOPE of Accreditation for at least 30% of the drugs/dressings/vaccines quoted for testing. 23. I/we undertake that the decision of D(M)D regarding Inspection of Testing Facilities at Laboratory shall be final and will be binding on me and that I/we shall not represent against the decision of D(M)D in any forum.

Yours faithfully

(Signature of tenderer with stamp) (Authorized Signatory) Verification: The undertaking given above is true to my knowledge and belief and signed in presence of me on th day of ______month of the Year ______.

(Signature of Notary with Full Name, date and stamp)

Page 24 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS

Annexure-B

Date ______

UNDERTAKING

I/WE undersigned is /are authorized signatory/signatories of the Laboratory M/s ______address ______do here by undertake that:

1. The Laboratory is in this business in continuation from Year 2014. 2. The laboratory is not blacklisted from any Government organization/institution.

• If any information in the tender submitted by me is found incorrect/false at any time Tender is liable to be rejected.

Authorized signatory (With stamp)

Page 25 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS Annexure”C”

Mandate form

Beneficiary’s customer’s option to receive payment through e-payment 1. Beneficiary name 2. Beneficiary address 3. Beneficiary account no. 4. Account type (S.B. Account/ current account for cash credit) with code 10/11/13 5. 9 digit code number of the Bank & branch appearing on the MICR cheque issued by 6. Bank name 7. Bank name , Address, Telephone no. 8. IFSC (Indian financial service code) 9. Photocopy of cancelled cheque to confirm correctness of IFSC code and account no. Given in C & H

I, hereby, declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reason of incomplete or incorrect information given by me as above, I would not hold the user institution responsible.

Dated ______(______) Signature of the beneficiary/customer

Certified that the particulates furnished above are correct as per our records.

Bank’s stamp Date ______(______) Signature of the authorized/official

Page 26 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS Annexure”D”

BANK GUARANTEE FORM FOR PERFORMANCE SECURITY (At the time of award of contract) To Director (Medical) Delhi E.S.I CORPORATION

WHEREAS______(Name and address of the Bidder)(Hereinafter called the service provider) has undertaken, in pursuance of contract No. DMU-16/55/RC/Testing of Drugs/2016/CS Dated ______to provide Testing Services (herein after called “The contract”).

AND WHEREAS it has been stipulated by you in the said contract that the service provider shall furnish you with a bank guarantee by a scheduled commercial bank recognized by you for the sum specified therein as security for compliance with obligations in accordance with the contract;

AND WHEREAS we have agreed to give the service provider such a bank guarantee; NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, on behalf of the service provider, up to a total of Rs.50,000/-(Rupees Fifty Thousand only) ,and we undertake to pay you , upon your first written demand declaring the service provider to be in default under control and without cavil or argument, any sum or sums within the limits of (amount of guarantee)as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

We hereby waive the necessity of your demanding the said debt from the service provider before presenting us with the demand.

We further agree that no change or addition to or other modification of the terms of the contract to be performed there under or of any of the contract documents which may be made between you and the service provider shall in any way release us from any liability under this guarantee and we hereby waive notice of any such change, addition or modification.

This guarantee shall be valid up to 36 (Thirty Six) months from the date of award of Rate contract i.e. up to ______(indicate date). ……………………………………………………………. (Signature with date of the authorized officer of the bank)

………..…….………………………………………………… (Name & designation of officer) {(Seal ,Name& Address of the bank and address of the branch along with e-mail address of the issuing officer}

Page 27 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS Annexure-E

Lowest Rate Certificate (On Firm/Company Letter Head)

We hereby undertake that rates offered by me/us in the ESIC Rate Contract for Testing of Drugs are the lowest rates offered to any Government organization/Institution, and no other Government organization/Institution has been offered rates lower than those being offered herein. We further undertake that in case there is any downward revision, the same will be passed on to the ESI Corporation from the effective date during the currency of the contract and in case of failure to do so we are liable to be debarred from future ESIC Tender Enquiry for a further period of two years along with forfeiting the earnest money/security deposit.

For and behalf of the firm (Firm Name & Address)

Page 28 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS Annexure”F”

CHECK LIST OF THE DOCUMENTS [ONLINE/HARD COPY WHICHEVER APPLICABLE]:

1) Hard Copy of Original Demand Draft /Banker’s Cheque of Rs.25,000/-(Rupees Twenty Five Thousand only) as EMD in Favour of ESIC Fund Account No.1 payable at New Delhi. (Soft copy also to be uploaded). 2) Hard Copy of Affidavits as per clause 5, NB.- 5.1 (if applicable) under Instruction to bidders. (Soft copy also to be uploaded). 3) Scanned Copies of Tender Document, duly signed & stamped by authorized signatory. 4) Scanned copy of Valid Documents in support of Registration of GST/GST registration certificate. 5) Scanned copy of Valid License for carrying out “Testing Of Drugs & Dressings” issued from Statutory Body, Authorized by Government of India with Approval under Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with schedule annexed therein. 6) Scanned copy of Form 71& Form 72 of NABL Latest Assessment having relevant SCOPE of Accreditation for at least 30% of the drugs/dressings/vaccines quoted for testing. 7) Scanned copy of List of Government Institutions duly signed & stamped, to which Testing of Drugs & Dressing Services are provided by the Testing Laboratories on their letter head. 8) Scanned copy of Satisfactory performance certificate from at least Two (02) Government/Autonomous Institutions, duly signed & stamped by such institutes, of last two consecutive years on their letter heads, to whom such services were provided. 9) Scanned copy of Affidavit of the Laboratory{On Non-Judicial stamp paper of Rs.100/-(As per Annexure A)} 10) Scanned copy of Undertaking by the laboratory that the Laboratory is not Blacklisted from any Government Organization/Institution and is in this business in continuation from Year 2014 (As per Annexure B). 11) Scanned copy of Mandate Form as per Annexure-C. 12) Scanned copy of undertaking (signed and stamped by tender signing authority) that the quoted items have not been / are not being tested for any other organization at the rates lower than being quoted here (As per Annexure E). 13) Scanned copy of Financial report (Balance Sheet, Profit & Loss account Clearly indicating the turnover in Testing of Drugs/dressings/vaccines etc. of Rupees One Crore or above) of last three Financial years (i.e. 2014-15, 2015-16, 2016-17) duly audited by Chartered Accountant. 14) Scanned copy of Covering letter clearly indicating the list of enclosures(As per Annexure F). 15) Scanned copy of Any other Supportive documents.

Page 29 of 112

Re-e-Tender Enquiry No.: DMU-16/55/RC/Testing of Drugs/2016/CS Annexure ”S”

VII. List of Items

Group Name S.No. ITEM NO. Dosage Form ITEM NAME and DESCRIPTION

Group No.1 1. 5 CAPSULE Cap-:Omeprazole 20 mg. Cap-: Fungal Diastase(1 : 2000) 20mg,Lactic acid Group No.1 2. 27 CAPSULE bacillus 150 million spores Group No.1 3. 77 CAPSULE Cap-: Gemfibrozil 300mg. Group No.1 4. 97 CAPSULE Cap-: Fluoxetine 20mg. Group No.1 5. 164 CAPSULE Cap-: Amoxycillin 250mg. Cloxacillin 250 mg. Group No.1 6. 175 CAPSULE Each cap.to contain: Tetracycline 250mg. Group No.1 7. 179 CAPSULE Each cap / tab to contain: Doxycycline Hcl 100mg. Each caps. to contain: Chloramphenicol I.P.1% Group No.1 8. 211 CAPSULE inpliable gelatin caps.with elongated tip 9. 260 CAPSULE ALFA CALCIDOL CAP - Each cap to contain: Alfa calcidol Group No.1 0.25mcg. Group No.1 10. 266 CAPSULE Cap-: Vitamin A 6000 IU,Vitamin D 1000 IU Cap-: Ferrous Sulphate 150mg. (in S.R.form) ,Folic acid Group No.1 11. 268 CAPSULE 0.5mg Group No.1 12. 285 CAPSULE Each cap to contain: Cyclosporine 50mg. Group No.1 13. 287 CAPSULE Cap-: Hydroxy urea 500 mg. Group No.1 14. 316 CAPSULE Cap-: Lansoprazole 30mg. Cap- : Lecithine 350mg. Eqv. to 175mg. Of Essential Group No.1 15. 317 CAPSULE Phospholipid Each cap to contain :Fenofibrate ( Micronised ) 200 Group No.1 16. 367 CAPSULE mg. Group No.1 17. 383 CAPSULE Each cap./tab. to contain: Cycloserine I.P.250mg. Group No.1 18. 386 CAPSULE Each cap.. to contain: Indinavir 400mg. Group No.1 19. 390 CAPSULE Each cap. to contain: Rifampicin 600mg. VITAMIN CAP - Cap-: Thiamine 10mg., Riboflavin 8mg., Pyridoxine 3mg., Vit. B12 5mcg., Niacinamide 50mg., Group No.1 20. 450 CAPSULE Calcuim Pantothenate 15mg., Folic Acid 1mg., Ascorbic Acid 125mg. Group No.1 21. 504 CAPSULE Cap-: Imatinib Mesylate 100mg. Group No.1 22. 523 CAPSULE Eachcap. to contain: Calcium Dobesilate 500mg. Each soft gelatin cap. to contain: Tizanidine Hcl. Group No.1 23. 524 CAPSULE I.P.2mg. +Ibuprofen I.P.400mg. Cap-: Streptococcus faecalis 30 million, Clostridium Group No.1 24. 534 CAPSULE butyricum 2 million, Bacillus mesentericus 1 million, Lactic acid bacillus sporogenes 50 mlllion.

Page 30 of 112

Cap-: Dextropropoxephen 65mg., Acetaminophen Group No.1 25. 584 CAPSULE I.P.400mg. CALCUIM (ABSORBABLE) CAP - Each cap to contain: Elemental Calcium 150mg. (in the form of Calcium Group No.1 26. 595 CAPSULE Hydroxide and Calcium Oxide and pretreated with heated algae) Cap-s: Dicyclomine Hcl I.P. 10 mg. Dextro- Group No.1 27. 1018 CAPSULE propoxyphene Hcl 65 mg ,Acetaminophen I.P. 400 mg. ENZYME CAP - Each cap to contain: Pepsin (1:3000) Group No.1 28. 1029 CAPSULE 12.5 mg., Fungal Diastase (1:2000) 18.75 mg. THEOPHYLLINE CR CAP - Each CR cap. to contain Group No.1 29. 1038 CAPSULE :Theophylline anhydrous 200 mg. Cap- :Citrous Bioflavonoid compound 150 mg., Ascorbic Acid 75 mg., Menadione (Vit.K) 0.66 mg., Group No.1 30. 1077 CAPSULE Ferrous Gluconate 67 mg., Tribasic Calcium Phosp. 144.43 mg. Group No.1 31. 1083 CAPSULE Cap-: Tramadol Hcl. 50 mg. Group No.1 32. 1094 CAPSULE Each cap/tab. To contain : Piroxicam 20 mg. Group No.1 33. 1099 CAPSULE Cap- : Indomethacin 25 mg. Group No.1 34. 1100 CAPSULE Each SR Capsule to contain : Indomethacin 75 mg. Group No.1 35. 1179 CAPSULE Cap- : Chloramphenicol 250 mg. Group No.1 36. 1193 CAPSULE Each Cap./ Tab. To contain: Cefadroxil 500mg. Group No.1 37. 1291 CAPSULE Cap-: Vit. A 50,000 I.U. Each Timed release Cap. to contain : Ferrous Fumarate Group No.1 38. 1295 CAPSULE 200mg., Cyancobalamin 15mcg., Folic Acid 1.5mg. MUTIVITAMIN+ZINC CAP - Each cap to contain: Zinc sulfate Monohydrate 61.8mg. (eqv. to 22.5mg. Of elemental Zinc). Vit. B1-10mg., Vit. B6-2mg., Vit.B12- Group No.1 39. 1307 CAPSULE 5mcg., Ca. Pantothenate 12.5mg., Vit. E Acetate 15mg., Vit. C 150mg., Nicotinamide 50mg. And Vit. B2- 10mg. Each capsule to contain: Ferrous Fumerate 350 mg. Group No.1 40. 1308 CAPSULE Vit. C 150 Mg., Vit B12 - 15 mcg., Folic Acid 1.5 mg. Cap-: Ferrous Fumerate 150 mg., L-Histidine Hcl 4 mg., L-Lysine Hcl 25 mg., Glycine 10 Mg. Riboflavin 3 mg. Group No.1 41. 1310 CAPSULE Thiamine mononitrate 5 mg., Pyridoxin Hcl 1.5 mg. Cynacobalamin 2.5 mcg., Folic Acid 0.5 mg.Ascorbic Acid 40 mg.

Page 31 of 112

AMINO ACID + VITAMIN CAP - Each cap to contain : L- Leucine 18.3 mg., L-Isoleucine 5.9 mg., L-Lysine Hydrochloride 25.0 mg., L-Phenylalanine 5.0 mg., L- Valine 6.7 mg., L-Tryptophan 5.0 mg., DL-Methionine 18.4 mg., 5-Hydroxy Anthranilic Acid Hydrochloride Group No.1 42. 1315 CAPSULE 0.2 mg., Vit.A concentrate 2500 IU, Vit D3 200 IU, Thiamine Mononitrate 5.0 mg., Vit.B2 3.0 mg.Nicotinamide 25 mg., Vit. B6 1.5 mg., Folic Acid 0.75 mg., Calcium Pantothenate IP 5.0 mg., Vit. B12 2.5 mcg., Vit. C 40.0 mg., Vit. E acetate 7.5 IU, L- Threonine 4.2 mg. Group No.1 43. 1347 CAPSULE Each cap to contain: Thiocolchicoside 4mg. Group No.1 44. 1388 CAPSULE Cap-: Mecobalamine 0.5mg, Alpha Lipoic Acid 100mg ANTI OXIDANT CAP - Each cap to contain: Natural Betacarotene with other mixed carotenoids 1000mcg, Spirulina 175mg, Vitamin A Conc. (oily form) 5000IU, Vitamin E (from natural source) 25IU, Pyridoxine HCL Group No.1 45. 1402 CAPSULE 3mg, Ascorbic Acid 75mg, L-Cysteine HCL 46.37mg, L- Glutamic Acid 40.0mg, Glycine 25mg, Zinc Sulphate 27.45mg, Mag. Sulphate 11.5mg, Maganese Sulphate 1.12mg, Copper Sulp. 0.8mg, Chromium Polynicotinate 0.2mg, Sod. Selenite 0.1mg. Each tabs/ caps. to contain: Thiocolchicoside I.P./ Group No.1 46. 1418 CAPSULE Fr.Ph. 8mg Group No.1 47. 1467 CAPSULE Cap-: Testosterone Undecanoate I.P.40mg LACTOBACILLUS CAP - Each cap to contain: 1billion Group No.1 48. 1494 CAPSULE C.F.U of Lactobacillus Rhamnosus GR-1, Lactobacillus Reuteri RC-14 Cap. Rabeprazole sodium 20mg I.P. Mosapride Citrate Group No.1 49. 1496 CAPSULE 15mg sustained release Group No.1 50. 1500 CAPSULE Cap-: Fenoverine 100mg Each cap.to contain: Streptocoocus Faecalis T - 110 JPC 60 Million, Closlridium Butyricum TO-A 4 Million Group No.1 51. 1507 CAPSULE Bacillus Mesentericus TO-A JPC 2 Million, Lactic Acid Bacillus 100 Million. (Lactobacillus Sporogenes) Cap- :Camphor I.P./B.P./USP 25mg Eucalyptol Group No.1 52. 1527 CAPSULE I.P./B.P./USP 125 mg Chlorothymol 5 mg menthol I.P. 55mg ,terpineol I.P. 120mg Group No.1 53. 1584 CAPSULE Cap-: Natural Micronised Progesterone I.P. 100 mg Group No.1 54. 1653 CAPSULE Cap-: Disopyramide I.P./B.P./USP 100mg. Group No.1 55. 1720 CAPSULE Each Caps. to contain: Isotretenoin 20mg Group No.1 56. 1721 CAPSULE Each Caps. to contain: Acitretin 25mg Group No.1 57. 1724 CAPSULE Each Caps. to contain: Orlistat 120 mg Group No.1 58. 1733 CAPSULE Cap-: Nilotinib 150mg

Each capsule contains Group No.1 59. 1744 CAPSULE Acerbrophylline Caps. -100mg -10Caps.

Page 32 of 112

CALCIUM CAP. - Each cap to contain: Elemental Calcium 150mg (In the form of Calcium hydroxide & Group No.1 60. 1795 CAPSULE calcium oxide pretreated with heated algae), zinc sulphate monohydrate equivalent to elemental zinc- 7.5 mg, Calcitriol -0.25 mcg Cap. NILOTINIB 200mg Group No.1 61. 1810 CAPSULE Each Cap. Contains : Nilotinib 200mg Group No.1 62. 1833 CAPSULE SILYMARIN CAP - Each cap to contain : Silymarin 70mg PRE & PROBIOTIC CAP - Each cap to contain: Group No.1 63. 1834 CAPSULE Lactobacillus Plantarum Lp299v 10 billion CFU PRE & PROBIOTIC CAP - Each cap to contain :2 billion Group No.1 64. 1835 CAPSULE spores of polyantibiotic resistant Bacillus Claussi EPL & ETOPHYLLINE CAP - Each cap to contain: Essential Phospholipids (EPL substances) 300 mg, Group No.1 65. 1837 CAPSULE Hydroxyethyl Theophylline (Etophylline ) BP. 50 mg Excipients QS. Approved colour used in Empty capsule shell. RIVASTIGMINE CAP - Each cap to contain: Group No.1 66. 1875 CAPSULE Rivastigmine 1.5mg (as Hydrogen Tartrate) 67. 1876 CAPSULE RIVASTIGMINE CAP - Each cap to contain: Group No.1 Rivastigmine 3 mg (as Hydrogen Tartrate) CEFIXIME AND PRE&PROBIOTIC CAP - Cap-: Cefixime IP as Trihydrate equivalent to Anhydrous Cefixime 200 mg and Each Inner cap to contain: Group No.1 68. 1902 CAPSULE Sterptococcus Faecalis T-110 JPC 60million Clostridium Butyricum TO-A 4 million Bacillus MesentericusTO-AJPC 2 million Lactic Acid Bacillus 100million CLOFAZIMINE CAP - Each cap to contain: Clofazimine Group No.1 69. 1910 CAPSULE 100mg MULTI VITAMIN CAP - Each hard gelatin cap to contain: Ferrous Fumarate I.P eqv. to Elemental Iron 30 mg, Folic Acid I.P. 250 mcg, Zinc Sulphate Monohydrate B.P. eqv. to Zinc 20 mg , Thiamine Group No.1 70. 1958 CAPSULE Mononitrate (Vit. B1) I.P. 1.2 mg Riboflavin (Vit. B2) I.P. 1.2 mg, Niacinamide I.P.10 mg, Pyridoxine Hydrochloride (Vit. B6) I.P. 1 mg , Cyanocobalamin (Vit. B12) I.P. 2.5 mcg Ascorbic Acid coated (Vit. C) I.P. 40 mcg

Page 33 of 112

MULTI VITAMIN WITH AMINO ACID CAP - Each cap to contain: L-Arginine Hydrochloride USP 13.28mg, L- Histidine Hydrochloride H20 BP 3.71mg, L-Isoleucine USP 5.9mg, L-Leucine USP 18.3mg, L-Lysine Hydrochoride USP 25.0mg, DL-Methionine BP 18.4mg, L-Phenylalanine USP 5mg, L-Threonine USP 4.2mg, L-Tryptophan USP 5mg, L-Valine USP 6.7mg, 5-Hydroxy Anthranilic Acid HCL 0.2mg, Group No.1 71. 1959 CAPSULE Cholecalciferol IP 200 IU, Nicotinamide IP 25mg, Pyridoxine Hydrochloride IP 1.5mg, Methylcobalamin 500mcg, Biotin USP 30mcg, Folic Acid IP 0.75mg, Copper Sulphate BP 4mg, Ferrous Sulphate IP 20.5mg, Magnesium Sulphate IP 7.43mg, Manganese Sulphate BP 1.4mg, Potassium Iodide IP 0.1mg, Sodium Selenite BP 10.0mcg, Zinc Sulphate IP 15mg, Chromium Polynicotinate 200mcg ANTI OXIDANT CAP - Each cap to contain: Methylcobalamin 500mcg, Folic Acid IP 1.5mg, Zinc Sulphate IP 25mg, Chromium Polynicotinate 200mcg, Selenium 65mcg as Sodium Selenite USP Pyridoxine Hcl IP 1.5mg, Inositol 100mg, Alpha Lipoic Acid USP Group No.1 72. 1961 CAPSULE 50mg Each Inner capsule contains: Streptococcus Faecalis T-110 JPC 30 million Clostridium Butyricum T-OA 2 million Bacillus Mesentericus T-OA JPC 1 million Lactic Acid Bacillus 50 million (Lactobacillus Sporogenes) LENALIDOMIDE CAP - Each cap to contain Group No.1 73. 1980 CAPSULE Lenalidomide 5mg LENALIDOMIDE CAP - Each cap to contain Group No.1 74. 1981 CAPSULE Lenalidomide 10mg 75. 1985 CAPSULE TEMOZOLOMIDE CAP - Each cap to contains : Group No.1 Temozolomide 100mg 76. 2053 CAPSULE Each Hard gelatin capsule contains: Rabeprazole Group No.1 Sodium IP 20 mg (as enteric coated pellets) Domperidone IP 30 mg (as sustained release pelletes) 77. 2062 CAPSULE Each cap contains : 143 mcg indacaterol maleate eqv. to 110 mcg Group No.1 indacaterol & 63 mcg Glycopyrronium Bromide eqv to 50 mcg Glycopyrronium. 78. 2080 CAPSULE Dabigatran Cap: Each Cap to contains: Dabigatran Group No.1 Etexilate 110 mg 79. 2110 CAPSULE Each Cap Contains: Calcium Carbonate 500mg, Calcitriol IP 0.25mcg, Mecobalamin 1500mcg, Group No.1 Eicosapentaenoic Acid 90mg, Docosahexaenoic Acid 60mg, Folic Acid 400mcg, Disodium Tetraborate Eq. to Elemental Boron 1.5mg 80. 2111 CAPSULE Each hard gelatin capsule contains: Group No.1 Calcium 300 mg (In the form of Calcium hydroxide and calcium oxide pretreated with heated algae)

Page 34 of 112

Cholecalciferol IP 1000 IU

81. 2114 CAPSULE EACH SOFT GELATIN CAPSULE CONTAINS : GINSENG DRY EXTRACT 43.5 MG, NIACINAMIDE 25 MG, VITAMIN B6 1 MG, MECOBALAMIN 500 MCG, VITAMIN D3 200 IU,FOLIC ACID 0.15 MG DIBASIC CALCIUM PHOSPHATE EQ. TO ELEMENTAL CALCIUM 75 MG & ELEMENTAL PHOSPHOROUS 58 MG FERROUS FUMARATE 30 MG ZINC SULPHATE MONOHYDRATE 10 MG MAGNESIUM Group No.1 SULPHATE EQ. TO ELEMENTAL MAGNESIUM 3 MG,MANGANESE SULPHATE EQ. TO ELEMENTAL MANGANESE 0.5 MG, COPPER SULPHATE PENTAHYDRATE EQ. TO ELEMENTAL COPPER 0.5 MG,POTASSIUM IODIDE EQ. TO ELEMENTAL IODINE 0.1 MG, POTASSIUM SULPHATE EQ. TO ELEMENTAL POTASSIUM 2 MG

82. 2117 CAPSULE Each hard gelatin capsule contains Alectinib 150 mg Group No.1 equivalent to Alectinib hydrocholoride 161.3 mg Group No.1 83. 2127 CAPSULE Each hard gelatin capsule to contains: Ceritinib 150mg 84. 2138 CAPSULE Crizotinib Capsules Group No.1 Each Hard Geletin Cap. contains : Crizotinib 250mg 85. 2143 CAPSULE Palbociclib Capsules Group No.1 Each hard gelatin cap contains : Palbociclib 125mg 86. 2150 CAPSULE Each Delayed Release capsules contains: dimethyl Group No.1 fumarate 240mg Each T.R. cap. to contain: Iso-sorbide Dinitrate Group No.1 87. 1064a CAPSULE I.P.20mg. Each T.R. cap. to contain: Iso-sorbide Dinitrate Group No.1 88. 1064b CAPSULE I.P.40mg. Each capsule to contain : Vit. E (alpha Tocopherol Group No.1 89. 1302b CAPSULE acetate) 200mg Each capsule to contain : Vit. E (alpha Tocopherol Group No.1 90. 1302c CAPSULE acetate) 400mg Group No.1 91. 1335b CAPSULE Cap- : Cyclosporine 25 mg. Group No.1 92. 160a CAPSULE Cap-: Ampicillin Trihydrate eqv. to Ampicillin 250mg. Group No.1 93. 160b CAPSULE Cap-: Ampicillin Trihydrate eqv. to Ampicillin 500mg. Cap-: Cephalexin Monohydrate eqv. to Cephalexin Group No.1 94. 169a CAPSULE 250mg. Cap-: Cephalexin Monohydrate eqv. to Group No.1 95. 169b CAPSULE Cephalexin500mg. Group No.1 96. 187a CAPSULE Cap-: Rifampicin 150mg. Group No.1 97. 187b CAPSULE Cap-: Rifampicin 450mg. Page 35 of 112

Group No.1 98. 319a CAPSULE Cap-: Ribavirin 100mg. Group No.1 99. 319b CAPSULE Cap-: Ribavirin 200mg. Group No.1 100. 333a CAPSULE Cap-: Zidovudine I.P. 100mg. Group No.1 101. 333b CAPSULE Cap-: Zidovudine 300mg. Group No.1 102. 373a CAPSULE Each cap to contain : Doxepin Hcl. 25mg. Group No.1 103. 373b CAPSULE Each cap to contain : Doxepin Hcl. 75mg. Group No.1 104. 51b CAPSULE Each caps. to contain: Nifedipne 10mg.

Group No.1 105. 234 DRESSING Elastic Adhesive Bandage Roll size 8cm x 4 mt. 106. 235 DRESSING HANDLOOM COTTON GAUZE - Handloom Cotton Group No.1 Gauze Absorbent (ISI marked) Size 18mx60cm 107. 236 DRESSING HANDLOOM COTTON BANDAGE CLOTH - Group No.1 Handloom Cotton Bandage Cloth (ISI marked) size 20 m X 100 cm. 108. 237 DRESSING COTTON WOOL ABSORBENT - Cotton Wool Group No.1 Absorbent 500 gm POVIDONE IODINE DRESSING - Containing: Povidone Group No.1 109. 484 DRESSING Iodine 10% sterile dressing FERACRYLUM 3% DRESSING - Containing: Feracrylum Group No.1 110. 1787 DRESSING 3% Gauze Dressing Sterile, Cotton dressing impregnated with water soluble base. PARAFFIN GAUZE - Each piece to contain: Paraffin Group No.1 111. 1956 DRESSING Guaze 10cm X 10cm HANDLOOM COTTON ROLLED BANDAGE - Handloom Group No.1 112. 1274a DRESSING Cotton Rolled Bandage (ISI Marked) Roll of 6 cm. X 4 m. HANDLOOM COTTON ROLLED BANDAGE - Handloom Group No.1 113. 1274b DRESSING Cotton Rolled Bandage (ISI Marked) Roll of 10 cm. X 4 m. PLASTER OF PARIS BANDAGE - Plaster of Paris Group No.1 114. 1276a DRESSING Bandage Roll of 10 cm. X 2.7 m. PLASTER OF PARIS BANDAGE - Plaster of Paris Group No.1 115. 1276b DRESSING Bandage Roll of 15 cm. X 2.7 m. COLLAGEN - Contain:Collagen Membrane in Dry Form Group No.1 116. 1626a DRESSING 5X5CM COLLAGEN - Contain:Collagen Membrane in Dry Form Group No.1 117. 1626b DRESSING 10X10CM COLLAGEN - Contain:Collagen Membrane in Dry Group No.1 118. 1626c DRESSING Form10X20CM COLLAGEN - Contain:Collagen Membrane in Dry Form Group No.1 119. 1626d DRESSING 15X30CM COLLAGEN - Contain:Collagen Absorbant Dressing Group No.1 120. 1627a DRESSING 10X10CM COLLAGEN - Contian:Collagen Absorbant Dressing Group No.1 121. 1627b DRESSING 10X20CM

Page 36 of 112

COLLAGEN - Contian:Collagen Absorbant Dressing Group No.1 122. 1627c DRESSING 15X30 CM

Group No.1 123. 239a DRESSING Plaster of paris powder 25Kg

Group No.1 124. 239b DRESSING Plaster of paris powder 50Kg

ADHESIVE TAPE - Adhesive Tape 5cmx5m, Group No.1 125. 452a DRESSING Hypoallergenic extra porous ADHESIVE TAPE - Adhesive Tape 7.5cmx5m, Group No.1 126. 452b DRESSING Hypoallergenic extra porous ADHESIVE TAPE - Adhesive Tape 10cmx5m, Group No.1 127. 452c DRESSING Hypoallergenic extra porous PAPER ADHESIVE TAPE - Paper Adhesive Tape Group No.1 128. 546a DRESSING Hypoallergenic with Acrylate Adhesive 2.5cmx9.14m PAPER ADHESIVE TAPE - Paper Adhesive Tape Group No.1 129. 546b DRESSING Hypoallergenic with Acrylate Adhesive 5cmx9.14m COTTON CREPE BANDAGE - Cotton Crepe Bandage Group No.1 130. 585a DRESSING (Stretched, BPC/ ISI marked) Roll of 8 cm. X 4 m. COTTON CREPE BANDAGE - Cotton Crepe Bandage Group No.1 131. 585b DRESSING (Stretched, BPC / ISI marked) Roll of 10 cm. X 4 m. COTTON CREPE BANDAGE - Cotton Crepe Bandage Group No.1 132. 585c DRESSING (Stretched, BPC / ISI marked) Roll of 15 cm. X 4 m. 133. 210 DROPS CHLORAMPHENICOL EYE DROP - Each vial to Group No.1 contain: Chloramphenicol 0.5%w/v. Group No.1 134. 212 DROPS Containing : Gentamycin 0.3% w/v Group No.1 135. 213 DROPS Containing: Ciprofloxacin 0.3%w/v. Group No.1 136. 216 DROPS Each ml. to contain: Framycetin sulphate 5mg. Group No.1 137. 218 DROPS Containing : Norfloxacin 0.3% w/v. Group No.1 138. 219 DROPS Each vial to contain: Oxymetazoline 0.05% w/v. Group No.1 139. 220 DROPS Each vial to contain: Xylometazoline 0.1%w/v. Containing: Dexamethasone Sodium Phosphate I.P. Group No.1 140. 312 DROPS 0.1 % , Chloramphenicol I.P.1.0 %, Chlorobutanol I.P.0.5 % Each vial. to contain: Boric Acid 1.25%, Sodium Chloride 0.05%, Chlorbutanol 0.05%, Naphazoline Hcl. Group No.1 141. 389 DROPS 0.056%, Zinc Sulphate 0.12% Chlorpheniramine Maleate 0.01%. Containing : Sodium Chloride 0.65%, Benzalkonium Group No.1 142. 392 DROPS Chloride0.001 %, Phenyl mercuric acetate 0.002 %. Containing : Polyvinyl Alcohol 1.4%, Povidone 0.6%, Group No.1 143. 439 DROPS Benzalkonium Chloride 0.01% Containing : Chloramphenicol I.P.5%, Lignocaine HCL Group No.1 144. 440 DROPS I.P. 2%, Beclomethasone Dipropionate I.P. 0.025%, Clotrimazole I.P. 1%, Propylene Glycol I.P. q.s. Containing: Ciprofloxacin 0.3%, Dexamethasone 0.1%, Group No.1 145. 482 DROPS Benzalkonium Chloride 0.01%

Page 37 of 112

Containing: Nephazoline Hydrochloride 0.1%, Group No.1 146. 483 DROPS Chlorpheniramine Maleate I.P.0.01%, Methyl- Cellulose I.P.0.1%,Benzalkonium Chloride I.P. 0.01%, Containing:4- Carboxymethylamino-4, Aminodiphenyl Group No.1 147. 533 DROPS sulphone 0.84%, dihydroxymethyl carbamide 0.42%, Dibucaine 1.1%. Group No.1 148. 562 DROPS Containing: Tropicamide 0.8% +Phenyl Ephrine Hcl 5% Group No.1 149. 564 DROPS Containing: Prednisolone Acetate I.P.1% Group No.1 150. 565 DROPS Containing: Betamethasone Sodium Phosphate 0.1% FLURBIPROFEN EYE DROPS - Containing: Flurbiprofen Group No.1 151. 1212 DROPS 0.03% w/v Each ml. to contain : Framycetin sulphate 5 mg , Group No.1 152. 1215 DROPS Dexamethasone Sod. Metabenzosulphonate 0.5 mg, Gramicidin 0.05mg Each ml to contain:Polymyxin B Sulphate Group No.1 153. 1217 DROPS I.P./U.S.P.5000 units Neomycin Sulphate I.P.1700 units Gramicidin 25 units 154. 1219 DROPS EYE DROPS - Containing: Dexamethasone Sod. Group No.1 Phosphate 0.1% Neomycin Sulphate 0.5% Benzalkonium Chloride in isotonic soln. 0.02% 155. 1220 DROPS BETAXOLOL EYE DROP - Each vial to contain: Betaxolol Group No.1 Hcl eqv. to Betaxolol 0.5% w/v containing :Gentamycin sulphate I.P. eqv. to 0.3% w/v Group No.1 156. 1221 DROPS Gentamycin base Betamethasone Sod. Phosphate I.P.0.1% w/v Benzalkonium soln. I.P.0.04% w/v Group No.1 157. 1222 DROPS Containing : Tropicamide I.P.1% Group No.1 158. 1223 DROPS Containing : Cyclopentolate I.P./U.S.P.1% Containing : Boric Acid I.P.1.80% Sod. Chloride Group No.1 159. 1225 DROPS I.P.0.85% Naphazoline Hcl I.P.0.02% Zinc sulphate I.P.0.10% Phenyl Ethyl Alcohol I.P.0.50% EYE DROPS - Containing : Hydroxypropyl Methyl Cellulose 0.7%, Borax 0.19%, Boric Acid 0.19%, Sod. Group No.1 160. 1226 DROPS Chloride 0.45% Pot. Chloride 0.37%, Benzalkonium Chloride 0.01% Containing : Atropine sulphate I.P.1% Prednesolone Group No.1 161. 1229 DROPS I.P.0.25% Chlorobutanol I.P. 0.5% WAX SOFTNER EAR DROPS - Containing : Para Group No.1 162. 1234 DROPS dichlorobenzene 2% w/v Benzocaine 2.7% w/v Chlorbutol 5% Turpentine Oil 15% w/v Group No.1 163. 1236 DROPS Containing: Xylometazoline 0.05% w/v Group No.1 164. 1237 DROPS Containing : Oxymetazoline 0.025% w/v IRON & FOLIC ACID DROP - Each ml to contain :Colloidal Iron eqv. to elemental iron 25 mg., Lysine Group No.1 165. 1313 DROPS Hydrochloride 200 mg.,Vit. B12- 5 mcg., Folic Acid 200 mcg. 166. 1318 DROPS GLYCINE SOLN - Each to contain: Glycine 1.5% (1.5 gm. Group No.1 / 100 ml.) Page 38 of 112

Containing: Naphazoline 0.01%, Benalkonium I.P. Group No.1 167. 1363 DROPS 0.01% 168. 1382 DROPS TOBRAMYCIN EYE DROP - Each vial to contain: Group No.1 Tobramycin 0.3% w/v Group No.1 169. 1383 DROPS Containing: Oflaxacin 0.3% w/v 170. 1432 DROPS OLOPATADIN EYE DROP - Each vial to contain: Group No.1 Olopatadin 1.0mg Containing: Chloramphenicol I.P.4mg + polymyxin B Group No.1 171. 1433 DROPS Sulphate I.P./B.P./U.S.P.5000 IU+ Dexamethasone Sulphate I.P.1mg 172. 1434 DROPS AZELASTINE EYE DROP - Each vial to contain: Group No.1 Azelastine 0.05% w/v Phenylephrine 0.12%+Naphazoline 0.05%+Menthol Group No.1 173. 1435 DROPS 0.005%+ Camphor 0.01% w/v POLYMYXIN, NEOMYCIN & HC EAR DROPS - Group No.1 174. 1463 DROPS Containing: Polymyxin B sulph 10000 IU, Neomycin Sulphate 3400 IU, Hydrocortisone 10mg w/w Group No.1 175. 1594 DROPS EYE DROPS - Containing: Gatifloxacin Soln 0.3% w/v LEVOFLOXACIN EYE DROP - Containing: Levofloxacin Group No.1 176. 1595 DROPS soln. 0.5% MOXIFLOXACIN EYE DROP - Containing: Moxifloxacin Group No.1 177. 1597 DROPS soln. 0.5% w/v MOXIFLOXACIN + PREDNISOLONE EYE DROP - Each Group No.1 178. 1598 DROPS vial to contain: Moxifloxacin 0.5%, Prednisolone Acetate 1%, OFLOXACIN+PREDNISOLONE EYE DROP - Containing: Group No.1 179. 1600 DROPS Ofloxacin 0.3% ,Prednisolone Acetate 1.0% DORZOLAMIDE+TIMOLOL EYE DROP - Each vial to Group No.1 180. 1601 DROPS contain: Dorzolamide 2% ,Timolol I.P. 0.5% 181. 1602 DROPS TRAVOPROST EYE DROP - Each vial to contain: Group No.1 Travoprost 0.004% Group No.1 182. 1603 DROPS Containing: Cycloserine I.P. 0.02% 183. 1604 DROPS NATAMYCIN EYE DROP - Each vial to contain: Group No.1 Natamycin I.P./B.P./USP 0.5% w/v TOBRAMYCIN+FLUOROMETHOLONE EYE DROP - Each Group No.1 184. 1606 DROPS vial to contain: Tobramycin sulphate 0.3%w/v, Fluorometholone 0.1% w/v Sterile aqueous base q.s. 185. 1607 DROPS LATANOPROST EYE DROP - Containing: Latanoprost Group No.1 50mcg, Benzalkonium Chloride 0.01% w/v Aqueous Buffered Vehicle q.s SODIUM CHLORIDE 5% EYE DROP - Each vial to Group No.1 186. 1781 DROPS contain: Sodium Chloride 5%. 187. 1911 DROPS CROMOLYN EYE DROP - Each ml to contain : Cromolyn Group No.1 sodium 40mg (4%), Benzalkonium chloride 0.01% (pH4 -7)

Page 39 of 112

188. 1912 DROPS BESIFLOXACIN EYE DROP - Each ml to contain: Besifloxacin 0.6% (6mg/ml), Excepients: Polycarbophil, Group No.1 Mannitol, Poloxamer 407, Sodium Chloride, Edetate Disodium Dihydrate, Sodium Hydroxide and water for injection FLUOROMETHOLONE EYE DROP - Each ml to contain : Group No.1 189. 1913 DROPS Fluorometholone 0.1% ATROPINE , CHLORAMPHENICOL EYE DROP - Each vial to contain:Atropine Sulphate 1% w/v, Group No.1 190. 1920 DROPS Chloramphenicol 0.5% w/v, Dexamethasone sodium phosphate 0.1% w/v 191. 1921 DROPS BRIMONIDINE EYE DROP - Each vial to contain: Group No.1 Brimonidine Tartrate 0.15% w/v BRIMONIDINE & TIMOLOL EYE DROP - Each vial to Group No.1 192. 1922 DROPS contain:Brimonidine 0.15% , Timolol 0.5% CARBOXY METHYL CELLULOSE EYE DROP - Each ml to Group No.1 193. 1923 DROPS contain: Sodium Carboxy methyl cellulose 5mg 194. 1924 DROPS DORZOLAMIDE EYE DROP - Each vial to contain: Group No.1 Dorzolamide 2% TRAVOPROST & TIMOLOL EYE DROP - Each vial to Group No.1 195. 1925 DROPS contain: Travoprost 0.004%, Timolol 0.5% HYDROXYPROPYLMETHYLCELLULOSE EYE DROP - Each Group No.1 196. 1927 DROPS vial to contain: Hydroxypropylmethylcellulose -0.3% 197. 1929 DROPS PROPARACAINE EYE DROP - Each vial to contain: Group No.1 Proparacaine HCL USP 0.5%, Chlorbutol IP 0.5% PROPARACAINE EYE DROP - Each vial to contain: Group No.1 198. 1930 DROPS Proparacaine 0.5% LIDOCAINE EAR DROP - Each vial to contain: Lidocaine BP 1.73% w/v, Clotrimazole IP 1.00% w/v, Ofloxacin IP Group No.1 199. 1934 DROPS 0.30% w/v, Beclomethasone Diapropionate Drops IP 0.025% w/v, Propylene Glycol & glycerin q.s. 200. 2097 DROPS Bepotastine Besilate Ophthalmic Solution 1.5% w/v Each ml contains: Bepotastine Besilate 15 mg, Group No.1 Benzalkonium Chloride IP 0.01% w/v, (As preservative) Sterile aqueous vehicle QS 201. 2099 DROPS Bimatoprost Opthalmic Solution 0.01% Each vial Group No.2 Contains ( Bimatoprost Equivalent to Bimatoprost 0.01% 3 ml vial 202. 2101 DROPS Lubricating Eye Drop- Each vial to contain: Povidone Group No.2 20mg/ml, preservative free, Phosphate free 203. 2102 DROPS Ketrolac Tromethamine Opthalmic Solutions Each Ml Group No.2 contains - Ketrolac Tromethamine IP-0.45% Group No.2 204. 1214a DROPS Containing: Homatropine Hydrobromide 1% HOMATROPINE EYE DROPS - Containing: Homatropine Group No.2 205. 1214b DROPS Hydrobromide 2% Group No.2 206. 1216a DROPS Containing: Phenylephrine Hcl I.P./B.P.5% Group No.2 207. 1216b DROPS Containing: Phenylephrine Hcl I.P./B.P.10% Page 40 of 112

TIMOLOL EYE DROP - Each ml to contain : Timolol Group No.2 208. 1218a DROPS Maleate 3.4 mg. (eqv. to Timolol 2.5 mg.) TIMOLOL MALEATE EYE DROPS - Each ml. to contain : Group No.2 209. 1218b DROPS Timolol Maleate 6.8 mg. (eqv. to Timolol 5.0 mg.) SULPHACETAMIDE EYE DROP - Each vial to contain: Group No.2 210. 209a DROPS Sulphacetamide Sod. 10%w/v. SULPHACETAMIDE EYE DROP - Each vial to contain: Group No.2 211. 209b DROPS Sulphacetamide Sod.20%w/v. Group No.2 212. 215a DROPS Containing : Pilocarpine Nitrate I.P.1% w/v PILOCARPINE EYE DROP - Each vial to contain: Group No.2 213. 215b DROPS Pilocarpine Nitrate 2% 214. 1611 DYE TRYPAN BLUE DYE - Each pkt to contain: Trypan Blue Group No.2 Dye 215. 1345 ENEMA LAXATIVE ENEMA - Each bot to contain: Glycerin Group No.2 I.P.15%, Sodium Chloride I.P.15% Group No.2 216. 455 FLUID Containing: Haemo Dialysis Fluid PERITONEAL DIALYSIS FLUID - Each to contain: Group No.2 217. 456 FLUID Peritoneal Dialysis fluid LOW CALCIUM CAPD - Each to contain: CAPD Bag 7.5% Group No.2 218. 1456 FLUID of lcodextrin with asymmetrical Y Connector 219. 1798 FLUID NORMAL SALINE INJ(IV FLUIDS) - Each to contain: Group No.2 Normal Saline Self Collapsible IV Fluid Bag FLUIDS - Each 100 ml to contain: Invert Sugar 10 g, Group No.2 220. 1800 FLUID Water for Injection q.s.

FLUIDS - Each 100 ml to contain: Invert Sugar 10 g, Group No.2 221. 1801 FLUID Sodium Chloride I.P. 0.9 g, water for injection q.s. 222. 1964 FLUID TRIPLE CHAMBER BAG - Each to contain: Triple Chamber Bag with Lipid Emulsion (80% Olive Oil & Group No.2 20% Soya Oil), Amino Acids, Glucose and Electrolytes separated by peel seals for Peripheral intravenous 223. 1965 FLUID TRIPLE CHAMBER BAG - Each to contain: Triple Chamber Bag with Lipid Emulsion (80% Olive Oil & Group No.2 20% Soya Oil), Amino Acids, Glucose and Electrolytes separated by peel seals for Central Intravenous. 224. 2035 FLUID FLUCONAZOLE 200MG IV INJ - Each 100ml to Group No.2 contain : Fluconazole 200mg IV TRIPLE CHAMBER BAG - Each to contain: Triple Chamber bag with Lipid Emulsion ( 80% Olive oil Group No.2 225. 2051 FLUID & 20% Soya oil) Amino Acids, Glucose and Electrolytes seperates by peel seals for central intravenous PERITONEAL DIALYSIS FLUIDS 1.5% - Each 100ml to Group No.2 226. 1409a FLUID contain: Dextrose Anhydrous 1.5gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg

Page 41 of 112

PERITONEAL DIALYSIS FLUIDS 1.5% - Each 100ml to Group No.2 227. 1409b FLUID contain: Dextrose Anhydrous 1.5gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg PERITONEAL DIALYSIS FLUIDS 2.5% - Each 100ml to Group No.2 228. 1410a FLUID contain: Dextrose Anhydrous 2.5gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg PERITONEAL DIALYSIS FLUIDS 2.5% - Each 100ml to Group No.2 229. 1410b FLUID contain: Dextrose Anhydrous 2.5gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg PERITONEAL DIALYSIS FLUIDS 4.25% - Each 100ml to Group No.2 230. 1411a FLUID contain: Dextrose Anhydrous 4.25gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg PERITONEAL DIALYSIS FLUIDS 4.25% - Each 100ml to Group No.2 231. 1411b FLUID contain: Dextrose Anhydrous 4.25gm, Sodium Lactate 448mg, Na Cl 538mg, Ca Cl 25.7mg, Mg Cl 5.08mg 232. 1455a FLUID LOW CALCIUM CAPD - Each to contain: CAPD Bags with 1.5% concentration containing 40 mEq/litre of Group No.2 lactate and 2.5 mEq/litre of Ca with asymmetrical Y connector 233. 1455b FLUID LOW CALCIUM CAPD - Each to contain: CAPD Bags with 2.5% concentration containing 40 mEq/litre of Group No.2 lactate and 2.5 mEq/litre of Ca with asymmetrical Y connector 234. 1455c FLUID LOW CALCIUM CAPD - Each to contain: CAPD Bags with 4.25% concentration containing 40 mEq/litre of Group No.2 lactate and 2.5 mEq/litre of Ca with asymmetrical Y connector LACTULOSE GRANULES - Each 15gm of granules to Group No.2 235. 1824 GRANULE contain : Lactulose BP 10 gm, Ispaghula Husk IP 3.50 gm 236. 2100 IMPLANT Dexamethasone intravitreal implant 0.7 mg Each Group No.2 Intravitreal Implant Contains : Dexamethasone 0.7mg IPRATROPIUM INHALER - Each metered dose to Group No.2 237. 359 INHALER contain : Ipratropium Bromide 20 mcg. Group No.2 238. 360 INHALER Each metered dose to contain: Salmeterol I.P.25 mcg. Each metered dose to contain : Budesonide I.P.100 Group No.2 239. 362 INHALER mcg. Each metered dose to contain: Ipratropium Group No.2 240. 421 INHALER I.P.20mcg., Salbutamol I.P.100mcg. BECLOMETHASONE INHALER - Each metered dose to Group No.2 241. 592 INHALER contain: Beclomethasone Dipropionate 200mcg. SALBUTAMOL INHALER - Each metered dose to Group No.2 242. 1039 INHALER contain :Salbutamol 100 mcg. SALBUTAMOL + BECLMETHASONE INHALER - Each Group No.2 243. 1041 INHALER metered dose to contain: Salbutamol 100 mcg., Beclmethasone dipropionate 50 mcg. Group No.2 244. 1239 INHALER Each actuation to deliver: Budesonide 100 mcg.

Page 42 of 112

INHALER - Each metered dose to contain: Budesonide Group No.2 245. 1519 INHALER 160 mcg, Formoterol Fumarate Dihydrate 4.5 mcg, Lactose Monohydrate 730 mcg. 246. 1520 INHALER INHALER - Containing: Moulded plastic device containing a foil strip with30/ 60 regularly placed Group No.2 blisters each containing 50 mcg of salmeterol xinafoate and 250 mcg of Fluticasone propionate INHALER - Each metered dose to contain: Tiotropium Group No.2 247. 1521 INHALER Bromide Monohydrate Equ. To Tiotropium 9mcg INHALER - Each metered dose to contain: Ipratropium Group No.2 248. 1522 INHALER 20mcg, Levosalbutamol 50mcg INHALER - Each metered dose to contain : Tiotropium Group No.2 249. 1665 INHALER 9mcg, Formoterol 6 mcg, Ciclesonide 200mcg (CFC Free) 250. 1749 INHALER INHALER - Each metered dose to contain: Group No.2 Levosalbutamol tartrate 50mcg AUTOHALER - Each delivered dose of Autohaler to contain: Formoterol Fumarate Dihydrate IP 6 mcg, Group No.2 251. 1839 INHALER Budesonide IP 200 mcg Suspended in propellant HFA 134a q.s Also contains Absolute alcohol IP 3.07% V/V INHALER - Each delivers dose to contain: Salmetrol Xinafoate IP Equivalent to Salmetrol 25 µg, Group No.2 252. 1840 INHALER Fluticasone Propionate IP 250µg, Excipients & Propellant 1, 1,1,2 Tetrafluoro Ethane HFA 134a INHALER - Each actuation to deliver:Formoterol Fumarate Dihydrate IP equivalent to Anhydrous Group No.2 253. 1841 INHALER Formoterol Fumarate 6µg, Budesonide IP 400µg Excipients & Propellant 1,1.1.2 Tetrafluoro Ethane HFA 134a AUTOHALER - Each delivered dose of Autohaler to contain: Levosalbutamol Tartrate equivalent to Group No.2 254. 1842 INHALER Levosalbutamol 50 mcg suspended in Propellant HFA 134a q.s Absolute alcohol content 21.49% V/V AUTOHALER - Each delivered dose of Autohaler to contain: Salmeterol ( as salmeterol Xinafoate) IP 25 Group No.2 255. 1843 INHALER mcg Fluticasone Propionate IP 250mcg Suspended in Propellant 134aq.s. ( contains Absolute Alcohol IP 5% V/V) SPACER DEVICE - Spacer-suitable for MDI inhaler of all Group No.2 256. 1844 INHALER brand BECLOMETHASONE DIPROPIONATE IP 200MCG (HFA TECHNOLOGY) INHALER - Each metered dose to Group No.2 257. 2015 INHALER contain: Beclomethasone Dipropionate IP 200mcg (HFA Technology) 258. 2063 INHALER Each inhaler to contains: Fluticasone Propionate Group No.2 250mcg + Formoterol Fumarate 6mcg

Page 43 of 112

Each metered dose to contain: Beclomethasone Group No.2 259. 1040b INHALER dipropionate I.P.100mcg. FLUTICASONE + SALMETEROL INHALER - Each metered Group No.2 260. 420a INHALER dose to contain: Salmeterol 25mcg., Fluticasone 50mcg. FLUTICASONE + SALMETEROL INHALER - Each metered Group No.2 261. 420b INHALER dose to contain: Salmeterol 25mcg. + Fluticasone 250mcg. Each ml. to contain: Metoclopramide Hcl. Eqv. to Group No.2 262. 10 INJECTION Metoclopramide 5 mg.

Group No.2 263. 14 INJECTION Each ml. to contain: Promethazine I.P.25mg.

Group No.2 264. 19 INJECTION Each 2ml. to contain: Dicyclomine I.P.10 mg.

Group No.2 265. 28 INJECTION Each. Ml. to contain : Aminophylline 25mg.

Each ml. to contain: Etophylline 84.7mg. Theophylline Group No.2 266. 29 INJECTION 25.3mg.

Group No.2 267. 57 INJECTION Each ml to contain : Dopamine Hcl 40 mg.

Group No.2 268. 58 INJECTION Each ml. to contain: Frusemide 10mg.

Group No.2 269. 63 INJECTION Each ml. to contain: Isoxsuprine 5mg.

Group No.2 270. 69 INJECTION Each ml. containing: Ethamsylate 125mg.

Group No.2 271. 71 INJECTION Each ml. to contain:Heparin Sod. 5000 IU.

Group No.2 272. 85 INJECTION Each ml. to contain: Diclofenac sodium I.P. 25 mg.

Group No.2 273. 86 INJECTION Each ml. to contain: Pantazocine (as lactate) 30mg.

Group No.2 274. 90 INJECTION Each ml. to contain: Hyaluronidase I.P.1500units

Group No.2 275. 93 INJECTION Each ml. to contain: Diazepam I.P.5mg.

METHYL ERGOMETRINE MALEATE INJ - Each ml to Group No.2 276. 111 INJECTION contain: Methyl Ergometrine Maleate 0.2mg. OXYTOCIN INJ - Each ml to contain: Synthetic Oxytocin Group No.2 277. 112 INJECTION 5 IU

Group No.2 278. 114 INJECTION Each ml. to contain:Valethamate Bromide 8mg.

Group No.2 279. 123 INJECTION Each ml. to contain: Pheniramine Maleate 22.75mg.

Each ml. to contain: Medroxy progesterone acetate Group No.2 280. 126 INJECTION suspn.150mg.

Page 44 of 112

281. 133 INJECTION DEXAMETHASONE INJ - Each ml to contain: Group No.2 Dexamethasone Sodium Phosphate 4 mg. Containing: Monocomponent Porcine Insulin ( soluble Group No.2 282. 141 INJECTION ) 40 units/ml. Containing: Monocomponent Porcine Protamine Group No.2 283. 142 INJECTION Insulin 40 units / ml Containing: Monocomponent Porcine Zinc Insulin inj. Group No.2 284. 143 INJECTION 40 units / ml containing highly purified porcine insulin (30 % plain + Group No.2 285. 144 INJECTION 70 % Isophane) 40 units/ml Each vial to contain: Sodium Benzyl Penicilllin 5lac PSU Group No.2 286. 145 INJECTION Item Each vial to contain:Sodium Benzyl Penicilllin 10lac Group No.2 287. 146 INJECTION PSU Item

Group No.2 288. 147 INJECTION Each vial to contain: Benzathine Penicillin 6lac

Group No.2 289. 148 INJECTION Each vial to contain: Benzethine Penicillin 12lac

Group No.2 290. 149 INJECTION Each vial to contain: Benzethine Penicillin 24lac

Group No.2 291. 150 INJECTION Each vial to contain : Fortified Procaine Penicillin 4 lac

Group No.2 292. 151 INJECTION Each vial to contain. Streptomycin Sulphate 0.75gm.

Group No.2 293. 152 INJECTION Each vial to contain streptomycin sulphate 1gm. 294. 167 INJECTION CLOXACILLIN INJ - Each vial to contain; Cloxacillin as Group No.2 Sodium 250mg, Each ml. to contain; Gentamycin Sulphate eqv. to Group No.2 295. 170 INJECTION Gentamycin 40mg.

Group No.2 296. 178 INJECTION Each 100ml. To contain :Ciprofloxacin 200mg.

Containing : Streptomycin Sul. Eqv. to 0.75gm. of Group No.2 297. 190 INJECTION Strep and Sod. Methane Sul of Isoni Acid Hydr 300mg. 298. 197 INJECTION CHLOROQUINE INJ - Each ml to contain: Chloroquine Group No.2 Phosphate eqv. to Chloroquine base 40mg.

Group No.2 299. 200 INJECTION Each ml. to contain: Quinine 300mg.

Each ml. to contain: Lignocaine I.P. 53.3 mg, Dextrose Group No.2 300. 248 INJECTION I.P. 75 mg.

Group No.2 301. 250 INJECTION Containing:Lignocaine 4% w/v

Group No.2 302. 251 INJECTION Containing: Lignocaine Hcl 2% w/v.

Group No.2 303. 257 INJECTION Each amp. to contain: Vecuronium 4mg.

Page 45 of 112

304. 258 INJECTION ATRACURIUM INJ - Each ml to contain: Atracurium Group No.2 besylate 10mg. VITAMIN INJ - Each 2ml. to contain: Thiamine 10mg. Riboflavin 4 mg. Nicotinamide 40 mg. Group No.2 305. 265 INJECTION Cyanocobalamine 8 mcg. Pyridoxine 4mg. D-Panthenol 6mg.Benzyl Alcohol 0.9% 306. 273 INJECTION DEXTROSE INJ - Each amp to contain: Dextrose Group No.2 anhydrous 25% w/v. IRRIGATION SOLN - Each bot to contain: Sod. Chloride 0.64%,Pot. Chloride 0.075%,Calcium Chloride 0.048% Group No.2 307. 274 INJECTION ,Mag. Chloride 0.03%, Sod. Acetate 0.39%, Sod. Citrate STERILE WATER FOR INJ - Each amp to contain: Sterile Group No.2 308. 277 INJECTION Water for injection SODIUM CHLORIDE INJ (FOR IV INFUSION) - Group No.2 309. 279 INJECTION Containing: Sodium chloride 0.9% w/v SODIUM CHLORIDE & DEXTROSE INJ(FOR Group No.2 310. 280 INJECTION I.V.INFUSION) - Containing: Dextrose anhydrous 5%w/v, Sodium chloride 0.9%w/v Each vial to contain: Snake venom antiserum ( Group No.2 311. 281 INJECTION effective against venom of Cobra,Common Krait, Saw- scaled and Russel viper ) CHICK EMBRYO CELL RABIES VACCINE - Each dose to Group No.2 312. 282 INJECTION contain: 2.5 IU inactivated rabies antigen. 313. 286 INJECTION 5-FLUOROURACIL INJ - Each vial to contain: Group No.2 Fluorouracil IP 250mg. 314. 288 INJECTION CYTOSINE ARABINOSIDE INJ - Each vial to contain: Group No.2 Cytosine Arabinoside 100mg. ETOPOSIDE INJ - Each vial to contain: Etoposide Group No.2 315. 290 INJECTION IP100mg. 316. 292 INJECTION BLEOMYCIN INJ - Each vial to contain: Bleomycin IP Group No.2 15mg. 317. 293 INJECTION VINCRISTINE INJ - Each vial to contain: Vincristine IP Group No.2 1mg. Group No.2 318. 303 INJECTION CEFPIROME INJ - Each vial to contain: Cefpirome 1 gm.

Group No.2 319. 326 INJECTION Each ml. to contain: Nitroglycerine 5mg. 320. 327 INJECTION DOBUTAMINE INJ - Each vial/amp to contain : Group No.2 Dobutamine Hcl. Eqv. to Dobutamine 250mg. Each vial to contain: Vancomycin Hcl. Eqv. to Group No.2 321. 332 INJECTION Vancomycin 500mg.

Group No.2 322. 388 INJECTION Each ml. to contain: Ondansetron 2 mg.

Group No.2 323. 398 INJECTION Containing: Xylocaine 1%

Group No.2 324. 402 INJECTION DOXORUBICIN INJ - Each vial to contain: Doxorubicin Page 46 of 112

10mg. 325. 405 INJECTION DESFERRIOXAMINE INJ - Each vial to contain : Group No.2 Desferrioxamine 500mg.

Group No.2 326. 426 INJECTION Each ml to contain: Neostigmine 0.5mg

Containing : Highly Purified Bovine Insulin ( 30% Group No.2 327. 435 INJECTION soluble + 70% NPH) 40 units/ ml. DNA 10-15mcg., RNA 5-10mcg., Tyrosine I.P.0.25- Group No.2 328. 438 INJECTION .35mg., total protein content not more than 0.65mg., nitrogen I.P. content not more than 0.08% per ml. 329. 447 INJECTION ROCURONIUM INJ - Each ml. to contain: Rocuronium Group No.2 10mg. STARCH INJ - Each 100ml to contain: Hydroxyethyl Group No.2 330. 454 INJECTION Starch 6gms., Sodium Chloride 0.9gm. Group No.2 331. 457 INJECTION IFOSFAMIDE INJ - Each vial to contain: Ifosfamide 1gm FLUDARABINE INJ - Each vial to contain: Fludarabine Group No.2 332. 458 INJECTION 50mg. Group No.2 333. 462 INJECTION ISOFLURANE - Each 100ml to contain: Isoflurane 334. 464 INJECTION ERYTHROPOIETIN INJ - Each pack to contain: Group No.2 Recombinant Human Erythropoietin 10000 units Each ml to contain :Methylprednisolone Sod. Group No.2 335. 467 INJECTION Succinate 40 mg

Group No.2 336. 476 INJECTION Each ml. to contain: Haloperidol I.P.5mg. 337. 499 INJECTION DACARBAZINE INJ - Each vial to contain: Dacarbazine Group No.2 100mg. Group No.2 338. 502 INJECTION Each ml to contain: Magnesium Sulfate I.P.50 %.

Each 2ml. to contain: Dicyclomine I.P.20mg., Group No.2 339. 517 INJECTION Diclofenac sodium I.P.50mg.

Group No.2 340. 522 INJECTION Each 5 ml.Inj. to contain: Tranxemic Acid 500mg.

Group No.2 341. 526 INJECTION GOSERELIN INJ - Each PFS to contain: Goserelin 3.6mg.

Group No.2 342. 536 INJECTION Each vial to contain: Pantoprazole 40mg.

Each PFS to contain: Sodium Hyaluronate 10mg. + Group No.2 343. 538 INJECTION Sodium chloride I.P.8.5mg. + Sodium Phosphate dibasic and monobasic qs. (for opthalmic surgical use) VERO CELL CULTURE RABIES VACCINE - Each dose to Group No.2 344. 542 INJECTION contain: Purified Vero Cell Culture Human Rabies Vaccine Each PFS to contain: Sodium Hyaluronate Group No.2 345. 543 INJECTION 25mg.,Sodium chloride, Sodium Phosphate dibasic and monobasic qs Each ml. to contain:Equine Rabies Immunoglobuline Group No.2 346. 544 INJECTION 300 IU

Page 47 of 112

ERYTHROPOIETIN INJ - Each Vial to contain: Group No.2 347. 545 INJECTION Recombinant Human Erythropoietin 20000 units METHYLPREDNISOLONE ACETATE INJ - Each vial to Group No.2 348. 569 INJECTION contain: Methyl Prednisolone Acetate 40mg. 349. 574 INJECTION METOPROLOL INJ - Each ml. to contain: Metoprolol Group No.2 1mg. LIGNOCAINE HCL+SODIUM CHLORIDE INJ - Each 1ml Group No.2 350. 581 INJECTION to contain: Lignocaine 21.3 mg, Sodium Chloride 6mg., water for Inj. to make 1ml. LIGNOCAINE WITH ADRENALINE INJ - Each ml. to Group No.2 351. 588 INJECTION contain: Lignocaine 21.3mg., Adrenaline 0.005mg.

Group No.2 352. 591 INJECTION Each 5 ml. to contain: Ritodrine 50mg.

AMIODARONE INJ - Each ml to contain: Amiodarone Group No.2 353. 597 INJECTION 50mg. INFLIXIMAB INJ - Each vial to contain: Infliximab Group No.2 354. 600 INJECTION 100mg. 355. 601 INJECTION VITAMIN K INJ - Each ml to contain: Phytomenadione Group No.2 10mg OFLOXACIN INJ - Each 100 ml. to contain: Ofloxacin Group No.2 356. 602 INJECTION 200mg. Each ml. To contain : Ranitidine Hcl eqv. To Ranitidine Group No.2 357. 1007 INJECTION 25 mg.

Group No.2 358. 1016 INJECTION Each ml. to contain : Prochlorperazine I.P.12.5 mg.

TERBUTALINE INJ - Each ml to contain :Terbutaline Group No.2 359. 1036 INJECTION sulphate 0.5 mg. 360. 1042 INJECTION ADRENALINE INJ - Each ml. to contain : Adrenaline Group No.2 acid tartrate eqv. to Adrenaline 1 mg. 361. 1062 INJECTION DILTIAZEM INJ - Each ml. To contain: Diltiazem Hcl 5 Group No.2 mg. Each ml. To contain : Aqueous solution of Haemocoagulase (one I U/CU/NIH unit) Isolated from Group No.2 362. 1078 INJECTION venom of Bothrops, Jararaca or Bothrops Atrox containing Sodium Chloride 0.9% 363. 1084 INJECTION BUPRENORPHINE INJ - Each ml to contain: Group No.2 Buprenorphine 0.3mg

Group No.2 364. 1096 INJECTION Each ml. To contain : Paracetamol 150 mg.

Group No.2 365. 1106 INJECTION Each ml. to contain: Glycopyrrolate I.P./ U.S.P.0.2mg.

Group No.2 366. 1114 INJECTION Each ml. to contain :Phenobarbitone Sod. I.P. 200 mg.

Group No.2 367. 1130 INJECTION Each ml. to contain : Phenytoin Sod. 50 mg.

Group No.2 368. 1136 INJECTION Each ml. to contain : Ethacridine Lactate 1 mg.

Page 48 of 112

369. 1137 INJECTION CARBOPROST INJ - Each ml to contain: Carboprost Group No.2 0.25mg. Group No.2 370. 1138 INJECTION Containing: Dinoprostone 0.5mg

Each ml to contain: Oestradiol benzoate I.P.1 mg., Oestradiol Phenylpropionate I.P.4 mg. Testosterone Group No.2 371. 1152 INJECTION Propionate I.P.4 mg., Testosterone Phenyl-propionate I.P.40 mg.,Testosterene Isocaproate 40 mg.

Group No.2 372. 1158 INJECTION Each inj. To contain: FSH 75 IU & LH-75 IU

Group No.2 373. 1159 INJECTION Each ml. to contain : Betamethasone I.P.4 mg.

Each ml. to contain : Nandrolone Phenyl Propionate Group No.2 374. 1161 INJECTION I.P.25 mg.

Group No.2 375. 1162 INJECTION Each ml to contain : Nandrolone Decanoate 25 mg.

Containing :Hydrocortisone Acetate 25 mg., Benzyl Group No.2 376. 1163 INJECTION Alcohol 0.9% HYDROCORTISONE SOD. SUCCINATE INJ - Each vial to Group No.2 377. 1164 INJECTION contain:Hydrocortisone Sod. Succinate eqv. to Hydrocortisone 100 mg. HUMAN INSULIN (SOLUBLE) - Each vial to Group No.2 378. 1167 INJECTION contain:Human Insulin (Soluble) 40 units / ml. Containing :Human Insulin (Zinc Suspension) 40 units / Group No.2 379. 1169 INJECTION ml. 380. 1170 INJECTION HUMAN INSULIN (NPH) - Each vial to contain:Human Group No.2 Insulin (NPH 100%) 40 units / ml. HUMAN INSULIN MIXED (25% + 75%) - Each vial to Group No.2 381. 1171 INJECTION contain :Human Insulin 25% soluble + 75% NPH 40 units / ml. containing :Human Insulin 50% soluble +50% NPH 40 Group No.2 382. 1172 INJECTION units / ml. HUMAN INSULIN BIPHASIC MIXED ( 30% + 70%) - Each Group No.2 383. 1173 INJECTION vial to contain: Human Insulin Biphasic 30% Soluble + 70% NPH 40 units / ml. CHLORAMPHENICOL INJ - Each vial to contain: Group No.2 384. 1181 INJECTION Chloramphenicol Sod. Succinate eqv. to Chloramphenicol 1 gm

Group No.2 385. 1184 INJECTION Each vial to contain : Ceftazidime 250 mg.

Group No.2 386. 1185 INJECTION Each vial to contain :Ceftazidime 1gm..

Each vial containing : Ceftriaxone Sod. Eqv. to Group No.2 387. 1186 INJECTION Anhydrous Ceftriaxone 250 mg. Each vial containing : Ceftriaxone Sod. Eqv. to Group No.2 388. 1187 INJECTION Anhydrous Ceftriaxone 1gm..

Page 49 of 112

Each vial to contain : Amikacin 500mg ( as Amikacin Group No.2 389. 1189 INJECTION sulphate) METHYL CELLULOSE OCULAR SOLU. - Containing : Group No.2 390. 1227 INJECTION Hydroxy propyl methyl cellulose 2% w/v THIOPENTONE SODIUM INJ - Each vial to contain : Group No.2 391. 1277 INJECTION Thiopentone Sodium IP 0.5 gm. PANCURONIUM INJ - Each ml to contain : Group No.2 392. 1286 INJECTION Pancuronium 2 mg.

Group No.2 393. 1289 INJECTION Each ml. to contain: Atropine Sulphate I.P. 0.6mg

Group No.2 394. 1290 INJECTION FENTANYL INJ - Each ml to contain : Fentanyl 50mcg. 395. 1294 INJECTION VITAMIN B COMPLEX INJ - Each amp to contain: Vit. B1 100 mg. , Vit. B2 5 mg., Vit. B6 100 mg., Vitamin Group No.2 B12 1000 mcg. Nicotinamide 100 mg., D- Panthenol 50 mg MULTI VITAMIN INJ (FOR IV INFUSION) - Each 10ml to contain : Vit.C 500 mg., Vit. A 10,000 IU, Vit. B1 50 Group No.2 396. 1304 INJECTION mg., Nicotinamide 100 mg., Vit. B6 15 mg., D- panthenol 25 mg., Alpha-tocopheryl Acetate 5 mg., Vit. D 1000 IU, Vit. B2 14 mg. IRON DEXTRAN INJ - Each ml to contain : Iron Dextran Group No.2 397. 1314 INJECTION eqv. to Elemental Iron 50 mg. Each 100 ml. to contain :Sodium lactate I.P. 0.32gm Group No.2 398. 1316 INJECTION Sod. Chl. I.P. 0.6 gm. Pot. Chl. I.P.0.04 gm. Cal. Chloride I.P.0.027 gm,Water for injection I.P. Q.S. AMINO ACID (FOR IV INFUSION) - Each ml to contain: L-Arginine Hcl 8.0 mg. L-Histidine Hcl. 4.0mg. L- Isoleucine 5.5mg. L-Lysine Hcl. 22.3mg. L-Methionine Group No.2 399. 1322 INJECTION 7.1mg. L-Threonine 5.4mg. L-Phenylalanine 8.7mg. L- Leucine 12.3 mg. L-Valine 6.1 mg. Glycine 10.0mg. L- Tryptophan 1.8mg.Sorbitol 50.0 mg. POLYMER OF DEGRADED GELATIN (FOR IV INFUSION) - Group No.2 400. 1324 INJECTION Each to contain: Polymer of Degraded gelatin 3.5 gm. Electrolytes & Distilled water to 100 ml. per 100 ml.

Group No.3 401. 1325 INJECTION Containing: Mannitol 20%

SODIUM BICARBONATE INJ - Each amp to contain: Group No.3 402. 1326 INJECTION Sodium Bicarbonate 7.5% POTASSIUM CHLORIDE INJ - Each ml to contain Group No.3 403. 1327 INJECTION :Potassium Chloride I.P. 0.15 gm

Group No.3 404. 1328 INJECTION Each vial To contain: Interferon Alpha 2A : 3 Mil. I.U. 405. 1332 INJECTION LEUCOVORIN CALCIUM INJ - Each ml. to contain: Group No.3 Leucovorin Calcium 3mg. METHOTREXATE INJ - Each vial to contain: Group No.3 406. 1333 INJECTION Methotrexate IP 50mg.

Page 50 of 112

TETANUS VACCINE (ADSORBED) - Each 0.5 ml. to Group No.3 407. 1341 INJECTION contain :Tetanus Toxoid 5/LFS Each vial to contain: Meropenem Trihydrate eqv. to Group No.3 408. 1352 INJECTION Anhydrous Meropenem 500mg. 409. 1354 INJECTION AMPICILLIN + SULBACTUM INJ - Each vial to Group No.3 contain: Ampicillin Sod. 1gm., Sulbactum Sod. 0.5gm. Each vial to contain: Methyl Prednisolone sod. Group No.3 410. 1356 INJECTION Succinate 125mg. Each vial to contain: Methyl Prednisolone sod. Group No.3 411. 1357 INJECTION Succinate I.P.500mg. DEXTROSE INJ - Each 100ml to contain: Dextrose anhydrous 5gm. Pot. Chl. 0.15gm., Dibasic Pot. Phos. Group No.3 412. 1360 INJECTION 0.13gm., Sod. Chloride 0.91mg, Sod. Acetate 0.28gm, Metabisulphite 21gm, water for inj. q.s. MANNITOL + GLYCERIN INFUSION - Each bot to Group No.3 413. 1389 INJECTION contain: Mannitol I.P. 10%, Glycerin I.P. 10% Group No.3 414. 1404 INJECTION DOCETAXEL INJ - Each Inj. to contain: Docetaxel 80mg

Group No.3 415. 1405 INJECTION Each Inj. to contain: Peginterferon Alfa -2A 180 IU

Group No.3 416. 1417 INJECTION Each ml to contain: Aceclofenac I.P.150mg

Group No.3 417. 1437 INJECTION Containing: Iron sorbitol citric Acid complex 50mg

Group No.3 418. 1438 INJECTION IRON INJ - Each ml to contain: Fe sucrose 20mg.

NIMOTUZUMAB INJ - Each vial to contain: Group No.3 419. 1448 INJECTION Nimotuzumab 50mg ANTI HEMOPHILLIC INJ - Each vial to contain:Anti Group No.3 420. 1450 INJECTION Hemophillic Factor VIII Monoclonal Purified - 250 IU ANTI HEMOPHILLIC INJ - Each vial to contain: Anti Group No.3 421. 1451 INJECTION Hemophillic IX - 600IU PACLITAXEL INJ - Each vial to contain: Paclitaxel Group No.3 422. 1465 INJECTION 300mg PEG-FILGRASTIM INJ - Each PFS to contain: Peg- Group No.3 423. 1466 INJECTION Filgrastim 424. 1468 INJECTION MEDROXY- PROGESTERONE INJ - Each ml to Group No.3 contain: Medroxy- Progesterone Acetate 150mg 425. 1469 INJECTION MENOTROPHIN INJ - Each amp/vial to contain: Group No.3 Recombinant FSH 75

Group No.3 426. 1471 INJECTION Containing: Human Albumin 20%

IMMUNOGLOBULIN INJ - Containing: Immunoglobulin Group No.3 427. 1472 INJECTION 5% PEMETREXDED DISOD. INJ - Containing: Pemetrexded Group No.3 428. 1477 INJECTION Disod. 500mg

Page 51 of 112

Group No.3 429. 1479 INJECTION Each 2ml to contain: Lornoxicam 8mg

CLARITHROMYCIN INJ - Each vial to contain: Group No.3 430. 1480 INJECTION Clarithromycin 500mg Each vial to contain: Cefotaxime I.P. 500mg , Group No.3 431. 1482 INJECTION Sulbactam I.P./U.S.P. 250mg Each vial to contain: Ceftriaxone I.P. 500mg, Group No.3 432. 1483 INJECTION Sulbactam I.P./U.S.P. 250mg IMIPENEM + CILASTATIN INJ - Each vial to contain: Group No.3 433. 1484 INJECTION Imipenem 500mg, Cilastatin 500mg 434. 1486 INJECTION INSULIN GLARGINE INJ - Each vial to contain: Insulin Group No.3 Glargine 100 units / ml 435. 1487 INJECTION INSULIN ASPART INJ - Each vial to contain: Insulin Group No.3 Aspart (R-DNA origin) 436. 1488 INJECTION BIPHASIC INSULIIN ASPART INJ - Each penfill to Group No.3 contain: Biphasic Insulin Aspart (R-DNA origin) 437. 1489 INJECTION DROTAVERINE INJ - Each ml to contain: Drotaverine Group No.3 20mg Group No.3 438. 1529 INJECTION ADENOSINE INJ - Each 2ml to contain: Adenosine 6mg

Group No.3 439. 1535 INJECTION Each vial to contain: Sodium Tetradecyl Sulphate 3%,

FONDAPARINUX SODIUM INJ - Each PFS to contain: Group No.3 440. 1536 INJECTION Fondaparinux Sodium 2.5mg VITAMIN K INJ - Each amp to contain: Vitamin K IP Group No.3 441. 1538 INJECTION 1.0 mg PARACETAMOL INJ - Each ml to contain: Paracetamol Group No.3 442. 1541 INJECTION 10 mg TERIPARATIDE INJ - Each 2.4ml PFS/PFP to contain: Group No.3 443. 1549 INJECTION Teriparatide 600 mcg

Group No.3 444. 1554 INJECTION Each vial to contain:Inj. Levofloxacin I.P. 500mg

Each vial to contain: Inj. Piperacillin Sodium Group No.3 445. 1555 INJECTION I.P./B.P./USP 2gm, Each vial to contain: Piperacillin Sodium I.P./B.P./USP Group No.3 446. 1556 INJECTION 4gm,Tazobactam Sodium 0.5gm 447. 1559 INJECTION LINEZOLID INJ - Each vial to contain: Linezolid Group No.3 600mg, ERTAPENEM SODIUM INJ - Each vial to contain: Group No.3 448. 1561 INJECTION Ertapenem 1 gm (equ. to Ertapenem sod.1.046 gm.) IV / IM ARTISUNATE INJ - Each vial to contain: Artisunate 60 Group No.3 449. 1564 INJECTION mg

Group No.3 450. 1566 INJECTION ACYCLOVI INJ - Each vial to contain: Acyclovir 500mg 451. 1585 INJECTION NORADRENALINE INJ - Each 2ml to contain: Group No.3 Noradrenaline 4 mg.

Page 52 of 112

SOMATROPIN (R-DNA) INJ - Each PFS contain: Group No.3 452. 1586 INJECTION Somatropin (r-DNA) origin Bio-synthetic Human growth hormone Solution 10mg/1.5ml.=30 iu Each ml to contain: Micronised Progesterone Group No.3 453. 1587 INJECTION I.P.50mg.

Group No.3 454. 1588 INJECTION Each ml to contain: Betamethasone I.P. 4mg.

LIRAGLUTIDE INJ - Inj Human GLP-1 analogue contains Group No.3 455. 1592 INJECTION : Liraglutide 6mg / ml 456. 1593 INJECTION INSULIN DETEMIR INJ - Each inj to contain: Insulin Group No.3 Detemir 100 IU/ml (R-DNA) Each 2ml to contain:Thiamine Hydrochloride I.P. 100mg,Riboflavine Phosphate Sodium Equivalent to Group No.3 457. 1630 INJECTION Riboflavin I.P. 5mg,Niacinamide I.P.100mg, D- Panthenol I.P.100mg,Inositol 5mg, Cynocobalamin I.P.100mcg, Benzyl Alcohol I.P.85 1%v/v

Group No.3 458. 1631 INJECTION Each ml. to contain:. Vit. C I.P. 100mg

VITAMIN D3 INJ - Each amp. to contain: Vitamin D3 3 Group No.3 459. 1632 INJECTION lac IU METHYLOCOBALAMIN INJ - Each ml to contain: Group No.3 460. 1633 INJECTION Methylocobalamin 500 mcg LEUPROLIDE DEPOT INJ - Each vial to contain: Group No.3 461. 1642 INJECTION Leuprolide Acetate 7.5 mg PACLITAXEL INJ - Each vial to contain:Inj. Paclitaxel IP Group No.3 462. 1645 INJECTION 30mg ALBUMIN BOUND PACLITEXEL INJ - Each vial to Group No.3 463. 1646 INJECTION contain: Nanoptechnology based albumin-bound paclitexel 100MG 464. 1647 INJECTION BEVACIZUMAB INJ - Each vial to contain:Inj. Group No.3 Bevacizumab 100mg 465. 1648 INJECTION TRASTUZUMAB INJ - Each vial to contain:Inj. Group No.3 Trastuzumab 440mg HUMAN INTERFERON BETA 1A INJ - Each PFS/vial to Group No.3 466. 1649 INJECTION contain: Recombinant Human Interferon Beta1a 44mcg POLYSACCHARIDE PNEUMOCOCCAL VACCINE - Each Group No.3 467. 1651 INJECTION 0.5ml contain: Polysaccharide Pneumococcal Vaccine 0.5ml RABEPRAZOLE INJ - Each amp/vial to contain: Group No.3 468. 1654 INJECTION Rabeprazole20mg PALONOSETRON HYDROCHLORIDE INJ - Each 1.5 ML Group No.3 469. 1657 INJECTION Contains: Palonosetron Hydrochloride equivalent to Palonosetron-0.075 mg water for Inj -q.s. Each 5 ml to contains : Essential phospholipids 250mg Group No.3 470. 1659 INJECTION Benzyl alcohol I.P. 45mg (Preservative) Water for Injection I.P. Q.S. Page 53 of 112

471. 1670 INJECTION HAEMOSTATIC - Each 5ml to contain: Haemostatic Group No.3 Matrix with Prefilled Gelatin Granules in Syringes ANTI COAGULANTS - Each to contain: Two componant Group No.3 472. 1672 INJECTION fibrin sealant with fast & slow setting of human thrombin ETANERCEPT INJ - Each PFP/PFS to contain:Etanercept Group No.3 473. 1677 INJECTION 50mg

Group No.3 474. 1679 INJECTION Each ml to Contain: Lorazepam 2mg

Group No.3 475. 1680 INJECTION Contain: Citicoline 250 mg 476. 1691 INJECTION INSULIN INJ - Each Cartridge to contain: 25% Lispro Group No.3 and 75% Lispro Protamine Suspension (100 IU/mL) [Monocomponent Insulin, recombinant DNA origin] 477. 1692 INJECTION INSULIN INJ - Each Cartridge to contain: 50% Lispro Group No.3 and 50% Lispro Protamine Suspension (100 IU/mL) [Monocomponent Insulin, recombinant DNA origin] COLISTIMETHATE SODIUM INJ - Each vial to contain: Group No.3 478. 1694 INJECTION Colistimethate Sodium BP 10,00,000 I.U. Each vial to contain: Cefpirome Sulphate Equivalent Group No.3 479. 1695 INJECTION to Cefpirome – 1.0g Sulbactam sodium Equivalent to Sulbactam – 0.5g 480. 1696 INJECTION MICAFUNGIN SODIUM INJ - Each vial to contain: Group No.3 Micafungin Sodium equivalent to 50mg Micafungin 481. 1697 INJECTION CASPOFUNGIN ACETATE INJ - Each vial to contain: Group No.3 Caspofungin Acetate 50mg ALPHA - BETA ARTEETHER INJ - Each vial to contain: Group No.3 482. 1699 INJECTION Alpha- Beta Arteether (150 mg) 483. 1726 INJECTION RINGER LACTATE INJ - Each to contain: Ringer Lactate Group No.3 500ml Self Collapsible IV Fluid PVC Bag 484. 1727 INJECTION DNS INJ - Each to contain: DNS 500ml Self Collapsible Group No.3 IV Fluid Bag ASPARAGINASE INJ - Each vial to contain: Group No.3 485. 1729 INJECTION Asparaginase 10000 unit 486. 1731 INJECTION RASBURICASE INJ - Each vial to contain: Rasburicase Group No.3 1.5 mg DECITABINE INJ - Each vial to contain: Decitabine – Group No.3 487. 1732 INJECTION 50mg OCTREOTIDE INJ - Each Pack to contain: Octreotide 10mg (in form of microspheres)- 1 vial, 1 pre filled Group No.3 488. 1734 INJECTION syringe of 2.5ml Vehicle for 2.5ml suspension 2 sterile injection needles 489. 1739 INJECTION PRALIDOXIME INJ - Each vial to contain: Group No.3 Pralidoxime 1gm OMALIZUMAB INJ - Each vial to contain: Omalizumab Group No.3 490. 1746 INJECTION 150mg

Page 54 of 112

Group No.3 491. 1752 INJECTION Inj. Tenecteplase tPA

Group No.3 492. 1760 INJECTION HYLAN G-F20 INJECTION - Each contain: Hylan G-F20

TOCILIZUMAB INJ 80MG - Each vial to contain: Group No.3 493. 1761 INJECTION Tocilizumab 80 mg

TOCILIZUMAB INJ 200MG - Each vial to contain: Group No.3 494. 1762 INJECTION Tocilizumab 200 mg

TOCILIZUMAB INJ 400MG - Each vial to contain: Group No.3 495. 1763 INJECTION Tocilizumab 400 mg

INSULIN LISPRO INJ - Each Cartridge contain: Insulin Group No.3 496. 1770 INJECTION Lispro (100 IU/ml) [Monocomponent Insulin, recombinant DNA origin]

CLINDAMYCIN INJ - Each vial to contain: Clindamycin Group No.3 497. 1772 INJECTION 600 mg

Tigecycline for Injection (Lyophilized Injection) Group No.3 498. 1773 INJECTION Each vial contains : Tigecycline 50mg -Vial

Group No.3 499. 1774 INJECTION Inj. Tobramycin 20mg -Vial

Group No.3 500. 1775 INJECTION Inj. Tobramycin 60mg -Vial

Group No.3 501. 1776 INJECTION Inj. Tobramycin 80mg -Vial

AMPHOTERICIN B INJ - Each vial to contain: Group No.3 502. 1777 INJECTION Amphotericin B 50 mg INTERFERON BETA 1-A INJ - Each PFP to contain: Group No.3 503. 1779 INJECTION Interferon beta 1-a 30 mcg (6 million IU). 504. 1783 INJECTION RANIBIZUMAB INJ - Each ml to contain: Ranibizumab Group No.3 10 mg. Group No.3 505. 1788 INJECTION Inj. Ropivacaine 0.5% -Amp/Vial

Group No.3 506. 1789 INJECTION Inj. Ropivacaine 0.75% -Amp/Vial

Group No.3 507. 1790 INJECTION Inj. Desflurane -Bottle

Page 55 of 112

DEXTROSE 5% INJ (IV FLUIDS) - Each to contain: Dextrose 5% Self Collapsible I.V. Fluid PVC Bag having Group No.3 508. 1796 INJECTION separate administration port with recessed membrane with plastic sterility barrier & self sealing Inj. Port with silicone septum, no air vent required DEXTROSE 10% INJ (IV FLUIDS) - Each to contain: Dextrose 10% Self Collapsible I.V. Fluid PVC Bag Group No.3 509. 1797 INJECTION having separate administration port with recessed membrane with plastic sterility barrier & self sealing Inj. Port with silicone septum, no air vent required. NORMAL SALINE INJ(IV FLUIDS) - Each to contain: Normal Saline Self Collapsible IV Fluid PVC Bag having Group No.3 510. 1799 INJECTION separate administration port with recessed membrane with plastic sterility barrier & self sealing Inj port with silicone septum, no air vent required. BORTEZOMIB 1MG INJ - Each vial to contain: Group No.3 511. 1808 INJECTION Bortezomib 1 mg

Group No.3 512. 1809 INJECTION Inj. Bortezomib 3.5 mg

CABAZITAXEL INJ - Each 1.5ml contains: Cabazitaxel 60mg Group No.3 513. 1811 INJECTION Diluent 5.7ml of 13% w/w Ethanol in water for injection 514. 1812 INJECTION CETUXIMAB 100MG INJ - Each ml to contain: Group No.3 Cetuximab 5mg 515. 1813 INJECTION CETUXIMAB 500MG INJ - Each ml to contain: Group No.3 Cetuximab 5mg IMMUNOGLOBULIN - Each to contain: Rho (D) Group No.3 516. 1814 INJECTION Immune Globulin (Human) 300 mcg.(1500 IU). FACTOR EIGHT BYPASSING ACTIVITY - Containing : Group No.3 517. 1815 INJECTION Factor Eight Bypassing activity, Anti-Inhibitor- Coagulant Complex. 500 IU. RECOMBINANT ANTI HEMOPHILLIC FACTOR-VIII - Group No.3 518. 1816 INJECTION Containing : Recombinant Anti Hemophillic Factor-VIII 250 IU

RECOMBINANT ANTI HEMOPHILLIC FACTOR-VIII - Group No.3 519. 1817 INJECTION Containing : Recombinant Anti Hemophillic Factor-VIII 500 IU

RECOMBINANT ANTI HEMOPHILLIC FACTOR-VIII - Group No.3 520. 1818 INJECTION Containing : Recombinant Anti Hemophillic Factor-VIII 1000 IU

IMMUNOGLOBULIN - Each 1 ml solution contain : Group No.3 521. 1819 INJECTION Active substance(s) Human plasma proteins 50 mg, IgM 6 mg (12%) , IgA 6 mg (12%) IgG 38 mg (76%) Group No.3 522. 1847 INJECTION VERAPAMIL INJ - Each ml to contain: Verapamil 2.5mg

Page 56 of 112

523. 1849 INJECTION LABETALOL INJ - Each ml to contain :Labetalol Group No.3 hydrochloride 5mg

Group No.3 524. 1853 INJECTION HEPARIN INJ - Each 10ml to contain : Heparin 100 IU

DEXMEDETOMIDINE INJ - Each ml to contain: Group No.3 525. 1867 INJECTION Dexmedetomidine Inj. 100mcg 526. 1885 INJECTION LEVETIRACETAM INJ - Each ml to contain : Group No.3 Levetiracetam100 mg BUSERELIN INJ - Each ml to contain : Buserelin MP (as Group No.3 527. 1892 INJECTION Buserelin Acetate) 1mg, Preservative Benzyl Alcohol IP 1% w/v, Water for injection IP qs 528. 1898 INJECTION INSULIN DEGLUDEC INJ - Each 1ml of the solution for Group No.3 subcutaneous inj to contain: Insulin Degludec (R-DNA origin) 100 unit/ml Pre Filled Pen 529. 1899 INJECTION INSULIN GLARGINE INJ - Each ml to contain: 100 units Group No.3 (3.64mg) Insulin Glargine 530. 1900 INJECTION INSULIN GLULISINE INJ - Each ml to contain:Insulin Group No.3 Glulisine 100IU, m-cresol 3.15mg (as preservative), excipients q.s. 531. 1901 INJECTION INSULIN GLULISINE INJ - Each ml to contain:Insulin Group No.3 Glulisine 100IU, m-cresol 3.15mg (as preservative), excipients q.s. LIPOSOMAL LYOPHILIZED –B INJ - Each vial to contain Group No.3 532. 1908 INJECTION : Liposomal Amphotericin -B P 50mg (Lyophilized) 533. 1914 INJECTION HYLUNONATE INJ - Each ml to contain : Sodium Group No.3 Hylunonate 14mg INTRACAMERAL ADRENALINE INJ - Each inj to contain : Group No.3 534. 1915 INJECTION Intracameral Adrenaline 1 : 1000, 1mg/ml INTRACAMERAL LIGNOCAINE INJ - Each inj to contain : Group No.3 535. 1916 INJECTION Intracameral Lignocaine 2%, Preservative free INTRACAMERAL MOXIFLOXACIN INJ - Each inj to Group No.3 536. 1917 INJECTION contain : Intracameral Moxifloxacin 0.5%, Preservative free INTRACAMERAL PILOCARPINE INJ - Each inj to contain Group No.3 537. 1918 INJECTION : Intracameral Pilocarpine 2%, Preservative free 538. 1919 INJECTION ANTI RABIES VACCINE - Each ml to contain : HRG Group No.3 (Rabies Immunoglobulin (Human)) 150IU Group No.3 539. 1931 INJECTION FLUORESCEIN INJ - Each inj to contain: Fluorescein 5% 540. 1932 INJECTION FLUORESCEIN INJ - Each inj to contain: Fluorescein Group No.3 10% FIBRIN SEALANT - Each to contain: Surgical Fibrin Group No.3 541. 1933 INJECTION Sealant LEUPROLIDE INJ - Each PFS/vial to contain: Leuprolide Group No.3 542. 1972 INJECTION Acetate Depot 3.75mg LEUPROLIDE INJ - Each PFS/vial to contain: Leuprolide Group No.3 543. 1973 INJECTION Acetate Depot 11.25mg

Page 57 of 112

LEUPROLIDE INJ - Each PFS/vial to contain: Leuprolide Group No.3 544. 1974 INJECTION Acetate Depot 22.5mg 545. 1975 INJECTION BOTULINUM INJ - Each vial to contain: Botulinum A Group No.3 Toxin 50 IU 546. 1976 INJECTION BOTULINUM INJ - Each vial to contain: Botulinum A Group No.3 Toxin 100 IU PEGYLATED INTERFERON INJ - Each PFS/vial to Group No.3 547. 1977 INJECTION contain: Pegylated Interferon 30mcg. 548. 1979 INJECTION LEUCOVORIN INJ - Each vial to contain: Leucovorin Group No.3 50mg 549. 1982 INJECTION OXALIPLATIN INJ - Each vial to contain: Oxaliplatin Group No.3 50mg 550. 1983 INJECTION OXALIPLATIN INJ - Each vial to contain: Oxaliplatin 100 Group No.3 mg 551. 1984 INJECTION PACLITAXEL INJ - Each vial to contain: Paclitaxel Group No.3 260mg 552. 1986 INJECTION ZOLEDRONIC ACID INJ - Each vial to contain: Group No.3 Zoledronic acid 4mg OCTREOTIDE INJ - Each vial/pack to contains: Group No.3 553. 1987 INJECTION Octreotide 30mg Long Acting Release 554. 1993 INJECTION PEGYLATED INTERFERON INJ - Each PFP to contain: Group No.3 Pegylated Interferon Alpha 2B Injection -50 mcg in prefilled pen 555. 1994 INJECTION PEGYLATED INTERFERON INJ - Each PFP to contain: Group No.3 Pegylated Interferon Alpha 2B Injection -80 mcg in prefilled pen DICLOFENAC 75MG IV INJ - Each 1ml to contain: Group No.3 556. 2027 INJECTION Diclofenac 75mg IV TERIPARATIDE 750 MCG INJ - Each 3 ml cartridge to Group No.3 557. 2029 INJECTION contain : Teriparatide 750 mcg PHENOBARBITAL SODIUM 200 MG INJ - Each ml to Group No.3 558. 2030 INJECTION contain: Phenobarbital Sodium 200 mg FOLLITROPIN ALPHA 1050 IU/1.75 ML INJ - Each vial Group No.3 559. 2032 INJECTION to contain: Follitropin alpha 1050 IU/1.75 ml INJ CAL.GLUCONATE - Each ml to contain: Calcium Group No.3 560. 2040 INJECTION Gluconate 100mg LEVO CARNITINE 1GM INJ - Each Inj to contain : Levo Group No.3 561. 2043 INJECTION Carnitine 1gm L-ORNITHINE L-ASPARTATE 5.0 G INJ - Each Inj to Group No.3 562. 2044 INJECTION contain: L-ornithine L-Aspartate 5.0 g FERRIC CARBOXY MALTOSE EQV. TO ELEMENTAL IRON Group No.3 563. 2049 INJECTION 50MG INJ - Each ml to contain: Ferric Carboxy Maltose eqv. To Elemental Iron 50mg DARBEPOETIN ALFA 40 MCG/0.4ML INJ - Each PFS to Group No.3 564. 2050 INJECTION contain: Darbepoetin Alfa 40 mcg/0.4ml 565. 2064 INJECTION Each amp to contain: Budesonide 0.5mg+ Group No.3 Levalbuterol 1.25mg

Page 58 of 112

566. 2077 INJECTION Hemostat containing: Hemostatic matrix with Group No.3 thrombin in prifilled syringe 10ml 567. 2083 INJECTION Aflibercept injection 40 mg / ml Aflibercept (r-DNA Origin) solution for intravitreal injection in Vial Each pack contains: Group No.3 1 vial and a 18 G Sterile filter needle 278 microliters/vial Each single dose vial provides a usable amount to deliver a single dose of 50 microliters containing 2mg Aflibercept. 568. 2086 INJECTION Piracetam inj.: Each ml to contains : Piracetam Group No.3 200mg 569. 2088 INJECTION Each vial to contains: Recombinanant Follicle Stimulating Hormone Group No.3 or r-FSH (Follitrophine Beta) 100 IU/0.5 mL soln. for Inj. 570. 2098 INJECTION Each Vial to contain : Group No.3 Bimatoprost 300mcg, Timolol Maleate 6.8mg equilant to Timolol 5 mg 571. 2104 INJECTION Each Phial to contain : Posaconazole oral soln Group No.3 40mg/ml 572. 2106 INJECTION DARBEPOETIN ALFA 60 MCG/0.6ML INJ: Each PFS Group No.3 to contains: Darbepoetin Alfa 60 mcg/0.6ml 573. 2109 INJECTION Each 2ml Amp contains : Mecobalamin 1500mcg, Pyridoxine Hydrochloride Group No.3 100mg, Nicotinamide 100mg, Benzyl Alcohol IP 2% V/V 574. 2118 INJECTION Each 20ml vial to contain: Atezolizumab injection Group No.3 1200mg 575. 2121 INJECTION Adalimumab Injection Each Pre-Filled Syringe contains : Adalimumab 20mg/ 0.4ml Composition Adalimumab 20mg Succinic Acid 0.472mg Group No.3 Sodium Hydroxide NF q.s. to pH 5.2 Sodium Chloride USP 2.336mg L-Arginine Monohydrochloride USP 2mg Sorbitol NF 4mg Polysorbate 80 NF 0.04mg WFI q.s. to 0.4ml 576. 2123 INJECTION Each vial to contain: Docetaxel Lipid Suspension Group No.3 80mg inj (Nanosomal) (Lyophilized) 577. 2132 INJECTION Each vial to contain : Group No.3 Pembrolizumab 50mg powder for solution for infusion Group No.3 578. 2133 INJECTION Each vial to contains: Obinutuzumab lOOOmg 579. 2134 INJECTION Each 4 mL vial to contains: Nivolumab 40mg Group No.3 (40mg/4 mL)

Page 59 of 112

580. 2135 INJECTION Each 10mL vial to contains: Nivolumab 100mg Group No.3 (100mg/10mL) 581. 2136 INJECTION Each 14ml vial to contain : Pertuzumab 420mg Group No.3 (30mg/ml) 582. 2137 INJECTION Each Single dose vial contains:(Sterile lypholized) Group No.3 Triptorelin Pamoate equivalent to Triptorelin 11.25mg Pamorelin LA 11.25 Inj. 583. 2139 INJECTION Each vial to contains Denosumab 120 mg Group No.3 (70mg/ml) Total fill 1.7ml in 5ml vial 584. 2140 INJECTION Each Single use vial of 5 ml contains Panitumumab Group No.3 100 mg (20mg/ml) 585. 2141 INJECTION Each vial to contains: Carfilzomib 60mg sterile Group No.3 lypholized powder Group No.3 586. 2146 INJECTION Paracetamol IV inj: Each 50ml to contain 500mg 587. 2147 INJECTION Adalimumab Injection Each Pre-Filled Syringe contains : Adalimumab 40mg/ 0.8ml Composition Adalimumab 40mg Succinic Acid 0.944mg Group No.3 Sodium Hydroxide NF q.s. to pH 5.2 Sodium Chloride USP 4.672mg L-Arginine Monohydrochloride USP 4mg Sorbitol NF 8mg Polysorbate 80 NF 0.08mg WFI q.s. to 0.8ml Group No.3 588. 2148 INJECTION Each 5ml vial to contains: Irinotecan 100 mg 589. 2149 INJECTION Each vial to contains : ado-trastuzumab emtansine Group No.3 160mg 590. 2151 INJECTION Eribulin mesylate solution for injection Each 2ml vial contains : Eribulin ŵesylate….. ϭŵg, Group No.3 eƋv. To EƌiďuliŶ …...Ϭ.88ŵg Ethanol Anhydrous 4.5% to 5.5% Group No.3 591. 2154 INJECTION Each vial to contains:Trabectedin 1 Mg Group No.3 592. 2155 INJECTION Each vial to contains: Permetrexed 100mg 593. 2156 INJECTION Each vial to contains : ado-trastuzumab emtansine Group No.3 100mg Group No.3 594. 2159 INJECTION Each vial to contains:Azacitidine 100 mg Group No.3 595. 2161 INJECTION Each vial to contains:Fulvestrant 250mg Group No.3 596. 2162 INJECTION Each vial to contains:Itolizumab 25MG/5ML 597. 2163 INJECTION Each vial to contain: Doxorubicin hydrochloride Group No.3 liposome 50mg/25ml Group No.3 598. 2164 INJECTION Each 15ml vial to contain: Natalizumab 300 MG 599. 2166 INJECTION Each vial to contains :Docetaxel Lipid Suspension Group No.3 20mg inj (Nanosomal) (Lyophilized) 600. 2167 INJECTION Inj Recombinant Human Granulocyte Macrophage Group No.3 Colony stimulatingFactor (r-hu-GMCSF) 500microgram

Page 60 of 112

601. 2168 INJECTION Each vial to contain: Doxorubicin hydrochloride Group No.4 liposome 20mg/10ml Group No.4 602. 2169 INJECTION Each vial to contains:Degarelix 80 mg Group No.4 603. 2170 INJECTION Each vial to contains: Transtuzumab 150mg Group No.4 604. 2171 INJECTION Each vial to contain : Pamidronate Disodium 60mg Group No.4 605. 2172 INJECTION Each vial to contain:Fosaprepitant 150mg Group No.4 606. 2173 INJECTION Each vial to contain :BCG for immunotherapy 40mg Group No.4 607. 2175 INJECTION Each vial to contains: Bendamustine HCL 100mg Group No.4 608. 2176 INJECTION Each 2ml vial to contains: Irinotecan 40 mg 609. 2179 INJECTION Ramucirumab Concentrate for Solution for Infusion Each vial contains : Ramucirumab 500mg / 50ml vial Group No.4 component : Ramucirumab 500mg L-Histidine 32.5mg L-Histidine Monohydrochloride 61.0mg Glycine 499mg Sodium Chloride 219mg Polysorbate -80 5.0mg Water for Injection q.s. 610. 2180 INJECTION Each 1 ml conatins: Secukinumab 150mg Sucrose 92.43mg Group No.4 L- Histidine / L- Histidine MCL Monohydrate 4.656 mg Polysorbate 80 - 0.60mg. 611. 2181 INJECTION Golimumab (r-DNA origin) Each single use Pre-Filled Syringe contians : Golimumab 50mg/0.5ml Group No.4 Component [amount per dose (mg)]: Golimumab (CNTO 148) -50mg, Sorbitol - 20.5mg, L-Histidine - 0.44mg, Polysorbate 80 - 0.075mg Water for Injection - 0.5mg 612. 2182 INJECTION Each ml contains: Phospholipids 25mg(derived from bovine lung lipid extract standarized by addition of Group No.4 colfosceril palmitate, tripalmitin and palmitic acid) and sodium chloride 9 mg, in WFI 613. 2185 INJECTION Meningococcal Group (A,C,Y and W135) Group No.4 Polysachharide Diphtheria Toxoid Conjugate Vaccine 614. 2186 INJECTION Snake Anti venin (Polyvalent) IP 10ml (Enzyme refined Equine Globulins) Each 1ml neutralises: 0.60mg of Cobra venom (Naja Naja), 0.45mg of Common Krait Group No.4 Venom(Bungarus Caeruleus), 0.60mg of Ruseells Viper Venom (Vipera russelli), 0.45mg of Saw scaled Viper Venom (Echis carinatus) Preservatives Phenol IP 50.25% w/v 615. 1069 INJECTION MEPHENTERMINE INJ - Each ml. To contain : Mephertermine (as Group No.4 b sulphate ) 30 mg. Each ml. To contain : Mephentermine (as sulphate ) Group No.4 616. 1069a INJECTION I.P.15 mg. MEPHENTERMINE INJ - Each ml. To contain : Group No.4 617. 1069b INJECTION Mephertermine (as sulphate ) 30 mg. Page 61 of 112

PARNAPARIN INJ - Each PFS to contain: Low Group No.4 618. 1079a INJECTION Molecular weight Heparin Sodium Salt (Parnaparin )- 3200 .I.U. PARNAPARIN INJ - Each PFS to contain: Low Group No.4 619. 1079b INJECTION Molecular weight Heparin Sodium Salt (Parnaparin )- 6400 I.U. TRAMADOL INJ - Each ml to contain:Tramadol Group No.4 620. 1082a INJECTION Hydrochloride 50 mg. 621. 1082b INJECTION TRAMADOL INJ - Each ml to contain: Tramadol Group No.4 Hydrochloride 50 mg. 622. 1118a INJECTION MIDAZOLAM INJ - Each ml to contain: Midazolam Group No.4 5mg. MIDAZOLAM INJ - Each ml. to contain: Midazolam Group No.4 623. 1118b INJECTION 1mg. HUMAN CHORIONIC GONADOTROPIN INJ - Each ml to Group No.4 624. 1157a INJECTION contain: Human Chorionic Gonadotropin 2000 IU HUMAN CHORIONIC GONADOTROPIN INJ - Each Group No.4 625. 1157b INJECTION amp/vial to contain : Human Chorionic Gonadotropin 5000 IU HUMAN CHORIONIC GONADOTROPHIN INJ - Each ml Group No.4 626. 1157c INJECTION to contain : Human Chorionic Gonadotrophin 10000 IU Each vial to contain: Amoxycillin 1gm. & Clavulanic Group No.4 627. 1192a INJECTION Acid 200mg. Each vial to contain: Amoxycillin 500mg & Clavulenic Group No.4 628. 1192b INJECTION Acid 100mg. Each vial to contain: Amoxycillin I.P. 250mg & Group No.4 629. 1192c INJECTION Clavulanic Acid I.P. 50mg.

Group No.4 630. 1285a INJECTION Each ml. to contain : Ketamine Hcl 10 mg.

KETAMINE INJ - Each ml to contain : Ketamine Hcl 50 Group No.4 631. 1285b INJECTION mg. 632. 1285c INJECTION KETAMINE INJ - Each ml to contain: Ketamine Hcl Group No.4 50mg. 633. 130a INJECTION PROGESTERONE INJ - Each Inj to contain: Hydroxy- Group No.4 progesterone 250mg. Each Inj. to contain: Hydroxy-progesterone I.P. Group No.4 634. 130b INJECTION 500mg. Each ml. to contain: Testosterone Propionate Group No.4 635. 131a INJECTION I.P.25mg. Each ml. to contain: Testosterone Propionate Group No.4 636. 131b INJECTION I.P.50mg. DEXTRAN INFUSION - Each to contain: Dextran 10% Group No.4 637. 1323a INJECTION in 5% Glucose. DEXTRAN INFUSION - Each to contain: Dextran 10% Group No.4 638. 1323b INJECTION in Normal Saline.

Page 62 of 112

639. 1328a INJECTION INTERFERON INJ - Each vial to contain: Interferon Group No.4 Alpha IP 2B : 3Mil I.U. 640. 1329 INJECTION CISPLATINUM INJ - Each vial to contain: Cisplatinum IP 50mg. Group No.4 b 641. 1329a INJECTION CISPLATINUM INJ - Each vial to contain: Cisplatinum IP Group No.4 10mg. CISPLATINUM INJ - Each vial to contain: Cisplatinum IP Group No.4 642. 1329b INJECTION 50mg. CYCLOPHOSPHAMIDE INJ - Each vial to contain: Group No.4 643. 1330a INJECTION Cyclophosphamide 100mg. CYCLOPHOSPHAMIDE INJ - Each vial to contain: Group No.4 644. 1330b INJECTION Cyclophosphamide IP 200mg. 645. 1331a INJECTION MITOMYCIN INJ - Each vial to contain: Mitomycin Group No.4 2mg. MITOMYCIN INJ - Each vial to contain: Mitomycin Group No.4 646. 1331b INJECTION 10mg. IONIC CONTRAST MEDIA - Each ml to contain : Diatrizoic Acid 471.78 mg., Meglumine 125.46 mg., Group No.4 647. 1337a INJECTION equivalent to Diatrizoate Sodium 80 mg., Diatrizoate Meglumine 520mg, Iodine content 5.84/20 ml. IONIC CONTRAST MEDIA - Each ml. to contain : Diatrizoic Acid 597.30 mg., Meglumine 159.24 mg., Group No.4 648. 1337b INJECTION equivalent to Diatrizoate Sodium 100 mg., Diatrizoate Meglumine 660 mg., Iodine content 7.4 gm./20ml. NON-IONIC CONTRAST MEDIA - Each ml. to contain : Group No.4 649. 1338a INJECTION Iohexol 518 mg eqv. to Iodine 240 mg. NON-IONIC CONTRAST MEDIA - Each ml. to contain : Group No.4 650. 1338b INJECTION Iohexol 647 mg eqv. to Iodine 300 mg. NON-IONIC CONTRAST MEDIA - Each ml. to contain Group No.4 651. 1338c INJECTION :Iohexol 647 mg eqv. to Iodine 300 mg. NON-IONIC CONTRAST MEDIA - Each ml. to contain Group No.4 652. 1338d INJECTION :Iohexol 755mg eqv. to Iodine 350 mg. NON- IONIC CONTRAST MEDIA - Each ml to contain: Group No.4 653. 1338e INJECTION Iohexol 755 mg eqv to iodine 350 mg 654. 1339 INJECTION HUMAN TETANUS SPECIFIC IMMUNOGLOBULIN - Group No.4 b Each vial to contain: Human Tetanus Specific Immunoglobulin 500 units. HUMAN TETANUS SPECIFIC IMMUNOGLOBULIN - Each Group No.4 655. 1339a INJECTION vial to contain: Human Tetanus Specific Immunoglobulin 250units. HUMAN TETANUS SPECIFIC IMMUNOGLOBULIN - Each Group No.4 656. 1339b INJECTION vial to contain: Human Tetanus Specific Immunoglobulin 500 units. Each vial to contain: Meropenem Trihydrate eqv. to Group No.4 657. 1352b INJECTION Anhydrous Meropenem 1gm. 658. 1407 INJECTION EPIRUBICIN INJ - Each Inj. to contain: Epirubicin Hydrochloride Group No.4 b 50mg

Page 63 of 112

EPIRUBICIN INJ - Each Inj to contain: Epirubicin Group No.4 659. 1407a INJECTION Hydrochloride10mg EPIRUBICIN INJ - Each Inj. to contain: Epirubicin Group No.4 660. 1407b INJECTION Hydrochloride 50mg

Group No.4 661. 1408a INJECTION Each Inj. to contain: Peginterferon Alfa -2B 50mcg

Group No.4 662. 1408b INJECTION Each Inj. to contain: Peginterferon Alfa -2B 80mcg

Containing: Highly Purified Bovine Insulin (soluble) 40 Group No.4 663. 141a INJECTION units /ml. REVIPARIN SOD. INJ - Each PFS to contain: Reviparin Group No.4 664. 1423a INJECTION Sod. REVIPARIN SOD. INJ - Each vial to contain: Reviparin Group No.4 665. 1423b INJECTION Sod. 666. 1439 INJECTION VITAMIN & MINERAL INJ - Each PFS to contain: Methoxy Group No.4 b Polyethylene Glycol Epoetin-beta 75mcg 667. 1439a INJECTION VITAMIN & MINERAL INJ - Each PFS to contain: Group No.4 Methoxy Polyethylene Glycol Epoetin-beta 50mcg VITAMIN & MINERAL INJ - Each PFS to contain: Group No.4 668. 1439b INJECTION Methoxy Polyethylene Glycol Epoetin-beta 75mcg 669. 1439c INJECTION VITAMIN & MINERAL INJ - Each PFS to contain: Group No.4 Methoxy Polyethylene Glycol Epoetin-beta 100mcg Containing: Highly Purified Bovine Insulin Zinc 40units Group No.4 670. 143a INJECTION per/ml.

Group No.4 671. 1449a INJECTION RITUXIMAB INJ - Each vial to contain:Rituximab 100mg

RITUXIMAB INJ - Each vial to contain: Rituximab Group No.4 672. 1449b INJECTION 500mg INTERFERON ALPHA 2B INJ - Each vial to contain: Group No.4 673. 1452a INJECTION Interferon Alpha 2B 18 MIU INTERFERON ALPHA 2B INJ - Each vial to contain: Group No.4 674. 1452b INJECTION Interferon Alpha 2B 30 MIU 675. 1486 INJECTION INSULIN GLARGINE INJ - Each vial to contain: Insulin Glargine 100 Group No.4 b units/ ml INSULIN GLARGINE INJ - Each vial to contain: Insulin Group No.4 676. 1486b INJECTION Glargine 100 units/ ml

Group No.4 677. 1514a INJECTION Each ml to contain: Bractant (as phospholipid) 25mg,

Group No.4 678. 1514b INJECTION Each ml to contain: Bractant (as phospholipid) 25mg,

HUMAN COAGULATION FACTOR VII INJ - Each vial to Group No.4 679. 1534a INJECTION contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 1mg HUMAN COAGULATION FACTOR VII INJ - Each vial to Group No.4 680. 1534b INJECTION contain: Human Recombinant Coagulation Factor VII activated (r-DNA origin) 2mg

Page 64 of 112

681. 1553 INJECTION DORIPENEM INJ - Each vial to contain: Doripenem 500 mg Group No.4 b 682. 1553a INJECTION DORIPENEM INJ - Each vial to contain: Doripenem 250 Group No.4 mg DORIPENEM INJ - Each vial to contain: Doripenem 500 Group No.4 683. 1553b INJECTION mg 684. 1557a INJECTION CEFTRIAXONE+TAZOBACTAM INJ - Each vial to Group No.4 contain: Ceftriaxone 250mg, Tazobactam Sodium 31.25mg Each vial to contain: Inj. Ceftriaxone Group No.4 685. 1557b INJECTION I.P.500mg,Tazobactam Sodium 62.5mg CEFTRIAXONE+TAZOBACTAM INJ - Each vial to Group No.4 686. 1557c INJECTION contain: Ceftriaxone1gm, Tazobactam Sodium 125mg CEFUROXIME INJ - Each vial to contain: Cefuroxime Group No.4 687. 1558a INJECTION 750mg

Group No.4 688. 1558b INJECTION Each vial to contain: Inj Cefuroxime I.P. 1.5gm

CEFUROXIME+CLAVULANATE POTASSIUM INJ - Each Group No.4 689. 1560a INJECTION vial to contain: Cefuroxime 250mg, Clavulanate Potassium 125mg. CEFUROXIME+CLAVULANATE POTASSIUM INJ - Each Group No.4 690. 1560b INJECTION vial to contain: Cefuroxime Axtil 500mg, Clavulanate Potassium 125mg. TRIAMCINOLONE INJ - Each ml to contain: Group No.4 691. 1590a INJECTION Triamcinolone 10mg TRIAMCINOLONE INJ - Each ml to contain: Group No.4 692. 1590b INJECTION Triamcinolone 40mg HYOSCINE BUTYL BROMIDE INJ - Each ml. to contain : Group No.4 693. 15b INJECTION Hyoscine Butyl Bromide 20mg.

Group No.4 694. 162a INJECTION Each vial to contain: Ampicillin 250mg.

Group No.4 695. 162b INJECTION Each vial to contain: Ampicillin 500mg. 696. 1650a INJECTION FILGRASTIM INJ - Each PFS/Vial to contain: Filgrastim Group No.4 150 mcg FILGRASTIM INJ - Each PFS/Vial to contain: Filgrastim Group No.4 697. 1650b INJECTION 300 mcg HEPATITIS B IMMUNOGLOBULIN INJ - Each 0.5ml to Group No.4 698. 1652a INJECTION contain:Inj Hepatitis B Immunoglobulin 100 IU HEPATITIS B IMMUNOGLOBULIN INJ - Each 1ml to Group No.4 699. 1652b INJECTION contain:Inj. Hepatitis B Immunoglobulin 200 IU Each vial to contain: Cefatoxime Sod. eqv. to Group No.4 700. 180a INJECTION Cefatoxime 250mg. Each vial to contain: Cefatoxime Sod. eqv. to Group No.4 701. 180b INJECTION Cefatoxime 1gm. SUCCINYL CHOLINE INJ - Each ml to contain: Succinyl Group No.4 702. 245a INJECTION Choline Chloride 50mg.

Page 65 of 112

SUCCINYL CHOLINE INJ - Each ml to contain: Succinyl Group No.4 703. 245b INJECTION Choline Chloride 50mg. Group No.4 704. 249a INJECTION BUPIVACAINE INJ - Containing: Bupivacaine Hcl 0.25%. BUPIVACAINE HEAVY INJ - Containing: Bupivacaine Hcl Group No.4 705. 249c INJECTION 0.5% DEXTROSE INJ(FOR I.V INFUSION) - Containing: Group No.4 706. 278a INJECTION Dextrose Anhydrous 5% w/v DEXTROSE INJ(FOR I.V INFUSION) - Containing: Group No.4 707. 278b INJECTION Dextrose Anhydrous 10% w/v HEPATITIS B VACCINE( R-DNA) - Each Vial to contain: Group No.4 708. 284a INJECTION 20mcg. of Hepatitis B surface Antigen. HEPATITIS B VACCINE( R-DNA) - Each vial to contain: Group No.4 709. 284b INJECTION 10 mcg of Hepatitis B surface antigen. HEPATITIS B VACCINE (R-DNA) - Each ml. to Contain: Group No.4 710. 284c INJECTION 20mcg of Hepatitis B surface Antigen

Group No.4 711. 323a INJECTION Each ml. to contain: Esmolol 10mg.

Group No.4 712. 328a INJECTION Each vail to contain: Urokinase I.P. 2.5 lakhs IU

UROKINASE INJ - Each vial to contain: Urokinase 5 Group No.4 713. 328b INJECTION lakhs IU ENOXAPRIN INJ - Each PFS to contain Enoxaprin Group No.4 714. 366a INJECTION Sodium 20 mg / 0.2 ml. ENOXAPARIN 60 MG/0.6ML INJ - Each PFS to contain: Group No.4 715. 366c INJECTION Enoxaparin 60 mg/0.6ml Group No.4 716. 400a INJECTION PROPOFOL INJ - Each vial to contain: Propofol 1%

Group No.4 717. 400b INJECTION PROPOFOL INJ - Each vial to contain: Propofol 2%

MALOGRAMOSTIM INJ - Each vial to contain: Group No.4 718. 404a INJECTION Malogramostim 150mcg. MALOGRAMOSTIM INJ - Each vial to contain: Group No.4 719. 404b INJECTION Malogramostim 300mcg. ERYTHROPOIETIN INJ - Each PFS to contain: Group No.4 720. 408a INJECTION Recombinant Human Erythropoietin 2000 units Each PFS to contain: Recombinant Human Group No.4 721. 408d INJECTION Erythropoietin 3000 IU TEICOPLANIN INJ - Each vial to contain :Teicoplanin Group No.4 722. 413a INJECTION 200mg. TEICOPLANIN INJ - Each vial. to contain Group No.4 723. 413b INJECTION :Teicoplanin400mg. GEMCITABINE INJ - Each vial to contain: Gemcitabine Group No.4 724. 459a INJECTION 200mg. 725. 459b INJECTION GEMCITABINE INJ - Each vial to contain: Gemcitabine Group No.4 1gm. Each injection containing :Human Anti-D Group No.4 726. 465b INJECTION Immunoglobulin 300 mcg (Ultrafiltered) Group No.4 727. 487a INJECTION PACLITAXEL INJ - Each vial to contain: Paclitaxel Page 66 of 112

100mg. PACLITAXEL INJ - Each vial to contain: Paclitaxel IP Group No.4 728. 487b INJECTION 200mg. CARBOPLATIN INJ - Each vial to contain: Carboplatin Group No.4 729. 488a INJECTION 150mg CARBOPLATIN INJ - Each vial to contain: Carboplatin Group No.4 730. 488b INJECTION 450mg. HUMAN GROWTH HORMONE - Each Cartridge to Group No.4 731. 509a INJECTION contain: Somatropin 16 IU (R-DNA origin) HUMAN GROWTH HORMONE - Each cartridge Group No.4 732. 509b INJECTION containing: Somatropin 18 IU (R-DNA origin) HUMAN GROWTH HORMONE - Containing: Group No.4 733. 509e INJECTION Somatropin 4 IU (R-DNA origin) DALTEPARIN SODIUM INJ - Each PFS to contain: Group No.4 734. 557a INJECTION Dalteparin Sodium 2500 IU units DALTEPARIN SODIUM INJ - Each PFS to contain: Group No.4 735. 557b INJECTION Dalteparin Sodium 5000 IU units

Group No.4 736. 587a INJECTION Containing : Sevoflurane 737. 587b INJECTION SEVOFLURANE INJ - Each 250ml to contain: Group No.4 Sevoflurane INTRAVENOUS LIPID SOLN. 10% - Each 100ml. to contain: Fat emulsion containing Fractionated Group No.4 738. 603a INJECTION Soyabean Oil 10gm., Fractionated Egg Phospholipids 1.2gm. Glycerol 2.2gm. INTRAVENOUS LIPID SOLN 20% - Each 100ml to contain: Fat emulsion containing Fractionated Group No.4 739. 603b INJECTION Soyabean Oil 20gm., Fractionated Egg Phospholipids 1.2gm. Glycerol 2.2gm. STREPTOKINASE INJ - Each vial to contain: Group No.4 740. 74a INJECTION Streptokinase I.P.7.5 lac IU STREPTOKINASE INJ - Each vial to contain: Group No.4 741. 74b INJECTION Streptokinase 15lac IU Group No.4 742. 226 LOTION Containing: Povidone Iodine 7.5% Group No.4 743. 241 LOTION Containing:Strong Cetrimide Solution 20% Group No.4 744. 247 LOTION Halothane Group No.4 745. 394 LOTION Each ml. to contain: Clotrimazole I.P.10mg. Group No.4 746. 397 LOTION Containing : Erythromycin I.P.2% 747. 411 LOTION CALAMINE LOTION - Each bot to contain: Calamine Group No.4 15%, Zinc Oxide 5% Containing: Oxybenzene 4.5%, Octyl methoxy- Group No.4 748. 445 LOTION cinnamate 7.5% Group No.4 749. 492 LOTION Containing: Proteolytic Enzymes, Presoak Plus Cleaner Containing: Alkaline Gluteraldehyde 2.4% without Group No.4 750. 493 LOTION surfactant with inert stabilizing system. Containing: Chlorhexidine Gluconate soln. 2.5%, Ethyl Group No.4 751. 494 LOTION Alcohol 70% Page 67 of 112

Containing: Clotrimazole I.P.1% + Lignocaine Group No.4 752. 551 LOTION Hydrochloride I.P.2% Containing : Choline Salicylate 9.0% w/v,Benzalkonium Group No.4 753. 1240 LOTION Chloride I.P.0.02% Group No.4 754. 1244 LOTION Containing: Miconazole 2% Group No.4 755. 1246 LOTION Containing: Gamma Benzene Hexachloride I.P. 1% Group No.4 756. 1248 LOTION Containing: Povidone Iodine 5.0% w/v Group No.4 757. 1267 LOTION Containing:Glutaraldehyde 2% with activator PSU Item Group No.4 758. 1271 LOTION GLYCERINE - Each bot to contain:Glycerine 500 gms Group No.4 759. 1272 LOTION PHENOL(CARBOLIC ACID) - Each bot to contain: Phenol CLOBETASOL LOTION - Each to contain: Clobetasol Group No.4 760. 1366 LOTION Propionate 0.05% Group No.4 761. 1385 LOTION Each 2ml to contain: Deca Peptite 2mg FLUOCINOLONE LOTION - Each to contain: Group No.4 762. 1394 LOTION Fluocinolone 0.01% w/v CLOTRIMAZOLE + BECLOMETHASONE DIPROPIONATE Group No.4 763. 1428 LOTION LOTION - Containing: Clotrimazole 1% w/w, Beclomethasone dipropionate 0.025% w/v base Containing: Betamethasone Dipropionate I.P. 0.05% + Group No.4 764. 1443 LOTION Zn. Sulphate I.P. 0.5 w/w Group No.4 765. 1446 LOTION Containing: 1% prepared coal tar w/w Containing: Clotrimazole I.P. 1% in Propylene Glycol Group No.4 766. 1464 LOTION I.P., Glycerin I.P. base Containing: Avobenzone 3%w/w,Oxybenzone Group No.4 767. 1623 LOTION I.P./B.P./USP 3%w/w,Octylmethoxycinnamate 7.5%, Titanium dioxide I.P./B.P./USP Group No.4 768. 1629 LOTION Containing: Liq. Paraffin I.P. Group No.4 769. 1705 LOTION LOTION - Containing: Minoxidil 5%, Amenexil 1.5% 770. 1706 LOTION PAINT / LOTION - Each to contain: Lactic Acid 16.7%, Group No.4 Salicylic Acid 16.7 % SERTACONAZOLE NITRATE LOTION - Each phial to Group No.4 771. 1711 LOTION contain: Sertaconazole Nitrate 2% w/v Propylene glycol base QS DESONIDE LOTION - Each bot to contain: Desonide Group No.4 772. 1784 LOTION 0.05% w/w. 773. 1940 LOTION KETOCONAZOLE LOTION - Each bot to contain: Group No.4 Ketoconazole 2% w/v 774. 1945 LOTION LULICONAZOLE LOTION - Each bot/phial to contain: Group No.4 Luliconazole 1% Group No.4 775. 1946 LOTION LOTION - Each bot to contain: Minoxidil 2% Group No.4 776. 1947 LOTION LOTION - Each bot to contain: Minoxidil 5% SODIUM PERBORATE - Each to contain: Sodium Group No.4 777. 1955 LOTION perborate monohydrate 50% w/w Group No.4 778. 1268a LOTION Containing:Alkaline Gluteraldehyde 2% Group No.4 779. 1268b LOTION Containing:Alkaline Gluteraldehyde 2%

Page 68 of 112

Each 100gm contain: Glutaraldehyde I.P. Group No.4 780. 1625a LOTION 10gms,Quaternary ammonium compounds 12gms. Each 100gm contain: Glutaraldehyde I.P. Group No.4 781. 1625b LOTION 10gms,Quaternary ammonium compounds 12gms. 782. 448a LOTION PERMETHRIN 1% LOTION - Each bot to contain: Group No.4 Permethrin 1% Group No.4 783. 1562 LOZENGES Each lozenges to contain: Clotrimazole Lozenges I.P.

Group No.4 784. 91 OINTMENT Containing: Piroxicam 0.5%w/w

Group No.4 785. 221 OINTMENT containing: Miconazole Nitrate 2%w/v.

Group No.4 786. 223 OINTMENT Containing: Clotrimazole 1% w/v 787. 224 OINTMENT BENZYL BENZOATE APPLICATION - Each bot to Group No.4 contain:Benzyl Benzoate 25%

Group No.4 788. 225 OINTMENT Containing: Povidone Iodine 5% w/v.

Group No.4 789. 227 OINTMENT Containing Framycetin Sulphate 1%

Group No.4 790. 229 OINTMENT Containing: Flucinolone Acetonide I.P. 0.025% w/w

Containing: Betamethasone Valerate I.P. 0.12% Group No.4 791. 230 OINTMENT Chinoform 3% in cream base Containing: Dexamethasone Acetate I.P. 0.1% w/w Group No.4 792. 231 OINTMENT Framycetin Sulphate 1% w/w Clotrimazole I.P. 1% w/w Containing: Precipitated Sulpur 5 % w/w Benzyl Group No.4 793. 233 OINTMENT Peroxide 10 % w/w

Group No.4 794. 240 OINTMENT Containing : White soft paraffin

Containing: Beclomethasone dipropionate I.P. 0.025 Group No.4 795. 358 OINTMENT %, Phenylepherine Hydrochloride I.P. 0.1 %, Lignocaine hydrochloride I.P.2.5 %. Each gm. to contain : Nimesulide 10mg., Methyl Group No.4 796. 371 OINTMENT Salicylate I.P.100mg., Menthol I.P. 50mg., Capsaicin 0.25mg.in cream base

Group No.4 797. 375 OINTMENT Each gm. to contain : Estriol 1mg.

Containing :Flucinolone Acetonide 0.025%, Neomycin Group No.4 798. 393 OINTMENT Sulphate 0.5% Miconazole Nitrate 2.0% 799. 395 OINTMENT CLOTRI, BECLOMETH OINT. - Containing: Group No.4 Clotrimazole 10mg., Beclomethasone Dipropionate 0.25mg. Containing: Silver Sulphadiazine 1%, Chlorhexidine Group No.4 800. 396 OINTMENT Gluconate 0.2%, Aloe Vera 15%, Allatoin 0.1%, Vitamin E 0.2%.

Page 69 of 112

Containing : Dithranol I.P. 1.15%, Salicylic Acid I.P. Group No.5 801. 442 OINTMENT 1.15%, Coal Tar solution 5.3%, white soft Paraffin I.P.q.s. Containing: Coal Tar 6%, Salicylic Acid I.P. 3%, Group No.5 802. 444 OINTMENT Precipitated sulpher I.P. 3%

Group No.5 803. 448 OINTMENT Containing: Permethrin 5% 804. 480 OINTMENT MUPIROCIN OINT - Each tube to contain: Mupirocin Group No.5 2% Containing: Hydroquionine I.P./B.P./U.S.P 2%, Group No.5 805. 491 OINTMENT Benzophenone-3 I.P. 2.5%, Octyl Methoxycinnamate 9.0% in crease base containing Titanium Dioxide

Group No.5 806. 510 OINTMENT Containing: Metronidazole 1%, Povidone Iodine 5% 807. 519 OINTMENT FLUOCINOLONE OINT. - Each tube to contain: Group No.5 Fluocinolone Acetonide 0.1% + Methyl Paraben 0.15% + Propyl Paraben 0.05%

Group No.5 808. 520 OINTMENT Containing : Bifonazole Ph.Eur.1%

Each gm. to contain: Tolnaftate 10mg., Nystatin Group No.5 809. 528 OINTMENT 100000 units Each gm. to contain : Framycetin sulphate I.P.10 mg. Hydrocortisone Acetate I.P. 5.5 mg. Heparin I.P.100 Group No.5 810. 1031 OINTMENT IU Esculoside 10 mg. Ethyl Amino Benzoate 10 mg,Butyl amino benzoate 10 mg. Each gm. To contain :Heparin Sod. 50 IU, Benzyl Group No.5 811. 1080 OINTMENT Nicotinate Containing : Methyl Salicylate 4% w/w, Mephensin 5% Group No.5 812. 1110 OINTMENT w/w, Iodine 0.5% w/w Containing: Diclofenac Diethylammonium salt 1.16 % Group No.5 813. 1111 OINTMENT w/w (equivalent to diclofenac Sod 1% w/w) ANALGESIC GEL - Each tube to contain: Diclofenac Diethylamine Salt 1.16% (eqv. to Diclofenac Sodium Group No.5 814. 1112 OINTMENT 1%), Linolenic acid 3%, Methyl Salicylate 10%, Menthol 5% ANTIBIOTIC EYE OINTMENT - Each gram to contain:Polymyxin B Sulphate 5000 IU Neomycin Group No.5 815. 1211 OINTMENT sulphate 3400 IU Zinc Bacitracin 400 IU Hydrocortisone 10 mg. in white sterilised petroleum jelly base. 816. 1213 OINTMENT ATROPINE EYE OINT. - Containing: Atropine sulphate Group No.5 1% ACYCLOVIR EYE OINT - Each tube to contain: Acyclovir Group No.5 817. 1228 OINTMENT I.P.3% Containing : Salicylic Acid I.P. 6% w/w Benzoic Acid Group No.5 818. 1241 OINTMENT I.P./ B.P. 12% w/w Hydrocortisone Acetate I.P. 0.5% w/w

Page 70 of 112

Containing :Urea I.P. 12% w/w Lactic Acid I.P. 6% w/w Glycine I.P. 3% w/w Ammonium Chloride I.P. 0.5% w/w Sod. Chloride I.P. 0.5% w/w Potassium Chloride Group No.5 819. 1242 OINTMENT I.P. 0.5% w/w Calcium Lactate I.P. 0.5% w/w Magnesium Chloride I.P. 0.3% w/w Sod. Dihydrogen Phosphate Group No.5 820. 1243 OINTMENT Each gm. to contain : Ciclopirox Olamine 10 mg.

Group No.5 821. 1245 OINTMENT Containing : Crotamiton I.P./ U.S.P.10%

FRAMYCETIN CREAM - Each tube to contain: Group No.5 822. 1249 OINTMENT Framycetin Sulphate 1% w/w containing per gm. Polymixin B Sulphate 5000 IU Group No.5 823. 1251 OINTMENT Neomycin sulphate 3400 IU Zinc Bacitracin 400 IU 824. 1252 OINTMENT CLOBETASOL OINT - Each tube to contain: Clobetasol Group No.5 Propionate 0.05% 825. 1253 OINTMENT BETAMETHASONE OINT - Each tube to contain: Group No.5 Betamethasone ( as Valerate ) 0.1%

Group No.5 826. 1257 OINTMENT Containing : Tretinoin (Trans retionic acid) 0.05% SALICYLIC ACID+ BETAMETHASONE OINT - Each tube Group No.5 827. 1364 OINTMENT to contain: Betamethasone IP 0.05%, Salicylic Acid IP 6% 828. 1365 OINTMENT CREAM - Each tube to contain: Dimethicone 20%, Zinc Group No.5 Oxide 5%, Calamine 1.5%, Cetrimide 1.125%, Cholocresol CIPROFLOXACINE EYE OINT. - Containing: Group No.5 829. 1384 OINTMENT Ciprofloxacin Hydrochloride 0.3% w/w 830. 1386 OINTMENT FUSIDATE SODIUM OINT - Each 1gm to contain: Group No.5 Sodium Fusidate 20mg CLINDAMYCIN GEL - Each tube to contain: Clindamycin Group No.5 831. 1387 OINTMENT (As Clindamycin Phosphate) 1% CLOBETASOL, GENTAMYCIN, MICONAZOLE OINT - Each tube to contain: Clobetasol Propionate 0.05% Group No.5 832. 1390 OINTMENT w/w, Gentamycin Sulphate 0.1% w/w, Miconazole Nitrate 2%w/w 833. 1391 OINTMENT ACYCLOVIR CREAM - Each tube to contain: Acyclovir Group No.5 5% w/w CLOTRIMAZOLE GEL - Each tube to Group No.5 834. 1397 OINTMENT contain:Clotrimazole 2% w/w Containing: Glyceryl paramino benzoate2.8%, Group No.5 835. 1429 OINTMENT Hydroquinone I.P./B.P./U.S.P.4% w/w, Methyl paraben 0.3% w/w

Group No.5 836. 1431 OINTMENT Containing: Ciprofloxacin Phosphate I.P.0.3% w/w

Group No.5 837. 1440 OINTMENT GEL - Containing: Feracrylum 1% w/w Containing: Betamethasone Dipropionate I.P. 0.5% + Group No.5 838. 1442 OINTMENT Zn. Sulphate I.P. 0.5 w/w Page 71 of 112

CREAM - Containing: Betamethasone Dipropionate Group No.5 839. 1444 OINTMENT 0.5% w/w, Neomycin Sulphate 0.5% w/w 840. 1445 OINTMENT CREAM - Containing: GBHC 1% Benzocaine 2% cream Group No.5 base HUMAN EPIDERMAL GROWTH - Each gm to contain: Group No.5 841. 1492 OINTMENT 150 µg of recombinant Human Epidermal growth factor gel ANALGESIC CREAM - Each contain: Cream Methyl Group No.5 842. 1547 OINTMENT Salicylate 8% w/w, Mephenesin 5%w/w, Methyl Nicotinate 1% w/w, Menthol 2% w/w 843. 1599 OINTMENT MOXIFLOXACIN EYE OINT - Each tube to contain: Group No.5 Moxifloxacin 0.5%

Group No.5 844. 1609 OINTMENT Containing:Tobramycin Sulphate I.P.Eye oint 0.3%

Group No.5 845. 1610 OINTMENT Containing:Fluconazole 0.3% Eye oint

SERTACONAZOLE CREAM - Each tube to contain: Group No.5 846. 1612 OINTMENT Sertaconazole Nitrate 2% Cream. 847. 1614 OINTMENT ZINC OXIDE OINT - Each tube to contain: Zinc Oxide Group No.5 I.P. Containing:Oint Recombinant Epidermal Growth Group No.5 848. 1615 OINTMENT Factor (Human) 0.01mg,Silver Sulphadiazine I.P./B.P./USP 10mg/1gm MOMETASONE+SALICYLIC ACID OINT - Containing: Group No.5 849. 1616 OINTMENT Mometasone Furoate 0.1 %, Salicylic Acid 5%. CLOBETASOL+SALICYLIC ACID OINT - Containing: Group No.5 850. 1617 OINTMENT Clobetasol Propionate 0.05% w/w, Salicylic Acid 6% w/w. HYDROQUINONE+GLYCOLIC ACID+KOJIC ACID CREAM Group No.5 851. 1618 OINTMENT - Each tube to contain: Hydroquinone 4.0% ,Glycolic Acid 10% w/w, Kojic Acid 2% HYDROQUINONE+TRETINOIN+MOMETASONE CREAM - Each tube to contain: Hydroquinone IP/BP/USP 4.0% Group No.5 852. 1619 OINTMENT w/w,Tretinoin IP/BP/USP 0.025% w/w,Mometasone Furoate IP/BP/USP 0.1% w/w

Group No.5 853. 1620 OINTMENT Containing: Urea Cream I.P. 12%,

BENZYDAMINE HYDROCHLORIDE - Each 5gm to Group No.5 854. 1701 OINTMENT contain: Benzydamine Hydrochloride 5% 855. 1703 OINTMENT TERBINAFINE OINTMENT - Containing: Terbinafine Hcl. Group No.5 1% 856. 1704 OINTMENT ANTIFUNGAL GEL - Each tube to contain: Adapalene 0.1%w/w (as microsheres) Clindamycin phosphate Group No.5 USP Equivalent to clindamycin 1.0%w/w In an aqueous gel base -q.s. Group No.5 857. 1707 OINTMENT Containing: Salicylic acid 12%

Group No.5 858. 1708 OINTMENT TACROLIMUS OINT - Each tube to contain: Tacrolimus Page 72 of 112

0.03%: 859. 1709 OINTMENT TACROLIMUS OINT - Each tube to contain: Tacrolimus Group No.5 0.1% Containing: Mupirocin 2%w/w Beclomethasone Group No.5 860. 1710 OINTMENT Dipropionate 0.025% w/w Water soluble base q.s. 861. 1712 OINTMENT BENZOYL PEROXIDE GEL - Each to contain: Benzoyl Group No.5 peroxide 2.5%

Group No.5 862. 1713 OINTMENT CREAM - Each tube to contain: Desonide 0.05%

MOMETASONE CREAM - Each tube to contain: Group No.5 863. 1714 OINTMENT Mometasone Furoate 0.1 % TRIAMCINOLONE ACETONIDE - Containing: Group No.5 864. 1715 OINTMENT Triamcinolone acetonide 0.1 MOMETASONE + FUSIDIC CREAM - Each tube to Group No.5 865. 1716 OINTMENT contain: Mometasone 0.1% & Fusidic 2% HYDROCORTISONE ACETATE OINT - Each tube to Group No.5 866. 1717 OINTMENT contain: Hydrocortisone Acetate 1% 867. 1718 OINTMENT ADAPELENE GEL - Each tube to contain: Adapelene Group No.5 0.1% Group No.5 868. 1719 OINTMENT CREAM - Containing: Azelaic acid 10% COAL TAR + SALICYLIC ACID OINT - Each to contain: Group No.5 869. 1722 OINTMENT Coal tar 6%, Salicylic acid 3%: HAEMORROIDAL OINT. - Containing: Lignocaine Hydrochloride 2% w/w, Group No.5 870. 1756 OINTMENT Hamamelis water 5%, Zinc Oxide 10% w/w ointment base q.s. SODIUM CHLORIDE 6% EYE OINT - Each tube to Group No.5 871. 1782 OINTMENT contain: Sodium Chloride 6%. CALCITRIOL OINT - Each gm to contain: Calcitriol Group No.5 872. 1786 OINTMENT 3mcg. HAEMORRHOIDAL CREAM - Each gm to contain: Euphorbia Prostrata dry extract ethanolic 80% (v/v) ((35-70):1) 10 mg (Containing 0.315 -0.825 mg total Group No.5 873. 1836 OINTMENT flavonoids calcluated as apigenin-7 glucoside and 1.26-4.40 mg total phenolics calculated as gallic acid)cream base q.s. ANALGESIC CREAM - Each tube to contain: Methyl Group No.5 874. 1866 OINTMENT salicylate 30% w/w, Menthol 10 % w/w, Camphor 4 % w/w Excipients q.s. 875. 1926 OINTMENT GATIFLOXACIN EYE OINT - Each tube to contain: Group No.5 Gatifloxacin 3% HYPROMELLOSE EYE GEL - Each tube to contain: Hypromellose 2%, Nacl 0.49%, KCL 0.075%, CaCl2 Group No.5 876. 1928 OINTMENT 0.048%, MgCl2 Hexahydrate 0.03%, Na Acetate 0.39%, Na Citrate Dihydrate 0.17%

Page 73 of 112

POTASSIUM NIT. & SOD. MONOFLUORO PHOSPHATE Group No.5 877. 1937 OINTMENT PASTE - Each tube to contain: Potassium Nitrate 5% w/w, Sodium Monofluoro Phosphate 0.7% w/w 878. 1938 OINTMENT METRONIDAZOLE ORAL GEL - Each tube to contain: Group No.5 Metronidazole 1%, Chlorhexidine 0.25% MOMETASONE + TERBINAFINE CREAM - Each tube to Group No.5 879. 1941 OINTMENT contain: Mometasone 0.1%w/w, Terbinafine 1% w/w CLOTRIMAZOLE + CLINDAMYCIN OINT - Each tube to Group No.5 880. 1943 OINTMENT contain : Clotrimazole 2% w/w, Clindamycin 2% w/w 881. 1944 OINTMENT LULICONAZOLE CREAM - Each tube to contain: Group No.5 Luliconazole 1% EPIDERMAL GROWTH FACTOR + SILVER SULFADIAZINE - Each gm to contain: Recombinant EGF 10µg, Silver Sulfadiazine 1%, Chlorhexidine Gluconate: 0.2%, Group No.5 882. 1948 OINTMENT Light Liquid Paraffin 10%, Pemulen TR-1 0.5%, Carbopol Ultrez 1.3%, Sodium Methyl Paraben 0.18% , Sodium Propyl Paraben :0.02% , Mannitol 5% , 20% Triethanolamine , QS Purified water, QS 883. 1949 OINTMENT EBERCONAZOLE CREAM - Each tube to contain : Group No.5 Eberconazole 1% w/w in a cream base 884. 1950 OINTMENT GLYCOLIC ACID - Each tube to contain: Glycolic acid Group No.5 6% 885. 1952 OINTMENT ISOTRETINOIN GEL - Each tube to contain: Isotretinoin Group No.5 Topical gel 0.05% KOJIC ACID GEL - Each tube to contain: Kojic Acid Group No.5 886. 1953 OINTMENT Dipalmitate2% w/w, Arbutin1.5%, Morus Alba extr. 1.5%, Octinoxate 7.5% 887. 1954 OINTMENT METHOXASALEN OINT - Each tube to contain: Group No.5 Methoxasalen 0.75% , Aminobenzoic 2% 888. 2031 OINTMENT ESTRADIOL 1 MG CREAM - Each gm to contain: Group No.5 Estradiol 1 mg FLUCINOLONE ACETONIDE 0.025% NEOMYCIN SULPHATE 0.05% MICONAZOLE NITRATE 2.0% CREAM Group No.5 889. 2037 OINTMENT - Containing: Flucinolone Acetonide 0.025% Neomycin Sulphate 0.05% Miconazole Nitrate 2.0% TRETINOIN 0.25% W/W AND CLINDAMYCIN 1% W/W Group No.5 890. 2038 OINTMENT CREAM/GEL - Each to contain: Tretinoin 0.25% w/w and Clindamycin 1% w/w 891. 2103 OINTMENT FERACRYLUM WITH CENTBUCRIDINE HYDROCHLORIDE GEL - Composition : Feracrylum 3% Group No.5 w/w Centbucridine 0.5% w/w (as Centbucridine HCL) Water miscible base Q.S. 892. 2105 OINTMENT Mupirocin USP 2%w/w, Beclomethasone Group No.5 Dipropionate IP 0.025%W/W Water soluble base q.s

Group No.5 893. 1247a OINTMENT Containing: Silver Sulphadiazine 1.0% w/w .

Page 74 of 112

Group No.5 894. 1247b OINTMENT Containing:Silver Sulphadiazine 1.0% w/w . 895. 1255 OINTMENT BETAMATH. + SALICYLIC ACID OINT. - Each gm. to Group No.5 b contain: Betamethasone Dipropionate 0.64 mg. Salicylic Acid 30 mg. BETAMATH. + SALICYLIC ACID OINT. - Each gm. to Group No.5 896. 1255a OINTMENT contain: Betamethasone Dipropionate 0.64 mg. Salicylic Acid 30 mg. BETAMATH. + SALICYLIC ACID OINT. - Each gm. to Group No.5 897. 1255b OINTMENT contain: Betamethasone Dipropionate 0.64 mg. Salicylic Acid 30 mg. 898. 1284 OINTMENT LIGNOCAINE JELLY - Containing: Lignocaine 2% Group No.5 b 899. 1284a OINTMENT LIGNOCAINE OINT - Each tube to contain: Lignocaine Group No.5 5% Group No.5 900. 1284b OINTMENT LIGNOCAINE JELLY - Containing: Lignocaine 2% 901. 1717 OINTMENT HYDROCORTISONE ACETATE OINT - Each tube to Group No.5 b contain: Hydrocortisone Acetate 1% HYDROCORTISONE ACETATE OINT - Each tube to Group No.5 902. 1717b OINTMENT contain: Hydrocortisone Acetate 1% BUPRENORPHINE TRANSDERMAL PATCH - Each Group No.5 903. 1857 PATCH Transdermal patch to contain : Buprenorphine 5 mcg/hr. Area containing active substance 6.25sqcm BUPRENORPHINE TRANSDERMAL PATCH - Each Group No.5 904. 1858 PATCH Transdermal patch to contain : Buprenorphine 10 mcg/hr. Area containing active substance 12.5sqcm BUPRENORPHINE TRANSDERMAL PATCH - Each Group No.5 905. 1859 PATCH Transdermal patch to contain : Buprenorphine 20 mcg/hr. Area containing active substance 25sqcm RIVASTIGMINE TRANSDERMAL PATCH - Each Transdermal patch (TTS) of 10sqcm to contain: Group No.5 906. 1877 PATCH Rivastigmine base 18mg in vivo release rate 9.5mg/24h. RIVASTIGMINE TRANSDERMAL PATCH - Each Transdermal patch (TTS) of 5sqcm to contain: Group No.5 907. 1878 PATCH Rivastigmine base 9mg in vivo release rate 4.6mg/24hr. 908. 2119 PATCH diclofenac transdermal patch: Each patch of 50 cm2 to Group No.5 contains: Diclofenac Diethylamine BP 100mg 909. 2122 PATCH ketoprofen transdermal patch: Each patch to contain: Group No.5 ketoprofen IP 20mg 910. 2122 X PATCH fentalyl transdermal patch 12.5mcg/hr: Each patch Group No.5 2085 to contain Fentanyl IP/BP 1.25mg POWDER - Containing: Zinc Bacitracin 400U, Group No.5 911. 1441 POWDER Polymyxin B sulphate 5000U, Neomycin Sulphate 3400U

Page 75 of 112

Containing: Polymyxin B Sulphate I.P./B.P./USP 5000 Group No.5 912. 1605 POWDER i.u.Chloramphenicol I.P. 5mg Dexamethasone sod.Phos I.P. 1mg BARIUM SULPHATE POWDER - Each to contain: Group No.5 913. 1622 POWDER Barium sulphate I.P. LAXATIVE POWDER - Each pouch to contain: Polyethylene Glycol 118 gm, Potassium Chloride 1.484 Group No.5 914. 1656 POWDER gm, Sodium Bicarbonate 3.37 gm, Sodium Chloride 2.93 gm, Sodium Sulphate 11.36 gm. CLOTRIMAZOLE DUSTING POWDER - Each to contain: Group No.5 915. 1942 POWDER Clotrimazole Dusting Powder 1% w/w 916. 2177 POWDER Degarelix powder 240mg: Each 2 vials to contains: Group No.5 Degarelix 120 mg

Group No.5 917. 481 RESP. SOL. Each ml. to contain: Ipratropiam Bromide 250 mcg.

BUDESONIDE+SALBUTAMOL RESP - Each 2.5 ml to Group No.5 918. 1523 RESPULES contain: Budesonide 0.5mg, Salbutamol 2.5mg BUDESONIDE RESP. - Each 2ml to contain :Budesonide Group No.5 919. 1524 RESPULES 1mg Steriod Nebulizing Fluid IPRATROPIUM+ LEVOSALBUTAMOL RESP - Each 2.5ml Group No.5 920. 1526 RESPULES to contain : Ipratropium I.P.500mcg, Levosalbutamol 1.25mg. SALBUTAMOL RESP. SOLN - Each 2.5 ml. to contain: Group No.5 921. 32a RESPULES Salbutamol sulphate eqv. to Salbutamol 2.5 mg in normal saline soln. Each Rotacap to contain: Salbutamol I.P. 200 mcg, Group No.5 922. 549 ROTACAPS Ipratropium Bromide I.P.40 mcg Each Rotacap to contain: Fluticasone 250 mcg + Group No.5 923. 550 ROTACAPS Salmetrol 50 mcg BECLOMETHASONE ROTACAP - Each cap to contain : Group No.5 924. 1044 ROTACAPS Beclomethasone 100mcg. SALMETEROL ROTACAP - Each rotacap to contain : Group No.5 925. 1045 ROTACAPS Salmeterol I.P.50mcg. TIOTROPIUM BROMIDE ROTACAP - Each rotacap to Group No.5 926. 1525 ROTACAPS contain : Tiotropium Bromide I.P./BP eqv. to Tiotropium Bromide Monohydrate 18mcg. IPRATROPIUM BROMIDE ROTACAP - Each Rotacap to Group No.5 927. 1666 ROTACAPS contain: Ipratropium bromide BP eqv. to Ipratropoium bromide (anhydrous) 40mcg. BUDENOSIDE 200 MCG + FORMOTEROL FUMARATE 6 Group No.5 928. 2016 ROTACAPS MCG ROTOCAP - Each Rotacap to contain: Budenoside 200 Mcg + Formoterol Fumarate 6 Mcg

Group No.5 929. 1043a ROTACAPS Each Rotacap to contain : Salbutamol 200mcg.

Group No.5 930. 1043b ROTACAPS ROTAHALER DEVICE - Rotahaler

Page 76 of 112

Each rotacap to contain : Fluticasone propionate Group No.5 931. 547a ROTACAPS I.P.50 mcg FLUTICASONE ROTACAP - Each rotacap to contain: Group No.5 932. 547b ROTACAPS Fluticasone I.P.100 mcg. BECLOMETHASONE ROTACAP - Each rotacap to Group No.5 933. 548b ROTACAPS contain: Beclomethasone 200 mcg. PAS GRANULES - Each gm to contain: Sodium Group No.5 934. 503 SACHET Aminosalicylate 800mg CHOLE CALCIFEROL GRANULES - Each gm to contain : Group No.5 935. 1299 SACHET Vit. D3 60,000 IU Containing: Sodium Chloride 2.6 gm., Potasssium Group No.5 936. 1321 SACHET chloride 1.5 gm., Sodium citrate 2.9 gm, Dextrose (Anhydrous) 13.5 gm. ANTACID - Each Sachet (0.67g) contains: Water Soluble Azulene Group No.5 937. 1413 SACHET (Sodium Azulenesulfonate) JPC 2.01 mg L-Glutamine JPC 663.3 mg PREBIOTIC AND PROBIOTIC - Each Sachet (0.5gm) contains: Streptococcus faecalis T-110 30million Group No.5 938. 1414 SACHET Clostridium butyricum To-A 2million bacillus mesentericus To A 1 Million Lactic Acid bacillus 50 million (Lactobacillus sporogenes) Each sachet to contain:Strontium Ranelate granules- Group No.5 939. 1548 SACHET 2gm PRE & PREBIOTIC AND ORAL REHYDRATION - Each Pack-in-Pack Sachet WHO ORS Pack 4.10g contains: Sodium Chloride 0.52gm,Sodium Citrate 0.58gm,Potassium Chloride 0.3gm,Dextrose Group No.5 940. 1742 SACHET Anhydrous 2.7gm Pre & Probiotic Pack 0.5g contains: Streptococcus Faecalis T- 110 7.5 Million,Clostridium Butyricum TO-A 0.5 Million,Bacillus Mesentericus TO-A 0.25 Million,Lactobacillus Sporogenes 20.0 Million. 941. 1990 SACHET SEVELAMER SACHET - Each sachet to Group No.5 contain:Sevelamer Carbonate 800 mg L-ORNITHINE -L-ASPARTATE 3G SACHET - Each Sachet Group No.5 942. 2045 SACHET to contain: L-Ornithine -L-Aspartate 3g Sachet CALCIUM POLYSTYRENE SULFONATE - Each Sachet to Group No.5 943. 2048 SACHET contain: Calcium polystyrene sulfonate 944. 2081 SEALANT ANTICOAGULANTS-Each Kit to contain:Two Group No.5 componant fibrin sealant with synthetic Aprotinin (4ml) 945. 559 SOLUTION COAL TAR + SALICYLIC ACID SOLN - Each bot to Group No.5 contain: Coal Tar Topical Sol. 4.25% + Salicylic Acid I.P. Sol. 2% POVIDONE IODINE MOUTH WASH - Each bot to Group No.5 946. 579 SOLUTION contain: Povidone Iodine 1%

Page 77 of 112

947. 580 SOLUTION COAGULANT SOLUTION - Each ml. to contain: Aqueous solution of Haemocoagulase Isolated from Group No.5 Bothrops Atrox or Bothrops Jararaca 0.2CU, Chlorhexadine Gluconate soln.0.1% (as preservative), Water for Injection q.s. GASTRIC REPLACEMENT SOLN - Each 100ml to contain : (in ME of ions per litre) Sodium 63 M Eq./Lt., Group No.5 948. 1317 SOLUTION Chloride 150 -do- Potassium 17 -do- Ammonium 70 -do- DEXTROSE WITH NACL SOLN - Each 100ml to contain: Group No.5 949. 1319 SOLUTION Dextrose Anhydrous 5gm., Sodium chloride 0.45 gm. MAINTENANCE SOLUTION FOR PAEDIATRIC USE - Each 100 ml to contain (in mmol/ L ) Sodium 23.0, Chloride Group No.5 950. 1320 SOLUTION 20.0, Potassium 20.0, Acetate 23.0, Magnesium 1.50, Phosphate1.50.

Group No.5 951. 1361 SOLUTION Containing:Surgical Spirit

Group No.5 952. 1613 SOLUTION Each ml to contain: Tolnaftate I.P./B.P./USP 10 mg.

HYDROGEN PEROXIDE - Each bot to contain: Hydrogen Group No.5 953. 1628 SOLUTION Peroxide IP 954. 1778 SOLUTION ENTECAVIR ORAL SOLN. - Each ml to contain: Group No.5 Entecavir 0.05 mg. MOMETASONE FUROATE SOLUTION - Containing: Group No.5 955. 1785 SOLUTION Mometasone Furoate 0.1% w/v. 956. 1936 SOLUTION CHLORHEXIDINE SOLN. - Each bot to contain: Group No.5 Chlorhexidine Gluconate 0.2% solution BENZYDAMINE ORAL SOLN - Each bot to contain: Group No.5 957. 1939 SOLUTION Benzydamine Hcl B.P. 0.15% w/v Alcohol IP 10% v/v in flavoured aqueous base, 958. 1963 SOLUTION SODIUM CHLORIDE SOLN - Each to contain: Nacl Group No.5 Solution 3% EUSOL SOLUTION PACK: 500 ML BOT. - Contains: Group No.5 959. 2039 SOLUTION Chlorinated lime 1.25% + Boric Acid 1.25% DEXTROSE ANHYDROUS 25% W/V - Each 100ml to Group No.5 960. 2052 SOLUTION contain : Dextrose Anhydrous 25% w/v 961. 2084 SOLUTION Diclofenac Diethyl Amine, Methyl Salicylate, Menthol And Absolute Alcoho Topical Solution 30ml Diclofenac Diethyl Amine BP-2.32% W/V Equivalent to Diclofenac Sodium IP 2% W/V Methyl Salicylate IP 10% Group No.5 W/V Menthol IP ...... 5.0% W/V Absolute Alcohol IP... 10% V/V Intopical Solution Base (Non Aqueous )...qs

Page 78 of 112

962. 21 83 SOLUTION Heparin Topical Solution 1000 IU/ml Group No.5 Each ml contains : Heparin Sodium IP 1000 IU Absolute Alcohol IP 10% V/V 963. 1265 SOLUTION ANTISEPTIC LIQUID - Each bot to contain: Chloroxylenol 4.8% w/v Group No.5 b Terpineol 9.0% v/v Alcohol absolute (denatured ) 13.10% v/v ANTISEPTIC LIQUID - Each bot to contain: Group No.5 964. 1265a SOLUTION Chloroxylenol 4.8% w/v Terpineol 9.0% v/v Alcohol absolute (denatured ) 13.10% v/v ANTISEPTIC LIQUID - Each bot to contain: Group No.5 965. 1265b SOLUTION Chloroxylenol 4.8% w/v Terpineol 9.0% v/v Alcohol absolute (denatured ) 13.10% v/v 966. 1270 SOLUTION CETRIMIDE SOLUTION - Each to contain:Cetrimide 3% w/v , Group No.5 b Chlorhexidine 1.5% w/v 967. 1270a SOLUTION CETRIMIDE SOLN - Each bot to contain:Cetrimide 3% Group No.5 w/v , Chlorhexidine 1.5% w/v CETRIMIDE SOLUTION - Each to contain:Cetrimide 3% Group No.5 968. 1270b SOLUTION w/v , Chlorhexidine 1.5% w/v 969. 32b SOLUTION SALBUTAMOL RESP. SOLN - Each ml to contain: Group No.5 Salbutamol sulphate eqv. to Salbutamol 5 mg. in normal saline soln. 970. 1238 SPRAY BECLOMETHASONE NASAL SPRAY - Each actuation to Group No.5 deliver: Beclomethasone Dipropionate 50 mcg. 971. 1355 SPRAY AZELASTINE NASAL SPRAY - Containing :Azelastine Group No.5 0.05% SPRAY - Containing: Spray Diclofenac Diethylmine 1.16%, Methyl Salicylate 10%w/w, Linseed oil (oleum Group No.5 972. 1546 SPRAY Lini)-3% w/w, Menthol 5% w/w, Excipients & Propellant q.s. 100 % w/w LIDOCAINE SPRAY - Containing: Spray Lidocaine 1.0%, Group No.5 973. 1624 SPRAY Cetrimide 0.1%, Polyvinyl Polymer 2.8% solvent & propellent q.s. Containing: Linoleic acid 10 % w/w,sodium chloride Group No.5 974. 1702 SPRAY 0.5 % w/w, sodium lactate 2 % w/w, sodium pyrrolidone carboxylate 2.5 % w/w: SPRAY - Each to contain: Isopropyl Alcohol -55% w/w, Group No.5 975. 1723 SPRAY Purified Water-10% w/w, Propellant Hydrocarbon- 35% w/w 976. 1868 SPRAY MIDAZOLAM NASAL SPRAY - Each Nasal spray to Group No.5 contain :75mg in 15ml canister; 0.1ml per actuation = 0.5mg midazolam FLUTICASONE NASAL SPRAY - Each spray delivers Fluticasone Propionate IP 50mcg to contain: Group No.5 977. 1935 SPRAY Fluticasone Propionate IP - 0.05% w/v, Benzalkonium Chloride IP - 0.01% w/v (as preservative) Phenyl Ethyl Alcohol Usp - 0.25% w/v (as preservative)

Group No.5 978. 1510 SUPPOSITORY Each suppository to contain: Glycerin I.P. 2mg

Page 79 of 112

BISACODYL SUPPOSITORY - Each suppository to Group No.5 979. 1825 SUPPOSITORY contain : Bisacodyl 10mg BISACODYL SUPPOSITORY - Each suppository to Group No.5 980. 1826 SUPPOSITORY contain : Bisacodyl 5mg PARACETAMOL SUPPOSITORY - Each suppository to Group No.5 981. 1863 SUPPOSITORY contain : Paracetamol 140mg 982. 1864 SUPPOSITORY PARACETAMOL SUPPOSITORY - Each suppository to Group No.5 contain : Paracetamol 70mg

Group No.5 983. 1419a SUPPOSITORY Each suppository to contain: Diclofenac 25mg

Group No.5 984. 1419b SUPPOSITORY Each suppository to contain: Diclofenac 100mg

Gel-ANTACID GEL - Each 10ml to contain:Mag. Hyd. Group No.5 985. 2 SYRUP 185mg, Dimethicone 50mg,Sodium Carboxy Methyl Cellulose 100mg.,Dried Al. Hyd. gel 830mg. Group No.5 986. 9 SYRUP Each 5 ml. to contain: Metoclopramide Hcl 5mg. PROMETHAZINE SYP - Each 5 ml to contain: Group No.5 987. 13 SYRUP Promethazine 5mg. ANTISPASMODIC DROPS/SUSPENSION - Each ml. to Group No.5 988. 16 SYRUP contain: Dicyclomine Hcl 10 mg, Activated Dimethicone 40mg. Group No.5 989. 21 SYRUP Each 5 ml. to contain: Furazolidone 25mg. Group No.5 990. 24 SYRUP Each ml to contain Metronidazole 5mg. Group No.5 991. 25 SYRUP Each 5 ml. to contain:Metronidazole 200 mg. Each 5 ml to contain: Salbutamol sulphate I.P. eqv. to Group No.5 992. 31 SYRUP Salbutamol 2 mg contain per 5 ml.Theopyllin ethanoate of Piperazine Group No.5 993. 33 SYRUP 80mg, Eph Hcl.12mg, Guaiphenesin 50mg, Alcohol 0.55ml, Absolute alcohol content 10.44 %. Group No.5 994. 36 SYRUP Each 5ml. to contain: Bromhexine Hcl. 4mg. Group No.5 995. 105 SYRUP Each 5ml. to contain: Nalidixic Acid I.P. 300mg. DISODIUM HYDROGEN CITRATE LIQUID - Each 5 ml to Group No.5 996. 107 SYRUP contain: Disodium Hydrogen Citrate 1.25gm. Group No.5 997. 122 SYRUP Each 5ml. to contain: Pheniramine Maleate I.P.15mg. 998. 161 SYRUP AMPICILLIN DRY SYP - Each 5ml to contain: Ampicillin Group No.5 125mg. Group No.5 999. 165 SYRUP Each 5ml. to contain: Cloxacillin 125mg. 1000. 168 SYRUP CEPHALEXIN SYP - Each 5ml to contain: Cephalexin Group No.5 125mg. Group No.6 1001. 172 SYRUP Each 5ml. to contain:Erythromycin 125mg. Each 5ml. to contain: Trimethoprim 40mg. Group No.6 1002. 173 SYRUP Sulphamethoxazole 200mg. Each 5ml. to contain: Amoxycillin I.P. 200 Group No.6 1003. 183 SYRUP mg.Clavulanic acid I.P. 28.5 mg. Group No.6 1004. 196 SYRUP Each 5ml. to contain: Chloroquine Phosphate 50mg. Group No.6 1005. 202 SYRUP Each 5ml. to contain: Diethyl Carbamazine Citrate

Page 80 of 112

120mg. Each 5ml to contain : Piperazine Citrate I.P. eqv. to Group No.6 1006. 206 SYRUP 0.75gm. of piperazine hydrate POTASSIUM CHLORIDE LIQUID - Each 15ml to contain: Group No.6 1007. 272 SYRUP Potassium Chloride 1.5gm. Each 5 ml to contain : Codeine phosphate I.P.10mg, Group No.6 1008. 301 SYRUP Chlorpheniramine maleate I.P.4 mg. Group No.6 1009. 321 SYRUP Each 5ml. To contain: Ribavirin 50mg. Each 15ml to contain :Dl methionine 100mg,Choline dihydrogen citrate 100mg,Riboflavin 3mg,Thiamine hydrochloride 3mg,Pyridoxine 1.5mg, Nicotinamide Group No.6 1010. 357 SYRUP 22.5mg,D-panthenol 4.5mg,Biotin 0.1mg,folic acid 0.5mg,Cynacobalamin 3mcg,Tocopheryl acetate 7.5 IU. Group No.6 1011. 379 SYRUP Each 30 ml. to contain : Norfloxacin I.P. 400mg. Group No.6 1012. 399 SYRUP Each ml. to contain: Tocopheryl Acetate I.P. 50mg. Each. 5 ml. to contain: Liquid Parafin I.P.1.25ml., Milk Group No.6 1013. 415 SYRUP of Magnesia I.P. 3.75ml., Sodium Picosulphate 3.33mg. ENZYME DROP - Each ml to contain: Alpha-Amylase Group No.6 1014. 417 SYRUP (Bacterial 1:800) 20mg., Papain 10mg., Dill Oil 2mg., Anise Oil 2mg., Caraway Oil 2mg. Each 15ml to contain: Iodised peptone 29 mg., Mag. Chl 20 mg., Mag. Sulph 4mg, Zn. Sulph. 6 mg., Sod. Group No.6 1015. 418 SYRUP Metavandate 0.66 mg., Pyridoxine HCL 0.75mg., Cyanocobalamin 0.5mcg., Nicotinamid 10mg. Alcohol 0.95 ml. Containg: Polyvinyl Polymer 2.52%, Benzocaine I.P. Group No.6 1016. 441 SYRUP 0.36%, Propellant I.P. 70%, Solvent and nontoxic perfume q.s. CALCUIM SYP - Each 5ml to contain :Vit. D3 200 IU, Group No.6 1017. 451 SYRUP Vit. B12 2.5 mcg., Calcium 82 mg. Group No.6 1018. 478 SYRUP Each 15 ml. to contain Lactulose 10gm. 1019. 496 SYRUP VIT. B COMPLEX SYP - Each 5ml to contain: Vit. A 2500 IU, Cholecalciferol 200 IU, Thiamine 2mg., Riboflavin Group No.6 1mg., Pyridoxine 1mg., Nicotinaminde 15mg., Ascorbic Acid 50 mg., D -Panthenol 2.5mg., Cyanocobalamin 1mcg., Citrus Bioflavonoid Compound 5mg.

HAEMATINIC SYP. - Each 15 ml to contain: Ferric Group No.6 1020. 500 SYRUP ammonium citrate 160 mg, vit. B 12 7.5 mcg, folic acid 0.5 mg, alcohol (95%) 0.87 ml. VIT. B COMPLEX + VIT.C SYP - Each 5ml to contain: Thiamine 2 mg, Riboflavin 2.54 mg, Pyridoxine 2 mg, Group No.6 1021. 501 SYRUP Niacinamide 20 mg, D -Panthenol 6 mg, Ascorbic acid 75 mg Group No.6 1022. 505 SYRUP Each 5 ml. to contain: Cefuroxime 125mg.

Page 81 of 112

ETOPHYLLINE & THEOPHYLLINE SYP. - Each 5 ml. to Group No.6 1023. 516 SYRUP contain: Etophylline 46.5mg. , Theophylline 14mg. Each 5 ml. to contain: Chlorpheniramine Meleate Group No.6 1024. 518 SYRUP 2.5mg., Guiphensin 100mg., Noscapine 15mg., Sodium Citrate 60 mg. Each 5ml. to contain: Dried Aluminium Hydroxide Gel Group No.6 1025. 583 SYRUP 300mg., Megnisium Hydroxide 150mg., Simethicone 40mg. 1026. 1002 SYRUP ANTACID GEL - Each 5ml to contain: Oxetacaine 10 Group No.6 mg, Al. Hydroxide 291 mg, Mag. Hydroxide 98 mg. Each 5 ml. to contain: Magnesium Hydroxide I.P.100 mg (added as mag. Hydroxide paste), Aluminium Group No.6 1027. 1004 SYRUP Hydroxide Gel I.P. 5 gm, Activated Dimethicone I.P. 125 mg,Sorbitol Solution I.P.645 mg. 1028. 1010 SYRUP LAXATIVE LIQUID - Each 15 ml to contain : Milk of Group No.6 Magnesia 11.25 ml. liquid paraffin 3.75 ml. Group No.6 1029. 1014 SYRUP Each ml . to contain : Domperidone I.P. 1 mg. ENZYME SYP - Each 10 ml. to contain : Fungal Diastase ( 1:2000) 40 mg. (Aspergillus Oryzae Group No.6 1030. 1028 SYRUP enzyme)Cinnamon Oil 0.25mg., Caraway Oil 0.5mg., Cardamon Oil 0.5 mg., In Glycerol sorbitol base. TERBUTALINE SYP. - Each 5 ml. to contain :Terbutaline Group No.6 1031. 1035 SYRUP Sulphate 1.5 mg. BRONCHODILATOR SYP. - Each 10 ml.to contain: Group No.6 1032. 1046 SYRUP Bromhexine Hcl 8 mg. Terbutaline Sulphate 4 mg, Guaphanesin 200 mg. PAEDIATRIC COUGH SYRUP - Each 5 ml. to contain : Group No.6 1033. 1047 SYRUP Promethazine Hcl 1.5 mg, Pholcodine 1.5 mg. (as citrate), COUGH SEDATIVE - Each 5 ml. to contain : Noscapine Group No.6 1034. 1048 SYRUP 7 mg., Chlorphenramine maleate 2 mg., Ammonium chloride 28 mg. Sodium Citrate 3.25 mg. PEDIATRIC COUGH LINCTUS SYP - Each ml to contain : Group No.6 1035. 1050 SYRUP Noscapine 1.83mg., Citric Acid 5.8mg., Sod. Citrate 0.67mg. Amm. Chloride 7mg. Group No.6 1036. 1092 SYRUP Each 5 ml. to contain : Ibuprofen I.P.100 mg. IBUPROFEN & PCM ORAL SUSP - Each 5 ml to contain: Group No.6 1037. 1093 SYRUP Ibuprofen 100 mg., Paracetamol 162.5 mg. Group No.6 1038. 1125 SYRUP Each 5 ml. to contain: Sodium Valproate I.P. 200 mg. Group No.6 1039. 1126 SYRUP Each 5 ml. to contain : Carbamazepin 100 mg. Each 5 ml. to contain :Amoxycillin trihydrate eqv. to Group No.6 1040. 1178 SYRUP Amoxycillin 125 mg. 1041. 1191 SYRUP AMOXYCILLIN. & CLOXACILLIN DRY SYP. - Each Group No.6 5ml. to contain: Amoxycillin 125mg, Cloxacillin125mg. Group No.6 1042. 1194 SYRUP Each 5ml. To contain: Cefadroxil 125mg. Group No.6 1043. 1197 SYRUP Each 5 ml. to contain : Rifampicin I.P.100 mg. Page 82 of 112

Group No.6 1044. 1208 SYRUP Each 5 ml. to contain : Albendazole 200 mg. Each 5 ml. to contain: Vit. B1 2 mg. , Vit. B2 2.5 mg., Group No.6 1045. 1293 SYRUP Vit. B6 0.75 mg., Nicotinamide 15 mg., Pentothenyl alcohol 3 mg., Vitamin B 12 2 mcg. AMINOACID AND IRON SYP - Each 10 ml. to contain: L- Histidine Hcl 4 mg., L-Lysine Hcl 25 mg.,Thiamine Hcl 5 mg, Riboflavin 3 mg., Nicotinamide 25 mg, Pyridoxin Group No.6 1046. 1311 SYRUP Hcl 1.5 mg., Cyanocobalamin 2.5 mcg., Folic Acid 0.5 mg., Ascorbic Acid 40.0 mg., D-Panthenol 2.5 mg., Ferrous Glycine Sulphate 275 mg. 1047. 1312 SYRUP IRON + VITAMIN SYP - Each 5ml to contain : Colloidal Group No.6 Iron eqv to elemental iron 250 mg, Folic Acid 500 mcg, Vitamin B12- 5mcg. CYCLOSPORIN SYP - Each ml to contain: Cyclosporin Group No.6 1048. 1336 SYRUP 100 mg. COUGH SYP. - Each 5 ml to contain : Methdilazine 2.5 Group No.6 1049. 1343 SYRUP mg , Amm. Chloride 100 mg, sodium citrate 50 mg. ANTACID GEL - Each 5ml. to contain: Aluminium Hydroxide 6g, Mag. Hydroxide 80mg., Activated Group No.6 1050. 1344 SYRUP Dimethicone 100mg., Deglycycrrhizinated Liquorice eqv. to Liquorice 400mg. Group No.6 1051. 1378 SYRUP OFLOXACIN SYP - Each 5ml to contain: Ofloxacin 50mg 1052. 1379 SYRUP AZITHROMYCIN SYP - Each 5ml to contain: Group No.6 Azithromycin 100mg COLISTIN SULPHATE SUSP - Each 5ml to contain: Group No.6 1053. 1380 SYRUP Colistin (As Colistin Sulphate) 12.5mg 1054. 1381 SYRUP CEFIXIME DRY SYP - Each 5ml to contain: Cefixime Group No.6 50mg CEFIXIME + LACTOBACILLUS SYP. - Each 5ml to Group No.6 1055. 1398 SYRUP contain: Cefixime 50mg, Lactic Acid Bacillus 30 million Spores 1056. 1427 SYRUP LORATADINE SYP. - Each 5ml. to contain: Group No.6 Loratadine 5mg. MULTIVITAMIN DROP - Each phial to contain: Vitamin A Concentrate (as palmitate) oily form:3000 Cholecalciferol 400 IU Ascorbic Acid 40mg Thiamine Mononitrate:2mg Riboflavin Sodium Phosphate eqv to Group No.6 1057. 1436 SYRUP Riboflavin: 1mg Nictoinamide 10.5mg Pyridoxine Hydrochloride:1mg D.panthenol 3mg Tocopheryl Acetate 5.25IU Flavoured Aqueous base(appropriate overages of vitamins added to compensate for loss on storage) COUGH SYP - Each 5ml to contain: Ambroxol Hydrochloride 30mg Terbutaline Sulphate eqv to Group No.6 1058. 1459 SYRUP Terbutaline 1.25mg, Guaiphenesin 50mg Menthol 0.5mg

Page 83 of 112

ANTACID GEL - Each 5ml contains: Dried Aluminium Group No.6 1059. 1495 SYRUP Hydroxide Gel 300mg Magnesium Hydroxide 250mg, Activated Simethicone 40mg Each 100ml to contain:Ofloxacin I.P. 200mg , Group No.6 1060. 1502 SYRUP Ornidazole I.P.700mg LIVER DISORDERS SYP - Each 5ml to contain: Tricholine Citrate 250 mg Kalmegh IP eq. to andographolides Group No.6 1061. 1503 SYRUP 250mcg,Sorbitrol-solution I.P. (70%) in a flavoured base LIVER DISORDERS SYP. - Each 10ml contain: Tricholine Group No.6 1062. 1504 SYRUP Citrate 0.55gm, Sorbitol 7.15gm. BACILLUS CLAUSII SPORES SUSP. - Each 5ml to contain: Group No.6 1063. 1506 SYRUP Bacillus clausii spores 2 Billion spores, susp.in 5ml distilled water Each 5ml to contain: Dextromethorphan Hydrobromide I.P. 7.5 mg, Cetrizine I.P. 2.5 mg,Zinc Group No.6 1064. 1515 SYRUP gluconate eq. to elimental Zinc I.P./B.P./USP 7.5mg, Menthol 1.5mg Each 5 ml to contains: Dextromethorphan Hydrobromide I.P.10mg.Phenylephrine Hydrochloride Group No.6 1065. 1516 SYRUP I.P./BP 5 mg Chlorpheniramine Maleate I.P. 4mg, Guaiphenesin I.P.100mg. COUGH SYP. - Each 5ml to contain:Terbutaline Sulp. Group No.6 1066. 1517 SYRUP 1.25mg, Ambroxol Hyd. 15mg, Guaiphensesin 50mg, Menthol 1mg COUGH SYP - Each 10ml to contain:Carbinoxamine Group No.6 1067. 1518 SYRUP Maleate I.P./B.P./USP 4mg, Ammonium Chloride I.P. 240mg, Sodium Citrate I.P. 240 mg 1068. 1528 SYRUP DIGOXIN ELIXIR - Each ml to contain : Elixir Digoxin Group No.6 0.05mg HYDROXYZINE HYDROCHLORIDE SYP. - Each 5ml To Group No.6 1069. 1570 SYRUP Contain: Hydroxyzine Hydrochloride 10mg 1070. 1571 SYRUP PHENOBARBITONE SYP - Each 5ml to contain: Group No.6 Phenobarbitone 20mg. 1071. 1572 SYRUP TRICLOFOS SYP - Each 5ml to contain: Triclofos sodium Group No.6 BP 500mg PIRACETAM SYP. - Each 5ml to contain: Piracetam Group No.6 1072. 1574 SYRUP 500mg. CETRIZINE HCL DROP - Each ml to contain: Cetrizine Group No.6 1073. 1583 SYRUP Hcl IP 10mg CALCIUM SYP. - Each 5ml to contain: Calcium Lactobionate 1.50 gms (equivalent 0.87 g of Calcium Gluconate), Calcium Gluconate 0.25 g, Cholecalciferol Group No.6 1074. 1635 SYRUP (Vitamin D3) – 200 IU, Cyanocobalamin – 2.5 mcg, Magnesium Chloride – 21.25 mg (equivalent to 2.5mcg of elemental Magnesium), flavoured base- q.s. Group No.6 1075. 1658 SYRUP SYRUP ZINC - Each 5ml to contain: Elemental Zinc

Page 84 of 112

20mg COUGH DROP - Each ml to contain: Phenylephrine Group No.6 1076. 1663 SYRUP hydrochloride IP - 2.5 mg, Chlorpheniramine Maleate IP 2.0 mg Flavoured base q.s. COUGH SYP. - Each 100ml solution to contain: Dried Group No.6 1077. 1664 SYRUP IVY leaf extract 0.7gm DROP - Each ml to contain: Peptonised Iron 117.67 mg (equivalent to 20 mg of elemental iron), Protein (as Group No.6 1078. 1725 SYRUP Peptone ) 30 mg, Folic Acid IP 200 mcg, Vitamin B12 - 4 mcg, Palatable base qs

ANTACID GEL - Each 10ml contains: Group No.6 1079. 1740 SYRUP Sucralfate 1000mg,Oxetacaine 20mg

Group No.6 1080. 1747 SYRUP Acebrophylline Syrup 50mg/5ml - 50ml/100ml Each 5ml: Cetirizine Hydrochloride 5mg Phenylephrine Hydrochloride 5mg Group No.6 1081. 1748 SYRUP Dextromethophane Hydrobromide 10mg Menthol - 1.5mg /5ml -50/60/100ml HAEMATINIC SYP. - Each 5 ml to contain: Peptonised Iron 176.5 mg (equivalent to 30 mg of elemental Iron), Group No.6 1082. 1792 SYRUP Protein (as Peptone) 100 mg, Folic Acid 200 mcg, Vitamin B12 2.5 mcg. 1083. 1822 SYRUP LACTULOSE SYP - Each 15ml to contain : Lactulose Group No.6 10gm 1084. 1823 SYRUP LACTULOSE SYP - Each 15ml to contain : Lactulose Group No.6 10gm 1085. 1828 SYRUP ONDANSETRON SYP - Each 5ml to contain: Group No.6 Ondansetron 2mg 1086. 1881 SYRUP PHENYTOIN SODIUM SYP - Each ml to contain: Group No.6 Phenytoin Sodium 25mg CHLORPHENIRAMINE & PHENYLEPHRINE SYP - Each Group No.6 1087. 1890 SYRUP 5ml to contain: Chlorpheniramine 1mg, Phenylephrine 2.5mg LIVER DISORDERS SYP - Each 15ml contains: DL- Methionine BP 100mg, Choline Dihydrogen Citrate NFXII 100mg, L-Leucine USP 19mg, L-Isoleucine USP Group No.6 1088. 1991 SYRUP 10mg ,L-Valine USP11mg , Pyridoxine Hcl IP 1.5mg, Nicotinamide IP 22.5mg, Biotin USP 0.1mg , Folic Acid IP 0.5mg, Cyanocobalamin IP 3.0mcg , Inositol BP 50mg, SUCRALFATE 1 G SUSP - Each 5 ml contain: Sucralfate Group No.6 1089. 2011 SYRUP 1 g

Page 85 of 112

PRE & PROBIOTIC DRY SYRUP - Each 5 ml to contains: Streptococcus faecalis T-110 30 million Clostridium butyricum TO-A 2 million Group No.6 1090. 2012 SYRUP Bacillus mesentericus TO-A 1 million Lactic acid bacillus (Lactobacillus sporogenes) 50 million Excipients q.s. CAMYLOFIN DIHYDROCHLORIDE 12.5MG + PARACETAMOL 125 MG SYRUP - Each 5ml to contain: Group No.6 1091. 2025 SYRUP Camylofin Dihydrochloride 12.5mg + Paracetamol 125 mg 1092. 2061 SYRUP Each 5 ml Contains Ambroxol Hrdrochloride IP 30 mg Terbutaline Sulphate IP equivalent Group No.6 to terbutaline 2.50mg Guaiphenesin IP 50 Mg Menthol IP 0.5 mg 1093. 2075 SYRUP Each 5ml contains : Potassium Citrate IP 1100mg, Magnesium Citrate USP 375mg, Pyridoxine HCL IP Group No.6 20mg, (Each ml to contains approx 1mEq Magnesium Ion, 2mEq Patassium Ion, 3mEq Citrate Ion and 4mg of Pyridoxine HCL) 1094. 2107 SYRUP Each 5ml contains : Calcium Lactobionate U.S.P. (eqv. to 35mg of calcium)- 700mg lodised Peptone (eqv. to 33mcg ov lodine)- 0.32mg Magnesium Chloride I.P. (eqv. to 0.8mg of Magnesium) - 6.66mg Manganese sulphate B.P. (eqv. Group No.6 to 0.33mg of Manganese) - 1.33mg Sodium Metavanadate 0.22mg Zinc Slphate I.P. (eqv. to 2.5 mg of zinc) 10.7mg Pyridoxine Hydrochloride I.P. 0.5mg Nicotinamide I.P. 7.5mg Palatable base q.s. 1095. 2115 SYRUP Hematinic with amino Acids,Vitamins and Zinc Syrup: Each 10 ml contains : Ferrous Glycine Sulphate 216.5 mg, L-Histidine Hydrochloride H2O BP 4 Mg, L- Lysine Group No.6 Hydrochloride USP 25 mg , Pyridoxine Hydrochloride IP 1.5 mg, Nicotinamide IP 25 mg, Folic Acid IP 0.5 mg , Cyanocobalamin IP 2.5 mcg, Zinc Ascorbate 50mg Each 5 ml to contain Chlorpheniramine maleate 3.0 Group No.6 1096. 347a SYRUP mg., Ammonium Chloride 110 mg., Sodium Citrate 46.0 mg., Menthol 0.9 mg. Each 5 ml to contain Diphenhydramine 14 Group No.6 1097. 346a SYRUP mg.,Ammonium chloride 135 mg., Sodium citrate 57 mg., Menthol 0.9 mg Each 5 ml to contain Diphenhydramine Group No.6 1098. 346b SYRUP 14mg.,Ammonium chloride 135 mg.,Sodium cxitrate 57 mg.,Menthol 0.9 mg. Each 5 ml to contain Chlorpheniramine maleate 3.0 Group No.6 1099. 347b SYRUP mg., Ammonium Chloride 110 mg., Sodium citrate 46.0 mg., Menthol 0.9 mg Page 86 of 112

Group No.6 1100. 82a SYRUP Each 5ml. to contain: Paracetamol 125mg. Group No.6 1101. 82b SYRUP Each 5ml. To contain: Paracetamol 125mg. Tab- Dried Aluminium Hydroxide Gel. 300mg., Group No.6 1102. 1 TABLET Magnesium Aluminium Silicate 50mg., Magnesium Hydroxide 25mg., Simethicone 25 mg. Group No.6 1103. 6 TABLET BISACODYL TAB - Each tab. to contain:Bisacodyl 5 mg. 1104. 8 TABLET METOCLOPRAMIDE TAB - Each tab to Group No.6 contain:Metoclopramide Hcl 10mg Group No.6 1105. 11 TABLET Tab-: Chlorpromazine 25mg. Group No.6 1106. 18 TABLET Tab-: Dicyclomine 20mg. Paracetamol 500mg. Group No.6 1107. 20 TABLET Tab-: Furazolidone 100Mg. Each Tab. to contain: Norfloxacin 400 mg.Tinidazole Group No.6 1108. 26 TABLET 600 mg. Group No.6 1109. 38 TABLET Tab-: Triprolidine 2.5mg. Pseudoephedrine 60mg. Group No.6 1110. 48 TABLET Tab-: Iso-sorbide Dinitrate 10mg. Group No.6 1111. 53 TABLET Tab-: Amlodipine 5mg. Group No.6 1112. 54 TABLET Tab-: Methyldopa 250mg. Group No.6 1113. 55 TABLET Tab-: Captopril 25mg. Group No.6 1114. 59 TABLET Tab-: Triamterine I.P. 50mg, Benzthiazide25mg. 1115. 60 TABLET FRUSEMIDE TAB - Each tab to contain: Frusemide Group No.6 40mg. Group No.6 1116. 70 TABLET Tab-: Dipyridamole I.P./ U.S.P.100mg. Each tab to contain: Acetyl salicylic acid Group No.6 1117. 73 TABLET 100mg+calcium carbonate 30mg+Anhydrous citric acid 10mg 1118. 75 TABLET FLUNARIZINE TAB - Each tab to contain: Flunarizine Group No.6 10mg. Group No.6 1119. 78 TABLET Tab-: Lovastatin 20mg. Group No.6 1120. 79 TABLET Tab-: Nimsulide 100mg. Group No.6 1121. 80 TABLET Tab-: Asprin 300mg. PSU ITEM Group No.6 1122. 81 TABLET Each Tab. to contain: Paracetamol 500 mg. Group No.6 1123. 84 TABLET Tab-: Diclofenac sodium 50mg. Group No.6 1124. 87 TABLET Tab-: Ibuprofen 400mg. Paracetamol 325mg. Group No.6 1125. 92 TABLET DIAZEPAM TAB - Each tab to contain: Diazepam 5mg. Group No.6 1126. 95 TABLET Tab-: Trifluperazine 5mg. PSU ITEM 1127. 96 TABLET IMIPRAMINE TAB - Each tab to contain: Imipramine Group No.6 25mg. 1128. 98 TABLET PHENYTOIN SODIUM TAB - Each tab to contain: Group No.6 Phenytoin sodium 100mg. CARBAMAZEPINE TAB - Each tab to contain: Group No.6 1129. 99 TABLET Carbamazepine 200mg. Group No.6 1130. 103 TABLET Tab-: Trihexyphenidyl Hydrochloride I.P.2mg. 1131. 104 TABLET NALIDIXIC ACID TAB - Each tab to contain: Nalidixic Group No.6 Acid 500 mg. Group No.6 1132. 119 TABLET Tab-: Povidone Iodine I.P. 200mg.

Page 87 of 112

1133. 121 TABLET PHENIRAMINE TAB - Each tab to contain: Pheniramine Group No.6 Maleate 25mg. Group No.6 1134. 124 TABLET Tab-: Cyproheptadine 4mg. 1135. 128 TABLET NORETHISTERONE - Each tab to contain: Group No.6 Norethisterone 5mg. Group No.6 1136. 134 TABLET Each tab to contain Prednisolone 5 mg. Group No.6 1137. 135 TABLET Each tab to contain Thyroxine sodium 100 mcg 1138. 136 TABLET CARBIMAZOLE TAB - Each tab to contain: Carbimazole Group No.6 5 mg. Group No.6 1139. 137 TABLET Each tab to contain: Acarbose 50 mg Group No.6 1140. 138 TABLET Each tab to contain: Glibenclemide I.P.5 mg Group No.6 1141. 139 TABLET Each tab to contain: Metformin HCL 500 mg Group No.6 1142. 140 TABLET Each tab to contain: Glipizide I.P.5 mg Group No.6 1143. 155 TABLET Tab- : Pot. Phenoxymethyl Penicillin 125mg. tab. Each Tab. to contain Pot. Phenoxymethyl Penicillin Group No.6 1144. 156 TABLET 250mg Tab-: Erythromycin Stearate eqv. to Erythromycin Group No.6 1145. 171 TABLET 250mg. Tab-: Trimethoprim 80mg. Sulphamethoxazole Group No.6 1146. 174 TABLET 400mg. Group No.6 1147. 176 TABLET Each tab to contain: Norfloxacin 400mg. 1148. 191 TABLET PYRAZINAMIDE KID TAB - Each Tab to contain: Group No.6 Pyrazinamide 300mg. Group No.6 1149. 192 TABLET Tab-: Dapsone I.P. 100mg. 1150. 194 TABLET GRISEOFULVIN TAB - Each tab to contain: Griseofulvin Group No.6 125mg. Group No.6 1151. 195 TABLET Each. tab. to contain: Chloroquine Phosphate 250mg. 1152. 198 TABLET ANTI MALARIAL TAB - Each tab to contain: Group No.6 Pyrimethamine 25mg. Sulphadoxine 500mg. Group No.6 1153. 199 TABLET Tab-: Quinine Sulphate 300mg. 1154. 201 TABLET DIETHYL CARBAMAZINE TAB - Each tab to contain: Group No.6 Diethyl Carbamazine Citrate 100mg. 1155. 204 TABLET MEBENDAZOLE TAB - Each tab to contain: Group No.6 Mebendazole 100mg Group No.6 1156. 262 TABLET Containing:NFI-III PROPHYLACTIC Group No.6 1157. 267 TABLET Tab-: Ferrous Sulphate 200mg. Group No.6 1158. 270 TABLET Tab-: Calcium Gluconate 500mg. Group No.6 1159. 271 TABLET Each tab to contain:calcium Lactate 300mg. Group No.6 1160. 289 TABLET containing Tamoxifen 10mg. 1161. 291 TABLET CYCLOPHOSPHAMIDE TAB - Each tab. to contain: Group No.6 Cyclophosphamide IP 50mg. Group No.6 1162. 302 TABLET Tab-: Levofloxacin 500 mg. Tab-: Calcium Carbonate I.P. 1250 mg eqv. to Group No.6 1163. 305 TABLET elemental calcium 500 mg from an organic source, Vitamin D3- I.P. 250 IU Group No.6 1164. 307 TABLET Each tab to contain: Cephalexin 125 mg. Page 88 of 112

Tab-: Diclofenac Potassium 50mg., Dicyclomine Hcl. Group No.6 1165. 309 TABLET 20mg. Group No.6 1166. 318 TABLET Tab-: Naproxen 250mg. 1167. 322 TABLET HAEMOSTATIC TAB - Each tab. to contain: Micronized Group No.6 purified Flavonoid fraction of Rutaceae 500mg LAMIVUDINE TAB - Each tab to contain: Lamivudine Group No.6 1168. 334 TABLET 150mg. Group No.6 1169. 342 TABLET Each S.R. tab. to contain: Diltiazem I.P.180mg. Group No.6 1170. 343 TABLET Tab-: Thyroxine sodium I.P.50mcg. 1171. 345 TABLET ANTACID TAB - Each tab to contain :Dried Aluminium Group No.6 Hydroxide gel 250 mg. + Magnesium Hydroxide 250 mg. + Methyl Polysiloxane 50 mg. 1172. 353 TABLET SOD. PICOSULPHATE 10MG TAB - Each Tab to Group No.6 contain: Sod. Picosulphate 10mg Each tab to contain : Dl methionine 200mg,Choline bitartrate 200mg,Thiamine mononitrate 3mg,Pyridoxine 1.5mg, Riboflavin 3mg,Nicotinamide Group No.6 1173. 356 TABLET 22.5mg,D-panthenol 4.5mg,Biotin 0.1mg,folic acid 0.5mg,Cynacobalamin 3mcg,Tocopheryl acetate 7.5 IU. Each CR tab to contain: Theophyllin anhydrous 400 Group No.6 1174. 363 TABLET mg. Each tab to contain : Losartan Potassium I.P.50 mg, Group No.6 1175. 365 TABLET Hydrochlorthiazide I.P.12.5 mg. Group No.6 1176. 377 TABLET Each tab to contain : Methyl Ergometrine 0.125mg. Each tab to contain: Mesalazine (5-Aminosalicylicacid) Group No.6 1177. 381 TABLET 400mg. Group No.6 1178. 382 TABLET Each tab. to contain: Ethionamide I.P. 250mg. Group No.6 1179. 384 TABLET Tab-: Rifampicin I.P. 100mg., Isoniazide I.P. 100mg. Group No.6 1180. 385 TABLET Each tab. to contain: Nevirapine 200mg. Group No.6 1181. 387 TABLET Each tab. to contain: Ondansetron 4mg. Group No.6 1182. 391 TABLET Tab-: Pyrazinamide I.P. 1000mg. Group No.6 1183. 403 TABLET Tab-: Methotrexate I.P.2.5mg. Group No.6 1184. 406 TABLET Tab-: Azathioprine I.P. 50 mg. VITAMIN TAB - Each Tab to contain: Thiamine Mononitrate I.P. 10mg, Pyridoxine Hcl 3mg, Group No.6 1185. 407 TABLET Cyanocobalamine 15mcg., Riboflavine 5mg, Nicotinamide 50mg, Calcium Pantothenate 5mg. Each tab to contain : Dried aluminium hydroxide Group No.6 1186. 414 TABLET 300mg, Magnesium hydroxide 150mg, Simethacone 40mg. 1187. 422 TABLET AMIODARONE TAB - Each tab to contain: Amiodarone Group No.6 HCL 100mg. Group No.6 1188. 424 TABLET Tab-: Clonidine Hcl I.P. 100mcg. Each sustained release tab to contain : Indapamide Group No.6 1189. 425 TABLET 1.5 mg

Page 89 of 112

1190. 427 TABLET SULPHASALAZINE TAB - Each tab. to contain: Group No.6 Sulphasalazine 500mg. 1191. 429 TABLET CLOPIDOGREL TAB - Each tab to contain: Clopidogrel Group No.6 75mg. Tab-: Frusemide I.P.20mg., Potassium Chloride 300 mg Group No.6 1192. 430 TABLET (controlled release ). Group No.6 1193. 453 TABLET Tab- Mesterolone 25mg. Group No.6 1194. 460 TABLET Tab-: Flutamide 250mg. Group No.6 1195. 471 TABLET Tab-: Tianeptine Sodium 12.5mg. Group No.6 1196. 479 TABLET Tab-: Prednisolone I.P.10 mg. Group No.6 1197. 485 TABLET Tab-: Tibolone 2.5mg 1198. 490 TABLET MYCOPHENOLATE MOFETIL TAB - Each tab to Group No.6 contain: Mycophenolate Mofetil 500mg. PROTHIONAMIDE TAB - Each tab to contain: Group No.6 1199. 507 TABLET Prothionamide 250mg 1200. 508 TABLET RIFAMP. & INH TAB - Each tab to contain: Isoniazide Group No.6 50mg., Rifampicin 100mg 1201. 512 TABLET ITOPRIDE TAB - Each tab. to contain: Itopride Group No.6 Hydrochloride 50mg. Group No.6 1202. 513 TABLET Tab-: Metformin Hcl. sustained release 1gm. Group No.6 1203. 514 TABLET Tab-: Glipizide sustained release 5mg. Group No.6 1204. 521 TABLET Tab-: Transxemic Acid 500mg. Group No.6 1205. 535 TABLET Tab-: Pantoprazole 40 mg. 1206. 540 TABLET SULBUTIAMINE TAB - Each tab to contain: Group No.6 Sulbutiamine 200mg. 1207. 553 TABLET FLAVOXATE TAB - Each tab to contain: Flavoxate Group No.6 Hydrochloride 200 mg. Tab-: Dried Aluminium Hydroxide gel I.P. 240mg, Mag. Group No.6 1208. 560 TABLET Hydroxide I.P.100mg, Mag. Carbonate I.P. 60mg, Activated Dimethicone I.P. 25mg. Each tab. to contain: Ferrous Calcium Citrate 278mg. Group No.6 1209. 561 TABLET Eqv. to 25mg. Iron, 36 mg. Calcium, 0.3 mg Folic Acid 1210. 568 TABLET CABERGOLINE TAB - Each tab to contain:Cabergoline Group No.6 0.5mg. Each controlled release tab. to contain: Pyridoxine Group No.6 1211. 572 TABLET Hydrochloride I.P. 100mg. Group No.6 1212. 573 TABLET Tab-: Piribedil 50mg. Group No.6 1213. 577 TABLET Tab-: Ursodesoxycholic acid 150mg. Tab-: Ambroxol I.P.30mg., Salbutamol I.P. 2mg., Group No.6 1214. 582 TABLET Theophylline (anhydrous) I.P.100mg. Tab-: Mecobalamin I.P. 500mcg., Lactic Acid Bacillus Group No.6 1215. 589 TABLET Spores 40 million, Alpha Lipoic Acid 100mg., Folic Acid I.P. 1.5mg., Vit. B1 I.P. 10mg., Vit. B6 I.P. 3mg. Group No.6 1216. 590 TABLET RITODRINE TAB - Each tab to contain: Ritodrine 10mg.

Page 90 of 112

1217. 599 TABLET DOXYLAMINE + PYRIDOXIN TAB - Each tab. to Group No.6 contain: Doxylamine succinate 10mg., Pyridoxin 10mg. Tab-: Mag. Hydroxide I.P.400 mg, Dried Aluminium Group No.6 1218. 1001 TABLET Hydroxide Gel I.P. 400 mg, Activated Dimethicone I.P.125 mg. Group No.6 1219. 1013 TABLET Tab- : Domperidone 10 mg. Group No.6 1220. 1019 TABLET Tab-:Drotavarine Hcl 80 mg. 1221. 1020 TABLET METRONIDAZOLE + DILOXANIDE TAB - Each Tab Group No.6 to contain: Metronidazole 200 mg. Diloxanide Furoate 250mg. Group No.6 1222. 1032 TABLET Tab- :Etophylline 77 mg.,Theophylline I.P. 23 mg. Each SR Tab. To contain :Etophylline 231 Group No.6 1223. 1033 TABLET mg.Theophylline 69 mg. Group No.6 1224. 1052 TABLET DIGOXIN TAB - Each Tab To contain :Digoxin 0.25 mg. 1225. 1055 TABLET BISOPROLOL TAB - Each tab to contain: Bisoprolol Group No.6 Fumerate 5 mg. Group No.6 1226. 1057 TABLET Tab- :Verapamil Hcl 40 mg. Group No.6 1227. 1063 TABLET Tab- :Trimetazidine Hcl 20 mg. Group No.6 1228. 1070 TABLET Tab- : Frusemide 20 mg., Spironolactone 50 mg. Group No.6 1229. 1071 TABLET Tab- :Acetazolamide 250 mg. Group No.6 1230. 1072 TABLET Tab-: Cinnarizine I.P. 25mg. Group No.6 1231. 1073 TABLET Tab- :Pentoxyfylline 400 mg. Group No.6 1232. 1074 TABLET Tab- :Isoxsuprine Hcl 10 mg. Tab-: Ergot Tartrate I.P.1mg. Caffeine I.P.100mg. Group No.6 1233. 1081 TABLET Prochlorperazine Maleate 2.5mg. Paracetamol I.P.250mg. Tab- : Paracetamol I.P. 500 mg., Pentazocin Hcl I.P. 15 Group No.6 1234. 1085 TABLET mg. Each tab to contain: Acetyl Salicylic Acid I.P.350 mg., Group No.6 1235. 1086 TABLET Cal. Carbonate I.P. 105 mg., Anhydrous citric acid I.P.35 mg. Group No.6 1236. 1089 TABLET Tab- Ticlopidine Hcl 250 mg. Group No.6 1237. 1090 TABLET Each S.R. Tab. To contain : Diclofenac Sodium 100 mg. Group No.6 1238. 1098 TABLET Tab- : Allopurinol 100 mg. Tab- : Carisoprodol 175 mg., Paracetamol 350 mg., Group No.6 1239. 1103 TABLET Caffeine 32 mg. Tab- :Dextro propoxyphene Napsylate 100 mg., Group No.6 1240. 1104 TABLET Aspirin 325 mg. PSU Item Group No.6 1241. 1105 TABLET Tab-: Tizanidine I.P.2mg. Each tab contains : Serratiopeptidase 5 mg. ( 10,000 Group No.6 1242. 1107 TABLET units of Serratiopeptidase) Group No.6 1243. 1108 TABLET Tab- : Trypsin and Chymotrypsin I.P.1 lakh units. Group No.6 1244. 1116 TABLET Tab- : Nitrazepan I.P. 5 mg. Group No.6 1245. 1117 TABLET Tab-: Buspirone Hcl I.P./ U.S.P.5 mg. Each CR tab. to contain : Lithium Carbonate I.P.450 Group No.6 1246. 1120 TABLET mg. Page 91 of 112

Group No.6 1247. 1121 TABLET Tab- : Imipramin Hcl 25 mg., Diazepam 2 mg. Group No.6 1248. 1122 TABLET Tab- : Pyritonol Hcl 100 mg. 1249. 1124 TABLET NIMODIPINE TAB - Each tab to contain: Nimodipine 30 Group No.6 mg. 1250. 1128 TABLET CARBAMAZEPIN TAB - Each tab to contain : Group No.6 Carbamazepin 400 mg. 1251. 1131 TABLET SODIUM VALPROATE TAB - Each Tab to contain: Group No.6 Sodium Valproate 200mg. 1252. 1132 TABLET LEVODOPA & CARBIDOPA TAB - Each tab to Group No.6 contain: Levodopa 250 mg, Carbidopa 25 mg. Group No.6 1253. 1133 TABLET Each tab to contain: Levodopa I.P. 500mg. Group No.6 1254. 1134 TABLET Tab- : Phenazopyridine 200 mg. 1255. 1135 TABLET ISOXSUPRINE SR TAB - Each SR tab to contain: Group No.6 Isoxsuprine Hcl 40 mg. Group No.6 1256. 1143 TABLET Tab- : Cetrizine Hydrochloride 10mg Group No.6 1257. 1145 TABLET Each tab to contain : Fexofenadine 120mg. Group No.6 1258. 1146 TABLET Tab- : Allylestrenol 5 mg. Group No.6 1259. 1147 TABLET Tab- : Stilboestrol I.P.5 mg. 1260. 1149 TABLET MEDROXY PROGESTERONE TAB - Each tab to Group No.6 contain: Medroxy Progesterone Acetate 10 mg Group No.6 1261. 1150 TABLET Tab- : Ethinyloestradiol I.P.0.05 mg. Tab- : Ethinyl Oestradiol I.P.4.4 mcg., Methyl Group No.6 1262. 1151 TABLET Testosterone I.P.3.6 mg. 1263. 1156 TABLET CLOMIPHEN CITRATE TAB - Each tab to contain: Group No.6 Clomiphen Citrate 50 mg. 1264. 1160 TABLET DEXAMETHASONE TAB - Each tab to contain: Group No.6 Dexamethasone 0.5 mg. Group No.6 1265. 1174 TABLET containing: Gliclazide 80mg. Group No.6 1266. 1204 TABLET Each tablet to contain : Griseofulvin 250 mg. Group No.6 1267. 1205 TABLET Each tablet to contain : Fluconazole 150 mg. Group No.6 1268. 1206 TABLET Each tablet to contain : Mefloquin 250 mg. Group No.6 1269. 1209 TABLET Tab- : Albendazole 400 mg. Group No.6 1270. 1297 TABLET Tab- : Folic Acid 5 mg. Group No.6 1271. 1305 TABLET Containing:NFI-IIIPROPHYLACTIC Group No.6 1272. 1334 TABLET Tab-:Tamoxifen 20mg. 1273. 1346 TABLET DICYCLOMINE + MEFENAMIC TAB - Each Tab to Group No.6 contain: Dicyclomine 10mg., Mefenamic Acid 250mg. Group No.6 1274. 1348 TABLET Tab-: Valsartan 80mg. Group No.6 1275. 1349 TABLET Each tab to contain Metolazone 5mg. Group No.6 1276. 1351 TABLET Tab-: Ezetimibe 10mg. Group No.6 1277. 1370 TABLET Tab-: Torsemide 10mg 1278. 1371 TABLET MEBEVERINE TAB - Each tab to contain: Mebeverine Group No.6 Hydrochloride 135mg

Page 92 of 112

1279. 1372 TABLET PERINDOPRIL+ INDAPAMIDE TAB - Each tab to Group No.6 contain: Perindopril Erbumine 4mg, Indapamide 1.25mg 1280. 1373 TABLET ATENOLOL + AMLODEPINE TAB - Each tab to Group No.6 contain: Atenolol 50mg, Amlodepine 5mg Group No.6 1281. 1374 TABLET Each SR tab. to contain: Trimatazidine 60mg 1282. 1376 TABLET HYDROXY CHLOROQUINE TAB - Each tab to Group No.6 contain: Hydroxy Chloroquine Sulfate 200mg Group No.6 1283. 1377 TABLET Tab-: Losartan Pottasium 50mg, Amlodepine 5mg 1284. 1392 TABLET OXCARBAZEPINE TAB - Each tab to contain: Group No.6 Oxcarbazepine 150mg 1285. 1393 TABLET MEFENAMIC + TRANEXAMIC ACID TAB - Each tab Group No.6 to contain: Mefenamic acid 250mg, Tranexamic acid 500mg 1286. 1395 TABLET MIFEPRISTONE TAB - Each Tab To contain: Group No.6 Mifepristone 200mg 1287. 1396 TABLET LEVONORGESTREL TAB - Each tab to contain: Group No.6 Levonorgestrel I.P.75mg Tab-: Cefixime I.P./U.S.P. 200mg, Lactic Acid Bacillus Group No.6 1288. 1399 TABLET 60 million Spores 1289. 1415 TABLET ORNIDAZOLE TAB - Each Tab to Group No.6 contain:Ornidazole 500mg Each tab to contain: Meclizine HCL 25mg + Caffeine Group No.6 1290. 1416 TABLET 20mg Group No.6 1291. 1420 TABLET Tab-: Telmisartan 40mg Group No.6 1292. 1421 TABLET Tab-: Perindropil 4mg ,Amlodipine I.P.5mg Group No.6 1293. 1453 TABLET Each tab to contain: Letrozole 2.5mg Group No.6 1294. 1458 TABLET Each tab to contain: Amiodarone I.P.200mg Group No.6 1295. 1460 TABLET Each tab to contain: Spiramycin I.P.3 MIU 1296. 1461 TABLET HYDROXYZINE HYDROCHLORIDE TAB - Each tab to Group No.6 contain: Hydroxyzine Hydrochloride 25mg Group No.6 1297. 1462 TABLET Each tab to contain: Itraconazole 100mg Group No.6 1298. 1470 TABLET Tab- Ethinylestradiol I.P.0.02mg + Desogestrel 0.15mg 1299. 1475 TABLET ANASTROZOLE TAB - Each tab to contain Anastrozole Group No.6 1mg 1300. 1478 TABLET LOW DOSE PROGESTERONE ORAL PILL - Each Tab Group No.6 To contain: Desogestrel 75mcg Tab-: Amoxycillin I.P. 200mg, Clavulanic acid I.P. Group No.6 1301. 1481 TABLET 28.5mg 1302. 1490 TABLET SITAGLIPTIN TAB - Each tab to contain: Sitagliptin Group No.6 100mg CALCIUM & MINERALS TAB - Each Tab To contain Calcium Citrate eqv to elemental calcium 200mg, Zinc Group No.6 1303. 1493 TABLET sulphate 4mg, Monohydrate Magnesium Hydroxide 50mg, Vit D3 200 I.U Excepients q.s.

Page 93 of 112

Each Tab.to contain: Meclizine HCL I.P. 12.5 mg, Group No.6 1304. 1498 TABLET Nicotinic Acid I.P.50 mg. Group No.6 1305. 1499 TABLET Each Tab.to contain: Otilonium Bromide 40 mg Each Tab.to contain:. Ofloxacin I.P. 200mg, Group No.6 1306. 1501 TABLET Ornidazole I.P.500mg. Group No.6 1307. 1505 TABLET Each Tab.to contain: Metadoxine 500mg Each tab.to contain: Euphorbia Prostata dry extract Group No.6 1308. 1511 TABLET ethanolic 80% (v/v) 100mg Each Tab.to contain:Ambroxol Hydrochloride I.P. 30 Group No.6 1309. 1512 TABLET mg, N - Acetyl - L - Cysteine I.P./B.P./USP 200 mg, Each Tab.to contain: Montelukast 10mg, Levocetrizine Group No.6 1310. 1513 TABLET I.P.5mg. 1311. 1530 TABLET IVABRADINE TAB - Each tab to contain: Ivabradine Group No.6 5mg Group No.6 1312. 1531 TABLET Tab-: Sustained release tablets of Nicorandil 20mg Group No.6 1313. 1532 TABLET Tab-: Isosorbide Dinitrate I.P. 5mg Group No.6 1314. 1542 TABLET Tab-: Paracetamol I.P.effervescent 1 gm Tab-: Thiocolchicoside Fr. Ph.4 mg diclofenac sodium Group No.6 1315. 1544 TABLET I.P. 50mg Group No.6 1316. 1550 TABLET Tab-: Linezolid 600mg Tab-: Fluconazole 150mg (1Tab) Azithromycin I.P. 1gm Group No.6 1317. 1563 TABLET (1Tab) Secnidazole I.P 1gm (2 Tab) Group No.6 1318. 1565 TABLET Tab-: Primaquine I.P. 15mg, 1319. 1567 TABLET LAMIVUDINE , NEVIRAPINE,STAVUDINE TAB - Each Group No.6 Tab to contain: Lamivudine 150mg, Nevirapine 200mg, Stavudine 30mg. Group No.6 1320. 1568 TABLET Tab-: Lorazepam I.P./B.P./USP 1mg, Group No.6 1321. 1569 TABLET Tab-: Chlordiazepoxide I.P. 10 mg. Group No.6 1322. 1573 TABLET Tab-: Piracetam I.P./ Fr. Ph..400mg, Group No.6 1323. 1578 TABLET ALFUZOSIN TAB - Each Tab to contain: Alfuzosin 10mg Each vaginal tab. to contain: Mix Lactobacilli Group No.6 1324. 1579 TABLET (L.brevis,L.salivarious and L.plantarum ) 10E9 Each vaginal tab. to contain: Sertaconazole Nitrate Group No.6 1325. 1580 TABLET B.P.500 mg Group No.6 1326. 1581 TABLET Tab-: Ebastine 10 Mg, Phenylephrine HCl I.P.10 Mg Group No.6 1327. 1582 TABLET Tab-: Levocetrizine I.P. 5mg, Group No.6 1328. 1589 TABLET Tab-: Betamethasone I.P. 1mg Group No.6 1329. 1591 TABLET Tab-: Saxagliptin tab. 2.5mg Tab-: Methoxasalen I.P./B.P./USP (8-Methoxy Group No.6 1330. 1621 TABLET Psoralen)10mg Tab-: (Calcium with Vitamin D NFI) Calcium Gluconate Group No.6 1331. 1634 TABLET NFI 0.5gm, Calcium Phosphate NFI 0.15 gm Calciferol NFI equ. To 500 units of Vit. D Group No.6 1332. 1640 TABLET LAPATINIB TAB - Each tab to contain: Lapatinib 250mg Group No.6 1333. 1643 TABLET Tab-: Sevelamer 400mg Group No.6 1334. 1644 TABLET Tab-: Alendronic Acid (Alendronate Sodium)-35mg Page 94 of 112

Group No.6 1335. 1655 TABLET Tab-: Ilaprazole 10mg Group No.6 1336. 1662 TABLET Tab-s: Ebastine 10mg, Montelukast 10mg Group No.6 1337. 1667 TABLET Each Tab to Contain: Dronedarone hcl 400 mg Group No.6 1338. 1669 TABLET Tab-s: Eplerenone 25mg Group No.6 1339. 1671 TABLET Tab-: Acenocoumarol 4mg Group No.6 1340. 1673 TABLET Tab-: Sumatriptan 25mg Group No.6 1341. 1674 TABLET Each Tab.to contains: Sumatriptan 50mg Each sustained release tab.to contain : Lornoxicam 16 Group No.6 1342. 1675 TABLET mg Group No.6 1343. 1676 TABLET Each Tab.To Contain:Aceclofenac 100mg Each Extended Release Tab. to contain: Zolpidem Group No.6 1344. 1678 TABLET Tartrate 12.5 mg 1345. 1681 TABLET CITICOLINE TAB - Each tab to contain: Citicoline 500 Group No.6 mg 1346. 1682 TABLET DIVALPROEX SOD. TAB - Each SR/ER/CR tab to Group No.6 contain: Divalproex Sod. 250mg 1347. 1683 TABLET DIVALPROEX SOD. TAB - Each SR/ER/CR tab to Group No.6 contain: Divalproex Sod. 500mg Group No.6 1348. 1684 TABLET Tab-: Bethanecol Chloride 25mg 1349. 1685 TABLET DEXCHLORPHENIRAMINE SR TAB - Each SR tab to Group No.6 contain: Dexchlorpheniramine 6mg 1350. 1686 TABLET FEXOFENADINE TAB - Each tab to contain: Group No.6 Fexofenadine 180mg 1351. 1687 TABLET LORATIDINE TAB - Each tab to contain: Loratidine Group No.6 10mg Group No.6 1352. 1688 TABLET Tab- : Thyroxine sodium 0.25mcg Group No.6 1353. 1689 TABLET Tab-: Saxagliptin-5mg Group No.6 1354. 1690 TABLET Tab-s : Vildagliptin 50mg 1355. 1693 TABLET CLARITHROMYCIN TAB - Each tab to contain: Group No.6 Clarithromycin 500mg Group No.6 1356. 1698 TABLET Tab-s: Terbinafine hydrochloride 250mg 1357. 1700 TABLET IVERMECTIN TAB - Each tab to contain: Ivermectin Group No.6 6mg Group No.6 1358. 1728 TABLET GEFITINIB TAB - Each tab to contain: Gefitinib 250mg Group No.6 1359. 1730 TABLET ERLOTINIB TAB - Each tab to contain: Erlotinib 50mg Tab-: Imatinib Mesylate Equivalent to Imatinib – 400 Group No.6 1360. 1735 TABLET mg Group No.6 1361. 1736 TABLET Tab-: Bicalutamide 50mg 1362. 1737 TABLET LEUPROLIDE TAB - Each tab to contain: Leuprolide Group No.6 Acetate 7.5mg 1363. 1738 TABLET SEVELAMER HCL TAB - Each tab to contain: Sevelamer Group No.6 Hcl 800mg Group No.6 1364. 1741 TABLET Troxipide Tab.100mg. -10Tab. Ademethionine Butadienesulfonate Tab.400mg - Group No.6 1365. 1743 TABLET 10Tab.

Page 95 of 112

Group No.6 1366. 1745 TABLET Doxofylline Tab. 400mg -10Tab.

Telmisartan 40 mg Amlodipine Besylate Group No.6 1367. 1753 TABLET equivalent to Amlodipine 5 mg -10Tab.

Tab Indapamide SR 1.5 mg + Amlodipine 5 mg -10 Group No.6 1368. 1754 TABLET Tabs. Each film coated sustained release Tablet contains: Group No.6 1369. 1755 TABLET Betahistine Hydrochloride IP 48 mg --7 Tab. Group No.6 1370. 1757 TABLET Tab. Etoricoxib (90 mg) -10Tab. Group No.6 1371. 1758 TABLET Diclofenac Colestyramine Caps. 145.6mg -10Caps. Group No.6 1372. 1759 TABLET Tolfenamic acid 200 mg -10 Tabs. Tab-: Zolpidem Tartrate 6.25 mg Extended Release Group No.6 1373. 1764 TABLET (Dual layer 60:40 ) tablets VOGLIBOSE TAB - Each Tab to contain: Voglibose 0.2 Group No.6 1374. 1765 TABLET mg 1375. 1766 TABLET SITAGLIPTINE 50MG + METFORMIN 500MG TAB - Group No.6 Each Tab To contain: Sitagliptin 50mg, Metformin 500 mg. Tab-:Sitaliptin phosphate 500mg+Metformin Group No.6 1376. 1767 TABLET hydrochloride 1000mg -14 Tabs. VILDAGLIPTIN 50 MG + METFORMIN HCL 500 MG TAB Group No.6 1377. 1768 TABLET - Each Tab To contain: Vildagliptin 50 mg, Metformin Hydrochloride 500 mg. Vildagliptin 50 mg,Metformin Hcl 1000 mg Tab. - Group No.6 1378. 1769 TABLET 10Tab. 1379. 1780 TABLET TELBIVUDINE TAB - Each Tab to contain: Group No.6 Telbivudine 600mg. VITAMIN & MINERAL TAB - Each Tab to contain: Thiamine Mononitrate 10mg, Riboflavin 10mg, Nicotinic Acid 25mg, Niacinamide 75mg, Pyridoxin Hydrochloride 3mg, Calcium Group No.6 1380. 1791 TABLET Pantothenate 50mg, Folic Acid 1.5mg, Vitamin B12 15mcg, Vitamin C 150mg, Biotin 260mcg, Light Magnesium Oxide Equivalent to elemental Magnesium 32.4mg. CALCIUM TAB - Each tab to contain: Calcium Citrate Group No.6 1381. 1793 TABLET Malate Equivalent to Elemental Calcium 250mg, Calcitriol 0.25 mcg,Vitamin K2-7 50mcg.

Page 96 of 112

CALCIUM & MINERALS TAB - Each Tab to contain: Calcium Carbonate 1000mg from Organic Source (Oyster Shell) Equivalent to Elemental Calcium 400mg, Heavy Magnesium Oxide 150mg Equivalent Group No.6 1382. 1794 TABLET to Elemental Magnesium 90mg, Zinc Sulphate Monohydrate 13.75mg Equivalent to Elemental Zinc 5 mg, L-Lysine hydrochloride 100 mg, Pyridoxine Hydrochloride 1.5 mg Cholecalciferol 200 IU Group No.6 1383. 1802 TABLET T. METHOTRAXATE 7.5 mg 1384. 1803 TABLET SORAFENIB TAB - Each tab to contain: Sorafenib Group No.6 Tosylate 200mg. Group No.6 1385. 1804 TABLET Tacrolimus 1mg TACROLIMUS 2MG TAB - Each tab to contain: Group No.6 1386. 1805 TABLET Tacrolimus 2mg. 1387. 1806 TABLET ERLOTINIB 25MG TAB - Each tab to contain: Erlotinib Group No.6 Hydrochloride equivalent to Erlotinib 25mg. ERLOTINIB 100MG TAB - Each Tab to contain: Erlotinib Group No.6 1388. 1807 TABLET Hydrochloride equivalent to Erlotinib 100mg ACTIVATED CHARCOAL TAB - Each tab to contain: Group No.6 1389. 1820 TABLET Activated Charcoal 500mg (For treatment of Poisoning) CHARCOAL TAB - Each tab to contain: standard weight Group No.6 1390. 1821 TABLET and strength of Charcoal (For Radiological procedures) MECLIZINE TAB - Each uncoated tab to contain: Group No.6 1391. 1827 TABLET Meclizine HCL I.P. 25mg 1392. 1829 TABLET MEFENAMIC ACID TAB - Each tab to contain : Group No.6 Mefenamic acid 500mg RACECADOTRIL DISPERSIBLE TAB - Each disp tab to Group No.6 1393. 1830 TABLET contain: Racecadotril 10mg RACECADOTRIL DISPERSIBLE TAB - Each disp tab to Group No.6 1394. 1831 TABLET contain: Racecadotril 30 mg GARENOXACIN TAB - Each film coated tab to Group No.6 1395. 1838 TABLET contains:Garenoxacin Mesylate equivalent to Garenoxacin 200mg exceipients qs METOPROLOL SUCCINATE SR TAB - Each SR tab to Group No.6 1396. 1845 TABLET contain: Metoprolol Succinate 23.75mg equivalent to Metoprolol Tartrate 25mg PROPRANOLOL TAB - Each tab to contain :Propranolol Group No.6 1397. 1846 TABLET 10mg LABETALOL TAB - Each tab to contain: Labetalol Group No.6 1398. 1850 TABLET 100mg 1399. 1851 TABLET MOXONIDINE TAB - Each tab to contain: Moxonidine Group No.6 0.2mg CILNIDIPINE TAB - Each tab to contain: Cilnidipine 10 Group No.6 1400. 1852 TABLET mg Group No.7 1401. 1854 TABLET CILOSTAZOL TAB - Each tab to contain: Cilostazol

Page 97 of 112

100mg TRAMADOL & ACETAMINOPHEN TAB - Each Film Group No.7 1402. 1855 TABLET coated tab to contain: Tramadol Hydrochloride IP 18.75 mg, Acetaminophen IP 162.5mg 1403. 1862 TABLET FEBUXOSTAT TAB - Each tab to contain : Febuxostat Group No.7 40mg TOLPERISONE & DICLOFENAC TAB - Each film coated Group No.7 1404. 1865 TABLET tab to contain: Tolperisone Hydrochloride JP 150mg + Diclofenac Sodium IP 50mg, Excipients q.s AMISULPRIDE TAB - Each tab to contain: Amisulpride Group No.7 1405. 1869 TABLET 50mg QUETIAPINE TAB - Each tab to contain: Quetiapine 25 Group No.7 1406. 1870 TABLET mg 1407. 1871 TABLET QUETIAPINE TAB - Each tab to contain: Quetiapine Group No.7 100 mg BUPRIPION ER TAB - Each ER tab to contain: Group No.7 1408. 1872 TABLET Bupripion 150mg LEVETIRACETAM TAB - Each tab to contain: Group No.7 1409. 1879 TABLET Levetiracetam 500mg LEVETIRACETAM TAB - Each tab to contain: Group No.7 1410. 1880 TABLET Levetiracetam 250mg LAMOTRIGINE DISP. TAB - Each disp tab to contain: Group No.7 1411. 1882 TABLET Lamotrigine 25mg 1412. 1883 TABLET LAMOTRIGINE TAB - Each tab to contain: Lamotrigine Group No.7 100mg GABAPENTIN, MECOBALAMIN & ALPHA LIPOIC ACID TAB - Each Film coated tab to contain:Gabapentin USP Group No.7 1413. 1884 TABLET 100mg, Mecobalamin JP 500mcg, Alpha Lipoic Acid USP 100mg 1414. 1886 TABLET ROPINIROLE TAB - Each tab to contain Ropinirole Group No.7 0.5mg Group No.7 1415. 1887 TABLET SILDENAFIL TAB - Each tab to contain: Sildenafil 50mg 1416. 1891 TABLET MISOPROSTOL TAB - Each tab to contain : Misoprostol Group No.7 25mcg LEVONORGESTREL - Each sterile Intrauterine system Group No.7 1417. 1893 TABLET to contain: Levonorgestrel 52mg (Levonorgestrel 20 Microgram / 24 hours intra uterine Delivery system) SAXAGLIPTIN & METFORMIN(ER) TAB - Each film Group No.7 1418. 1894 TABLET coated tab to contain:Saxagliptin 5 mg + Metformin Hcl 500mg (ER) SAXAGLIPTIN & METFORMIN(ER) TAB - Each film Group No.7 1419. 1895 TABLET coated tab. to contain:Saxagliptin 5 mg + Metformin Hcl 1000mg (ER ) LINAGLIPTIN TAB - Each film coated tab to contain: Group No.7 1420. 1896 TABLET Linagliptin 5mg

Page 98 of 112

GLICLAZIDE & METFORMIN ER TAB - Each uncoated bi- Group No.7 1421. 1897 TABLET layered scored tab to contain: Gliclazide IP (ER) 60 mg;Metformin Hydrochloride IP (ER) 500mg. NITROFURADANTIN SR TAB - Each SR tab to Group No.7 1422. 1903 TABLET contain:Nitrofuradantin 100mg 1423. 1904 TABLET FEROPENEM TAB - Each tab to contain: Feropenem Group No.7 200mg Group No.7 1424. 1905 TABLET RIFAXIMIN TAB - Each tab to contain: Rifaximin 200mg VORICONAZOLE TAB - Each tab to contain: Group No.7 1425. 1907 TABLET Voriconazole 200mg ANTI-MALARIAL KIT - Each Combikit to contain: (A) 2 Group No.7 1426. 1909 TABLET tab Sulphadoxine 750mg & Pyrimethamine 37.5mg (B) 3 tab Artisunate 200mg.. 1427. 1957 TABLET FERROUS ASCORBATE TAB - Each film coated tab to contain: Ferrous Ascorbate equivalent to elemental Group No.7 Iron 100mg, Folic Acid IP 1.5mg, Cyanocobalamin IP 15mcg, Zinc Sulphate Monohydrate IP eqv. to elemental Zinc 22.5mg, excepients q.s.

FERROUS ASCORBATE WITH AMINOACIDS & ZINC TAB - Each film coated tab to contain:Ferrous Ascorbate equivalent to elemental Iron 100mg, Methylcobalamin Group No.7 1428. 1962 TABLET 1000mcg, Folic Acid 1.5mg, L -Histidine Hcl H2O 4mg, L - Lysine Hcl 25mg, Glycine 10mg, Pyridoxine Hcl 1.5mg, Zinc Sulphate 50mg Group No.7 1429. 1966 TABLET SIROLIMUS TAB - Each tab to contain: Sirolimus 1mg Group No.7 1430. 1967 TABLET SIROLIMUS TAB - Each tab to contain: Sirolimus 2mg VALGANOCICLOVIR TAB - Each tab to Group No.7 1431. 1968 TABLET contain:Valganociclovir 450mg MYCOPHENOLATE TAB - Each tab to contain: Group No.7 1432. 1969 TABLET Mycophenolic acid (as Sodium salt) 180mg MYCOPHENOLATE TAB - Each tab to contain: Group No.7 1433. 1970 TABLET Mycophenolic acid (as Sodium salt) 360mg MYCOPHENOLATE TAB - Each tab to contain: Group No.7 1434. 1971 TABLET Mycophenolic acid (as Sodium salt) 540mg FLUDROCORTISONE TAB - Each tab to contain: Group No.7 1435. 1989 TABLET Fludrocortisone 0.1mg LIVER DISORDERS TAB - Each tab to contain: DL- Methionine BP 200mg , Choline Bitartrate (as coated) USP 200mg, L-Leucine USP 19mg, L-Isoleucine USP Group No.7 1436. 1992 TABLET 10mg, L-Valine USP 11mg, Pyridoxine Hydrochloride IP 1.5mg,Nicotinamide IP 22.5mg, Biotin USP 0.1mg, Folic Acid IP 0.5mg, Cyanocobalamin IP 3.0mcg , Inositol BP 50mg MONTELUKAST SODIUM 10MG TAB - Each Tab to Group No.7 1437. 2014 TABLET contain: Montelukast Sodium 10mg

Page 99 of 112

TELMISARTAN 40 MG + AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE (HCTZ) 12.5 MG TAB - Each Group No.7 1438. 2017 TABLET Tab to contain: Telmisartan 40 mg + Amlodipine 5 mg + Hydrochlorothiazide (HCTZ) 12.5 mg PERINDOPRIL ERBUMINE 8MG, AMLODIPINE BESILATE EQUIVALENT TO AMLODIPINE 5MG Group No.7 1439. 2018 TABLET EXCIPIENTS Q.S. TAB - Each uncoated Tab to contain : perindopril erbumine 8mg, amlodipine besilate equivalent to amlodipine 5mg excipients q.s. INDAPAMIDE (AS SR)1.5MG , AMLODIPINE BESILATE EQUVALENT TO AMLODIPINE 2.5MG, EXCEPIENTS QS FILM COATED BI-LAYERED TAB - Each film coated bi- Group No.7 1440. 2019 TABLET layered Tab contains: Indapamide (as SR)1.5mg , amlodipine besilate equvalent to amlodipine 2.5mg, excepients qs TELMISARTAN 40 MG + AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE (HCTZ) 12.5 MG TAB - Each Group No.7 1441. 2020 TABLET Tab to contain: Telmisartan 40 mg + Amlodipine 5 mg + Hydrochlorothiazide (HCTZ) 12.5 mg PERINDOPRIL ERBUMINE 8MG, INDAPAMIDE 2.5MG EXCIPIENTS Q.S. SCORED TAB - Each uncoated scored Group No.7 1442. 2021 TABLET Tab to contain: perindopril erbumine 8mg, indapamide 2.5mg excipients q.s. ACENOCOUMAROL / NICOUMALONE 2MG TAB - Each Group No.7 1443. 2022 TABLET Tab to contain: Acenocoumarol / Nicoumalone 2mg 1444. 2024 TABLET PARACETAMOL 650MG TAB - Each Tab to Group No.7 contains: Paracetamol 650mg N-ACETYL CYSTEINE 600MG TAB - Each Tab to contain: Group No.7 1445. 2026 TABLET Acetylcysteine 600mg S-ETODOLAC 200MG + THIOCOLCHICOSIDE 4MG TAB - Group No.7 1446. 2028 TABLET Each Tab to contain: s-Etodolac 200mg + Thiocolchicoside 4mg Tab 1447. 2033 TABLET DIENOGEST 2MG TAB - Each Tab to contain: Group No.7 Dienogest 2mg TENELIGIPTIN 20MG TAB - Each Tab to contain: Group No.7 1448. 2034 TABLET Teneligiptin 20mg ARTEMETHER 20MG & LUMEFANTRINE 120MG TAB - Group No.7 1449. 2036 TABLET Each Tab to contain: Artemether 20mg & Lumefantrine 120mg METHYLCOBALAMIN 500MCG TAB - Each Tab to Group No.7 1450. 2041 TABLET contain: Methylcobalamin 500mcg L-CARTNITINE TARTRATE EQ. TO LEVO CARNITINE Group No.7 1451. 2042 TABLET 330MG TAB - Each Tab to contain: L-Cartnitine Tartrate eq. to Levo Carnitine 330mg

Page 100 of 112

CALCIUM CITRATE 1000 MG, VIT. D3 200 IU, METHYLCOBALMIN 500 MCG, FOLIC ACID 5 MG, PYRIDOXIN IP 10MG TAB - Each Tab to contain: Group No.7 1452. 2047 TABLET Calcium citrate 1000 mg, Vit. D3 200 IU, Methylcobalmin 500 mcg, Folic acid 5 mg, Pyridoxin IP 10mg 1453. 2054 TABLET Each Enteric Coated tablet (as extended release) Group No.7 contains: Mesalamine USP 1.2gm. Group No.7 1454. 2055 TABLET Each Tablet to contain : Prucalopride 1mg 1455. 2056 TABLET Each tablet to contain : Group No.7 Chlordiazepoxide 5mg, Clidinium Bromide 2.5mg Group No.7 1456. 2057 TABLET Each tab to contains: Ursodoxycholic Acid 300mg 1457. 2058 TABLET Each enteric coated tablet contains: Pancreatin Group No.7 170mg Activated Dimethicone 80mg 1458. 2059 TABLET Each Film coated Tablet to contains : Metadoxine 500mg, Silymarin 140mg, L-Ornithine L- Group No.7 Aspartate 150mg, Pyridoxine Hydrochloride 3mg, Folic Acid 1.5mg 1459. 2060 TABLET Each Uncoated tablet contains Ambroxol Group No.7 Hrdrochloride 30 MG Terbutaline Sulphate equivalent to terbutaline 2.5 mg 1460. 2066 TABLET Varenicline Tartrate Tab Group No.7 Each film coated tab. To Contains : Varenicline (as tartrate) 0.5mg 1461. 2067 TABLET Each Prolonged Release Film coated Tablet to contain : Group No.7 S(-)Metoprolol succinate 47.50 mg Eqv. to S(-) Metoprolol Tartrate 50 mg Group No.7 1462. 2068 TABLET Each Tablet to contain : S-Metoprolol 25 mg Group No.7 1463. 2069 TABLET Each Tab to contains:Ticagrelor 90mg 1464. 2070 TABLET Each Film Coated tab contain: Ivabradine hcl Group No.7 equivalent to Ivabradine7.5mg 1465. 2071 TABLET Each film coated tablet contains: Group No.7 24mg sacubitril and 26mg valsartan as sodium salt complex 1466. 2072 TABLET Each film coated tablet contains: Group No.7 49mg sacubitril and 51mg valsartan as sodium salt complex 1467. 2073 TABLET Each Film coated Tablet Contains:Azilsartan Group No.7 Kamedoxomil Equivalent to Azilsartan Medoxomil 40mg 1468. 2074 TABLET Each film coated bilayered tablet contains indapamide Group No.7 (as sustained release) 1.5mg and amlodipine besilate equivalent to amlodipine 10mg

Page 101 of 112

1469. 2076 TABLET Each film coated tablet contains micronised - purified flavonoid fraction 1000mg composed of diosmin Group No.7 900mg (90%) and flavonoids expressed as hesperidin 100mg (10%) 1470. 2078 TABLET Apixaban Tab Group No.7 Each film coated tablet to contains : Apixaban 2.5mg 1471. 2079 TABLET Apixaban Tab Group No.7 Each film coated tablet to contains : Apixaban 5mg 1472. 2082 TABLET Each tab to contain Dexketoprofen 25mg + Group No.7 Paracetamol 325mg 1473. 2087 TABLET Each tab to contain: Estradiol 1mg + Group No.7 Dydrogesterone 5mg Group No.7 1474. 2089 TABLET Dapagliflozin: Each Tab. to contains Dapagliflozin 5mg 1475. 2090 TABLET SAROGLITAZAR tab: Each uncoated tab to Group No.7 contains: Saroglitazar 4 mg 1476. 2091 TABLET Each film coated tab to contains Canagliflozin Group No.7 hemyhydrate equivaltent to Canagliflozin 100mg 1477. 2092 TABLET Each uncoated tablet contains: Metformin Group No.7 Hydrochloride IP 500 mg (as a Sustained Release, Glimepiride IP 2 mg 1478. 2093 TABLET Each uncoated tablet contains: Metformin Group No.7 Hydrochloride IP 500 mg (as a Sustained Release) Glimepiride IP 1 mg 1479. 2094 TABLET Empagliflozin Tab: Each film coated tab to Group No.7 contains: Empagliflozin 10 mg 1480. 2095 TABLET Each kit to contains: Tab Clarithomycin 250mg+ Tab Group No.7 Tinidazole 500mg+ Cap Lansoprazole 30mg 1481. 2096 TABLET Each film coated tablet contains : Cefditoren Pivoxil Group No.7 equivalent to Cefditoren 200 mg Excipients q.s. 1482. 2108 TABLET Each Film CoatedTablet to contain : Ferrous ascorbate equivalent to elemental Iron 100 Group No.7 mg + Folic Acid 1.1 mg + Mecobalamin 1.5 mg + Zinc Sulphate Monohydrate equivalent to elemental Zinc 22.5 mg 1483. 2112 TABLET Each film coated tablet contains:Calcium Aspartate 500mg, Calcium Orotate 500mg, Calcitirol 0.25mcg, Group No.7 Zinc(as Zinc Sulphate monohydrtae IP) 7.5mg, Magnesium Hydroxide IP 50mg, Hydroxocobalamin IP 100mcg, Folic Acid IP 1.5mg, Excepientsq.s. 1484. 2113 TABLET Each tab to contains: Atorvastatin Calcium IP Group No.7 equivalent to Atorvastatin 10mg + Methylcobalamin 500 mcg+Folic Acid IP 5mg + Pyridoxine Hcl IP 10mg

Page 102 of 112

1485. 2116 TABLET Ipriflavone,Calcium,Vit D3 Tablets Each Filmcoated tablet Contains Calcium Carbonate Group No.7 1.0 gm from organic Source(Oyster Shell) Equivalent to Elemental Calcium 400 Mg, Ipriflavone 300 mg, Cholecalciferol IP 200 IU 1486. 2120 TABLET Tofacitinib Tab: Each film coated tablet contains : Group No.7 Tofacitinib Citrate equivalent to Tofacitinib 5mg 1487. 2124 TABLET Each film coated tablet to contains Pazopanib Group No.7 Hydrochloride equivalent to 400mg Pazopanib 1488. 2125 TABLET Each film coated tablet to contains:Eltrombopag Group No.7 Olamine equivalent to 25mg of eltrombopag as eltrombopag free acid 1489. 2126 TABLET Each film coated tablet to contains:Eltrombopag Group No.7 Olamine equivalent to 50mg of eltrombopag as eltrombopag free acid Group No.7 1490. 2129 TABLET Each tablet to contains Ruxolitinib 15mg Group No.7 1491. 2130 TABLET Each tablet contains Ruxolitinib 20mg Group No.7 1492. 2131 TABLET Each tablet contains Ruxolitinib 5mg Group No.7 1493. 2144 TABLET Each tab to contains: Afatinib 20 mg Group No.7 1494. 2145 TABLET Each tab to contains: Afatinib 30 mg Group No.7 1495. 2152 TABLET Each tab to contains:Nilutamide 150 MG Group No.7 1496. 2153 TABLET Each film coated tab to contains: Axitinib 5 mg Group No.7 1497. 2157 TABLET Each tab to contains: Afatinib 40 mg Group No.7 1498. 2160 TABLET Each Tab to contains:Regorafenib 40mg Group No.7 1499. 2165 TABLET Each tab to contain: Abiraterone acetate 250 mg Group No.7 1500. 2174 TABLET Each tab to contain:Erlotinib 150 MG Group No.7 1501. 2178 TABLET Each Tab to contains: Everolimus 05 mg Group No.7 1502. 2184 TABLET Each tab to contains:Tenofovir Alafenamide 25mg FAMOTIDINE TAB - Each tab to contain :Famotidine 20 Group No.7 1503. 1005a TABLET mg. FAMOTIDINE TAB - Each tab to contain :Famotidine 40 Group No.7 1504. 1005b TABLET mg. PROCHLORPERAZINE TAB - Each Tab to contain : Group No.7 1505. 1015a TABLET Prochlorperazine Maleate 5 mg. Group No.7 1506. 1015b TABLET Tab-: Pro Chlorperazine Maleate 25 mg. Group No.7 1507. 1034a TABLET Each tab to contain:Terbutaline sulphate 2.5 mg Group No.7 1508. 1034b TABLET Each tab. to contain: Terbutaline sulphate I.P. 5 mg Group No.7 1509. 1056a TABLET Tab- : Metoprolol Tartrate I.P.50 mg. Group No.7 1510. 1060a TABLET Tab-: Iso-sorbide-5-mononitrate 20 mg. Group No.7 1511. 1060b TABLET Tab-: Iso-sorbide-5-mononitrate 40 mg. Group No.7 1512. 1061a TABLET Each CR Tab. To contain : Glyceryl trinitrate 2.6 mg. Group No.7 1513. 1061b TABLET Each CR tab. to contain : Glyceryl trinitrate I.P.6.4 mg. 1514. 1065 TABLET LISINOPRIL TAB - Each tab to contain : Lisinopril 5 mg. Group No.7 b Group No.7 1515. 1065a TABLET Tab- : Lisinopril 2.5 mg.

Page 103 of 112

Group No.7 1516. 1065b TABLET Tab- : Lisinopril 5 mg. Group No.7 1517. 1065c TABLET Tab-: Lisinopril 10mg. Group No.7 1518. 1066b TABLET Each tab to contain :Terazocin 2 mg. Group No.7 1519. 1066c TABLET Each tab to contain :Terazocin 5 mg. 1520. 1067 TABLET PRAZOSIN SR TAB - Each SR tab to contain: Prazosin Hcl 2.5 mg. Group No.7 b Group No.7 1521. 1067b TABLET Tab- : Prazosin Hcl I.P.2.5 mg. Group No.7 1522. 1067c TABLET Each. Tab. to contain: Prazosin Hcl. I.P. 5mg. 1523. 1115 TABLET PHENOBARBITONE TAB - Each tab to contain: Phenobarbitone- Group No.7 b 30mg. Group No.7 1524. 1115b TABLET Tab-: Phenobarbitone-30mg. Group No.7 1525. 1119a TABLET Tab- : Lithium Carbonate I.P.150 mg. Group No.7 1526. 1119b TABLET Tab- : Lithium Carbonate I.P.300 mg. 1527. 1127 TABLET CARBAMAZEPIN CR TAB - Each CR tab to contain : Carbamazepin 400 Group No.7 b mg. 1528. 1127a TABLET CARBAMAZEPIN CR TAB - Each CR tab to contain: Group No.7 Carbamazepin 200 mg Group No.7 1529. 1127b TABLET Tab- : Carbamazepin 400 mg. Group No.7 1530. 1148a TABLET Tab- : Dydrogestrone I.P./U.S.P. 5 mg. 1531. 1148b TABLET DYDROGESTRONE TAB - Each tab to contain : Group No.7 Dydrogestrone I.P./U.S.P.10 mg. Group No.7 1532. 1153a TABLET Tab-: Conjugated Oestrogen 0.625 mg. Group No.7 1533. 1153b TABLET Each tab to contain Conjugated oestrogen 1.25mg. Group No.7 1534. 1154a TABLET Tab-: Estriol Succinate 1mg. Group No.7 1535. 1154b TABLET Tab- Estriol Succinate 2mg. Group No.7 1536. 1177c TABLET Tab-: Amoxcyllin 875mg, Clavulanic Acid 125mg CLOTRIMAZOLE VAGINAL TAB - Each tab to contain: Group No.7 1537. 117a TABLET Clotrimazole 200mg with applicator Group No.7 1538. 1188b TABLET Tab- : Demeclocycline Hcl 300 mg. Group No.7 1539. 1195a TABLET Tab-: Ofloxacin 200mg. Group No.7 1540. 1195b TABLET Tab-: Ofloxacin 400mg. Group No.7 1541. 1207a TABLET Tab-: Secnidazole I.P. 500mg. Group No.7 1542. 1207b TABLET Each tab.to contain: Secnidazole I.P.1gm. Group No.7 1543. 1210b TABLET Tab-: Levamisole I.P. 150 mg. Group No.7 1544. 1306a TABLET Tab-: Ascorbic Acid 100mg PSU Item Group No.7 1545. 1306b TABLET Tab-: Ascorbic Acid 500mg. PSU Item 1546. 1370 TABLET TORSEMIDE TAB - Each tab to contain: Torsemide 20mg Group No.7 b Group No.7 1547. 1370b TABLET Tab-: Torsemide 20mg 1548. 1375a TABLET LEFLUNOMIDE TAB - Each tab to contain: Leflunomide Group No.7 10mg Group No.7 1549. 1375b TABLET Tab-: Leflunomide 20mg 1550. 1426 TABLET EBASTINE TAB - Each tab to contain: Ebastine 20mg. Group No.7 b

Page 104 of 112

Group No.7 1551. 1426a TABLET EBASTINE TAB - Each Tab to contain: Ebastine 10mg. Group No.7 1552. 1426b TABLET EBASTINE TAB - Each tab to contain: Ebastine 20mg. 1553. 1430a TABLET MIRTAZAPINE TAB - Each tab to contain: Mirtazapine Group No.7 7.5mg Group No.7 1554. 1430b TABLET Tab-: Mirtazapine 15mg 1555. 1447 TABLET DASATINIB TAB - Each tab to contain: Dasatinib 50mg. Group No.7 b Group No.7 1556. 1447a TABLET DASATINIB TAB - Each tab to contain: Dasatinib 20mg Group No.7 1557. 1447b TABLET Tab-: Dasatinib 50mg. Group No.7 1558. 1447c TABLET DASATINIB TAB - Each tab to contain: Dasatinib 70mg 1559. 1454 TABLET CAPECITABINE TAB - Each tab to contain: Capecitabine 500mg Group No.7 b 1560. 1454a TABLET CAPECITABINE TAB - Each tab to contain: Capecitabine Group No.7 150mg Group No.7 1561. 1454b TABLET Each tab to contain: Capecitabine 500mg 1562. 1473 TABLET SUNITINIB MALATE TAB/CAP - Each tab/cap to contain: Sunitinib Group No.7 b Malate 25mg Group No.7 1563. 1474b TABLET Each tab to contain: Everolimus 0.5mg Group No.7 1564. 1474c TABLET Each tab to contain: Everolimus 0.75mg 1565. 1476 TABLET DEFERASIROX TAB - Each tab to contain Deferasirox 400mg Group No.7 b 1566. 1476a TABLET DEFERASIROX TAB - Each tab to contain Deferasirox Group No.7 100mg Group No.7 1567. 1476b TABLET Tab- Deferasirox 400mg 1568. 1485 TABLET ENTECAVIR TAB - Each tab to contain Entecavir 1mg Group No.7 b Group No.7 1569. 1485a TABLET ENTECAVIR TAB - Each tab to contain: Entecavir 0.5mg Group No.7 1570. 1485b TABLET ENTECAVIR TAB - Each tab to contain Entecavir 1mg Group No.7 1571. 1497a TABLET Tab-: Esomeprazole Magnesium I.P. 20 mg with buffer Each tab to contain: Esomeprazole Magnesium I.P. 40 Group No.7 1572. 1497b TABLET mg with buffer Group No.7 1573. 1533a TABLET Tab-: Hydrochlorothiazide I.P. 12.5mg. Group No.7 1574. 1533b TABLET Tab-: Hydrochlorothiazide I.P. 25mg Group No.7 1575. 1537a TABLET Tab-: Warfarin Sodium I.P. 2mg - Group No.7 1576. 1537b TABLET Tab-: Warfarin Sodium I.P. 5mg. Group No.7 1577. 1539a TABLET Tab-: Betahistine Dihydrochloride I.P. 8mg. Group No.7 1578. 1539b TABLET Tab-: Betahistine Dihydrochloride I.P. 16mg. Group No.7 1579. 1540a TABLET Tab-: Rosuvastatin I.P. 10mg Group No.7 1580. 1540b TABLET Tab-: Rosuvastatin I.P. 20mg Group No.7 1581. 1545a TABLET Tab-: Tolperisone Hcl. JPC 150 mg Group No.7 1582. 1545b TABLET Tab-: Tolperisone Hcl. JPC 450mg Tab-: Amoxycillin Trihydrate Equ. to Amoxycillin I.P. 500mg Clavulanate Potassium I.P. Equ. to Clavulanic Group No.7 1583. 1551a TABLET acid 125mg Lactic Acid bacillus – 60 million Spores

Page 105 of 112

Tab-:Amoxicillin Trihydrate Equ. to Amoxicillin I.P. Group No.7 1584. 1551b TABLET 250mg Clavulanate Potassium I.P. Equ. to Clavulanic acid 125mg Lactic Acid bacillus – 60 million Spores 1585. 1552 TABLET CEFUROXIME + CLAVULANATE POTASSIUM TAB - Group No.7 b Each Tab to contain:Cefuroxime axetil 250mg, Clavulanate potassium 62.50Mg Tab-:Cefuroxime axetil I.P. 125mg, Clavulanate Group No.7 1586. 1552a TABLET potassium I.P. 31.25Mg Tab-:Cefuroxime axetil I.P. 250mg ,Clavulanate Group No.7 1587. 1552b TABLET potassium I.P. 62.50Mg Tab-: Cefuroxime axetil I.P. 500mg ,Clavulanic Group No.7 1588. 1552c TABLET potassium I.P. 125Mg Group No.7 1589. 157a TABLET Tab-:Roxythromycin 50mg. Group No.7 1590. 157b TABLET Tab-: Roxythromycin 150mg. 1591. 15a TABLET HYOSCINE BUTYL BROMIDE TAB - Each tab to Group No.7 contain: Hyoscine Butyl Bromide 10mg. Tab- : Ciprofloxacin Monohydrate eqv. to Group No.7 1592. 177a TABLET Ciprofloxacin 250mg. Tab- : Ciprofloaxin Monohydrate eqv. to Ciprofloxacin Group No.7 1593. 177b TABLET 500mg. 1594. 184a TABLET ETHAMBUTOL TAB - Each tab to contain: Ethambutol Group No.7 200mg. 1595. 184b TABLET ETHAMBUTOL TAB - Each tab to contain: Ethambutol Group No.7 400mg. 1596. 185a TABLET PYRAZINAMIDE TAB - Each tab to contain: Group No.7 Pyrazinamide 500mg. 1597. 185b TABLET PYRAZINAMIDE TAB - Each tab to contain: Group No.7 Pyrazinamide 750mg. 1598. 186a TABLET ISONIAZIDE TAB - Each tab to contain: Isoniazide Group No.7 100mg. 1599. 186b TABLET ISONIAZIDE TAB - Each tab to contain: Isoniazide Group No.7 300mg. Group No.7 1600. 203a TABLET Tab-: Tinidazole 300mg. Group No.8 1601. 203b TABLET Tab-: Tinidazole 500mg. Group No.8 1602. 23a TABLET Tab-: Metronidazole 200 mg. Group No.8 1603. 23b TABLET Tab-:Metronidazole 400 mg. Group No.8 1604. 304a TABLET Tab-: Sparfloxacin 100 mg. Group No.8 1605. 304b TABLET Each tab to contain: Sparfloxacin 200 mg. 1606. 30a TABLET SALBUTAMOL TAB - Each Tab to Group No.8 contain:Salbutamol 2mg. 1607. 30b TABLET SALBUTAMOL TAB - Each Tab to Group No.8 contain:Salbutamol 4 mg. Group No.8 1608. 324a TABLET CLOBAZAM TAB - Each tab to contain: Clobazam 5 mg 1609. 324b TABLET CLOBAZAM TAB - Each tab to contain: Clobazam Group No.8 I.P.10 mg Group No.8 1610. 329a TABLET Tab-: Glimepiride 1mg.

Page 106 of 112

Group No.8 1611. 329b TABLET Tab-: Glimepiride 2mg. Group No.8 1612. 335a TABLET Tab-: Acyclovir 200mg. 1613. 335b TABLET ACYCLOVIR TAB - Each tab to contain: Acyclovir Group No.8 400mg. 1614. 336a TABLET CARVEDILOL TAB - Each Tab to contain: Carvedilol Group No.8 3.125mg. Group No.8 1615. 336b TABLET Each tab. to contain: Carvedilol 6.25mg. Group No.8 1616. 336c TABLET Tab-: Carvedilol 12.5mg. Each S.R. tab. to contain: Iso-sorbide Group No.8 1617. 341a TABLET mononitrate30mg. Each S.R. tab. to contain: Iso-sorbide mononitrate Group No.8 1618. 341b TABLET 60mg. Group No.8 1619. 364a TABLET Each tab to contain : Losartan Potassium I.P.25 mg. Group No.8 1620. 364b TABLET Each tab to contain : Losartan Potassium I.P.50 mg. Group No.8 1621. 368a TABLET Each tab to contain : Atorvastatin 10 mg. Group No.8 1622. 368b TABLET Each tab to contain : Atorvastatin 20 mg. Group No.8 1623. 372a TABLET Each tab to contain : Dothiepin Hcl. I.P.25mg. Group No.8 1624. 372b TABLET Each tab to contain : Dothiepin Hcl. I.P. 75mg. Group No.8 1625. 374a TABLET Each tab to contain : Sertraline 25mg. Group No.8 1626. 374b TABLET Each tab to contain : Sertraline . 50mg. Group No.8 1627. 376a TABLET Each tab to contain : Cefuroxime I.P.125mg. Group No.8 1628. 376b TABLET Each tab to contain : Cefuroxime I.P.250mg. Group No.8 1629. 376c TABLET Each tab to contain : Cefuroxime I.P.500mg. 1630. 423a TABLET NICORANDIL TAB - Each tab to contain Nicorandil Group No.8 5mg. Group No.8 1631. 423b TABLET Tab-: Nicorandil 10mg. 1632. 428a TABLET ACETYL SALICYLIC ACID TAB - Each Gastro-resistant Group No.8 tab to contain :Acetyl Salicylic Acid 75 mg Each enteric coated tab.to contain: Acetyl Salicylic Group No.8 1633. 428b TABLET Acid 150 mg. Each enteric coated tab to contain : Acetyl Salicylic Group No.8 1634. 428c TABLET Acid I.P.325 mg. Each controlled release tab. to contain: Sodium Group No.8 1635. 433a TABLET Valproate + Valproic Acid eqv. to Sodium Valproate 200mg. Each controlled release tab. to contain: Sodium Group No.8 1636. 433b TABLET Valproate + Valproic Acid eqv. to Sodium Valproate 500mg. Group No.8 1637. 434a TABLET Tab-: Pioglitazone 15mg. Group No.8 1638. 434b TABLET Tab-: Pioglitazone 30mg. Group No.8 1639. 43a TABLET Tab-: Atenolol 25mg. Group No.8 1640. 43b TABLET Each tab. to contain: Atenolol 50mg. 1641. 44b TABLET PROPRANOLOL TAB - Each tab. to contain: Propranolol Group No.8 40mg. Group No.8 1642. 463a TABLET Tab-: Zolpidem 5mg. Group No.8 1643. 463b TABLET Tab-: Zolpidem 10mg.

Page 107 of 112

Group No.8 1644. 466a TABLET Each tab to contain :Methylprednisolone 4mg Group No.8 1645. 466b TABLET Each tab to contain : Methylprednisolone I.P.16 mg Group No.8 1646. 470a TABLET Tab-: Perindopril 2mg. Group No.8 1647. 470b TABLET Tab-: Perindopril 4mg. 1648. 470c TABLET PERINDOPRIL TAB - Each tab to contain: Perindopril Group No.8 Erbumine 8mg. Group No.8 1649. 472a TABLET Tab-: Clonazepam I.P.0.5mg. Group No.8 1650. 472b TABLET Tab-: Clonazepam 1mg. Group No.8 1651. 473a TABLET Tab-: Resperidone 1mg. Group No.8 1652. 473b TABLET Tab-: Resperidone 2mg. Group No.8 1653. 474a TABLET Tab-: Olanzapine I.P.2.5mg. 1654. 474b TABLET OLANZAPINE TAB - Each tab to contain: Olanzapine Group No.8 5mg Group No.8 1655. 475a TABLET Tab-: Haloperidol I.P.1.5mg Group No.8 1656. 475b TABLET Tab-: Haloperidol I.P.5mg. Group No.8 1657. 477a TABLET Tab-: Amitriptyline I.P.10mg. Group No.8 1658. 477b TABLET Tab-: Amitriptyline I.P.25mg. Group No.8 1659. 486a TABLET Tab-: Paroxetine 10mg. Group No.8 1660. 486b TABLET Tab-: Paroxetine 20mg. Group No.8 1661. 49a TABLET Tab-: Diltiazem 30mg. Group No.8 1662. 49b TABLET Each tab to contain: Diltiazem 60mg. Group No.8 1663. 4a TABLET Tab-: Ranitidine Hcl eqv. to Ranitidine 150 mg. Group No.8 1664. 4b TABLET Tab-:Ranitidine Hcl eqv. to Ranitidine 300 mg. Group No.8 1665. 50a TABLET Each S.R. tab to contain: Diltiazem I.P.90 mg Group No.8 1666. 50b TABLET Each S.R. tab to contain: Diltiazem I.P.120mg. METOPROLOL ER TAB - Each ER tab to contain: Group No.8 1667. 525a TABLET Metoprolol Succinate 47.5mg equivalent to Metoprolol Tartrate 50mg. Group No.8 1668. 527a TABLET Tab-: Gabapentin I.P./B.P./U.S.P.300mg. Group No.8 1669. 527b TABLET Tab-: Gabapentin I.P./B.P./U.S.P. 400mg. Group No.8 1670. 532a TABLET Tab-: Cefpodoxime proxetil 100 mg. Group No.8 1671. 532b TABLET Tab-: Cefpodoxime proxetil 200mg. Group No.8 1672. 554a TABLET Tab-: Bromocriptine (as mesylate) I.P.1.25mg. 1673. 554b TABLET BROMOCRIPTIN TAB - Each tab to contain: Group No.8 Bromocriptin (as mesylate) 2.5mg. Group No.8 1674. 555a TABLET Tab-: Clozapine 25mg. Group No.8 1675. 555b TABLET Tab-: Clozapine 100mg. 1676. 556a TABLET ESCITALOPRAM TAB - Each tab to contain: Group No.8 Escitalopram 10 mg. 1677. 556b TABLET ESCITALOPRAM TAB - Each tab to contain: Group No.8 Escitalopram 20 mg. Group No.8 1678. 558a TABLET Tab-: Finaestride 1mg. 1679. 558b TABLET FINASTERIDE TAB - Each tab to contain: Finasteride Group No.8 5mg. Group No.8 1680. 563a TABLET MISOPROSTOL TAB - Each tab to contain: Misoprostol Page 108 of 112

100mcg 1681. 563b TABLET MISOPROSTOL TAB - Each tab to contain: Misoprostol Group No.8 200mcg. Group No.8 1682. 567b TABLET Tab-: Rabeprazole I.P.20 mg. Group No.8 1683. 56a TABLET Tab-: Enalapril Maleate I.P.2.5mg. 1684. 56b TABLET ENALAPRIL MALEATE TAB - Each tab to contain: Group No.8 Enalapril Maleate 5mg. Group No.8 1685. 56c TABLET Tab-: Enalapril Maleate 10mg. Group No.8 1686. 571b TABLET Tab-: Simvastatin 10 mg. Group No.8 1687. 575a TABLET Tab-: Cefixime 50mg. Group No.8 1688. 575b TABLET Tab-: Cefixime 100mg. Group No.8 1689. 575c TABLET Tab-: Cefixime 200mg. Each Modified Release tab. to contain: Gliclazide Group No.8 1690. 576a TABLET 30mg. Each Modified Release tab. to contain: Gliclazide Group No.8 1691. 576b TABLET 60mg. Group No.8 1692. 578a TABLET Tab-: Alendronate 35mg. 1693. 578b TABLET ALENDRONATE TAB - Each tab to contain: Alendronate Group No.8 70mg. Group No.8 1694. 61a TABLET Tab-: Spironolactone 25mg. 1695. 61b TABLET SPIRONOLACTONE TAB - Each tab to contain: Group No.8 Spironolactone 100mg. Group No.8 1696. 62b TABLET Each S.R. tab. to contain: Xantinol Nicotinate 500mg. Group No.8 1697. 68a TABLET Each Tab to Contain Ethamsylate 250 mg. Group No.8 1698. 68b TABLET Each Tab to contain Ethamsylate 500 mg. Group No.8 1699. 72a TABLET Each tab to contain Acenocoumarol I.P.1mg Group No.8 1700. 83a TABLET Each tab to contain: Ibuprofen 200mg. Group No.8 1701. 83b TABLET Each tab to contain Ibuprofen 400 mg. Group No.8 1702. 94a TABLET Tab-: Alprazolam 0.25mg. Group No.8 1703. 94b TABLET Tab-: Alprazolam 0.5mg. 1704. 1403 TABLET/CAPS ANTI OXIDANT TAB/CAP - Each tab/cap to ULE contain:Carotenoids and micronutrients from carrots 100mg (Eqv. To 100mcg of carotenoids calculated as Group No.8 beta carotene) Beta Carotene 7.5% dispersion 40mg (Natural carotenoids), Vit. C 150mg, Vit. E Acetate 25mg, Selenium dioxide 75mcg (eqv to 45.9mcg of Selenium), Zinc Sulphate 70mg (eqv to 15.9mg Zinc). TABLET/CAPS Group No.8 1705. 1406 Each tab./ cap. to contain: Temozolomide I.P. 250mg ULE TABLET/CAPS Group No.8 1706. 1424 Each tab./caps. to contain: Tamsulosine I.P. 0.4mg ULE TABLET/CAPS Each tab./ cap To contain: Tamsulosine 0.4mg + Group No.8 1707. 1425 ULE Dutasteride 0.5mg TABLET/CAPS Group No.8 1708. 1543 Each tab./cap. to contain: Diacerein 50mg, ULE

Page 109 of 112

TABLET/CAPS Each tab./cap. to contain: Pregabalin 75 mg, Group No.8 1709. 1575 ULE Methylcobalamine 750 mcg, TABLET/CAPS Each tab./cap. to contain: Gabapentine I.P./B.P./USP Group No.8 1710. 1576 ULE 300 mg,Mehylcobalamin 500mcg, TABLET/CAPS Group No.8 1711. 1577 Each tab./cap. to contain: Dutasteride 0.5 mg, ULE APREPITANT TAB/CAP - Each pack to contain: TABLET/CAPS Group No.8 1712. 1641 Aprepitant (125 mg one tab/cap and 80 mg two ULE tab/cap) TABLET/CAPS Group No.8 1713. 1668 Each Tab./cap to contain : Olmesartan 20mg. ULE TABLET/CAPS Group No.8 1714. 1750 Tab/Cap Nebivolol 2.5mg ULE TABLET/CAPS Group No.8 1715. 1751 Tab/Cap Nebivolol 5mg ULE TABLET/CAPS CLINDAMYCIN TAB/CAP. - Each Tab/Cap to contain: Group No.8 1716. 1771 ULE Clindamycin 300mg 1717. 1832 TABLET/CAPS RACECADOTRIL TAB/CAP - Each tab/cap to contain: Group No.8 ULE Racecadotril 100 mg 1718. 1848 TABLET/CAPS RANOLAZINE TAB/CAP - Each tab/cap to contain: Group No.8 ULE Ranolazine 500mg TRAMADOL & PARACETAMOL TAB/ CAP - Each TABLET/CAPS Group No.8 1719. 1856 tab/cap to contain:Tramadol 37.50 mg, Paracetamol ULE 325mg TABLET/CAPS PAROXETINE CR TAB/CAP - Each CR tab/cap to Group No.8 1720. 1873 ULE contain: Paroxetine 25mg 1721. 1874 TABLET/CAPS DULOXIPINE TAB/CAP - Each tab/cap to contain: Group No.8 ULE Duloxipine 30mg TABLET/CAPS TAMSULOSIN & FINASTERIDE TAB/CAP - Each tab/cap Group No.8 1722. 1888 ULE to contain: Tamsulosin 0.4 mg + Finasteride 5mg 1723. 1951 TABLET/CAPS ISOTRETINOIN TAB/CAP - Eac tab/cap to contain: Group No.8 ULE Isotretinoin 10mg TABLET/CAPS VITAMIN E TAB/CAP - Each tab/cap to contain: Vit. E Group No.8 1724. 1960 ULE (Tocopherol Acetate) 400mg, L-Carnitine 150mg TABLET/CAPS TACROLIMUS TAB/CAP - Each tab/cap to contain: Group No.8 1725. 1988 ULE Tacrolimus0.5mg LANSOPRAZOLE 15MG (ENTERIC COATED) TAB/CAP - TABLET/CAPS Group No.8 1726. 2009 Each Tab /cap (Enteric Coated) to contain: ULE Lansoprazole 15mg (Enteric Coated) PANTAPRAZOLE 40MG + DOMPERIDONE 30 MG SR TABLET/CAPS Group No.8 1727. 2010 TAB - Each Tab/Cap to contain: Pantaprazole 40mg + ULE Domperidone (SR) 30 mg PANCREATIC LIPASE TAB/CAP - Each cap/Tab to TABLET/CAPS Group No.8 1728. 2013 contain: Lipase 10000 units, Amylase 8000 units, ULE Protease 600 units 1729. 2046 TABLET/CAPS SOFOSBUVIR 400 MG TAB/CAP - Each Tab/Cap to Group No.8 ULE contain : Sofosbuvir 400 mg Page 110 of 112

1730. 2128 TABLET/CAPS Each cap/tab to contain : Ibrutinib 140mg. Group No.8 ULE

1731. 2142 TABLET/CAPS Each tab/cap to contains: Nilotinib 400mg Group No.8 ULE

1732. 2158 TABLET/CAPS Each Tab/ cap to contain: Certinib 150 mg Group No.8 ULE

Each tab./cap. to contain: Ramipril 1.25mg TABLET/CAPS Group No.8 1733. 1068a ULE

Each tab./cap. tocontain: Ramipril 2.5mg. TABLET/CAPS Group No.8 1734. 1068b ULE

Each tab./cap. to contain: Ramipril 5mg. TABLET/CAPS Group No.8 1735. 1068c ULE

Each cap. / tab. To contain : Amoxycillin Trihydrate TABLET/CAPS eqv. to Amoxycillin 250 mg. Group No.8 1736. 1175a ULE

TABLET/CAPS Each cap. / tab. To contain : Amoxycillin Trihydrate Group No.8 1737. 1175b ULE eqv. to Amoxycillin 500 mg. TABLET/CAPS Each cap/ tab to contain : Amoxycillin I.P.500 mg. Group No.8 1738. 1177a ULE Clavulanic acid I.P. 125 mg. TABLET/CAPS Each cap/ tab to contain : Amoxycillin I.P. 250 mg. Group No.8 1739. 1177b ULE Clavulanic acid I.P. 125 mg. 1740. 132a TABLET/CAPS DANAZOL TAB/CAP - Each tab/cap to contain: Danazol Group No.8 ULE 100mg. 1741. 132b TABLET/CAPS DANAZOL TAB/CAP - Each tab/cap to contain; Danazol Group No.8 ULE 200mg. 1742. 1353 TABLET/CAPS CEFACLOR TAB/CAP - Each tab/cap to contain: Group No.8 b ULE Cefaclor 250mg. Each cap./tab. to contain: Cefaclor I.P. 500mg. TABLET/CAPS Group No.8 1743. 1353a ULE

CEFACLOR TAB/CAP - Each tab/cap to contain: TABLET/CAPS Group No.8 1744. 1353b Cefaclor 250mg. ULE

TABLET/CAPS Group No.8 1745. 1473a Each cap / tab. to contain: Sunitinib Malate 12.5mg ULE TABLET/CAPS Group No.8 1746. 1473b Each cap / tab to contain: Sunitinib Malate 25mg ULE TABLET/CAPS Group No.8 1747. 1473c Each cap / tab to contain: Sunitinib Malate 50mg ULE TABLET/CAPS Group No.8 1748. 1474a Each tab to contain: Everolimus 0.25mg ULE

Page 111 of 112

TABLET/CAPS Group No.8 1749. 529a Each cap./tab. to contain: Azithromycin 250mg. ULE TABLET/CAPS Each tab./cap. to contain: Azithromycin 500mg. Group No.8 1750. 529b ULE TABLET/CAPS Each S.R cap/Tab. to contain: Nifedipine 10mg. Group No.8 1751. 52a ULE TABLET/CAPS Each S.R cap/Tab. to contain: Nifedipine 10mg. Group No.8 1752. 52b ULE

Page 112 of 112